COVID-19 Treatment and Vaccine Tracker

	C	D	E	F	G	H	I	J	K	L	M	N	O
2			0 Best Practices - Expand the formula bar so that you don't miss the additional info found in some of the cells. Reference the image to the right for more help. - Use filters to explore and organize the information for your own use. When accessing through this view-only link, filters are temporary to that search/find. - This document is also available for download under the File tab. - To find the latest additions or updates to the tracker, command+F or control+F and search for an asterisk. All cells with new information have an added at the end.							Last Update: May 21, 2020 \| 12:37 pm ET © 2020 Milken Institute00 2020
3	Treatment vs. Vaccine	Product Category	Product Description	Stage of Development	Anticipated Next Steps	Clinical Trials for COVID-19	Developer / Researcher	Funder	Published Results	Clinical Trials for Other Diseases (T only) Related Use / Platform (V Only)	FDA-Approved Indications	Sources	Date Last Updated

4	Treatment	Antibodies	Polyclonal hyperimmune globulin (H-IG), unbranded	Pre-clinical	Phase 1 trials start in summer 2020. To patients between December 2020 and December 2021		CoVIg-19 Plasma Alliance (Takeda, CSL Behring, Biotest AG, Bio Products Laboratory, LFB, and Octapharma, ADMA Biologics, BioPharma Plasma, GC Pharma, Sanquin)/ National Institute of Allergy and Infectious Disease (NIAID)/ Microsoft (CoVIg-19 PlasmaBot)				N/A	Sources	5/10/2020
5	Treatment	Antibodies	Antibodies from mice, REGN3048-3051, against the spike protein	Pre-clinical	Start Phase 1 June 2020		Regeneron	Biomedical Advanced Research and Development Authority (BARDA)			N/A	Sources	Prior to 4/20/2020
6	Treatment	Antibodies	CT-P59; Antibodies from recovered COVID-19 patients	Pre-clinical	Start Phase 1 in July 2020		Celltrion	The Korea Health Industry Development Institute			N/A	Sources	5/14/2020
7	Treatment	Antibodies	Super-antibody or antibody cocktail to target potential mutations of SARS-CoV-2	Pre-clinical			Celltrion				N/A	Sources	Prior to 4/20/2020
8	Treatment	Antibodies	COVI-SHIELD antibody cocktail that binds to three different epitopes	Pre-clinical	Start Phase 2 trial 3Q 2020		Sorrento Therapeutics/ Mount Sinai Health System				N/A	Sources	5/20/2020
9	Treatment	Antibodies	Antibodies from recovered COVID-19 patients	Pre-clinical			Kamada/ Kedrion Biopharma				N/A	Sources	5/4/2020
10	Treatment	Antibodies	VIR-7831 and VIR-7832, antibodies from recovered SARS patients	Pre-clinical	Start Phase 2 ~ July-September 2020		Vir Biotechnology/GSK/ Samsung/WuXi Biologics/Biogen				N/A	Sources	5/20/2020
11	Treatment	Antibodies	Antibodies from recovered COVID-19 patients	Pre-clinical	Start Phase 1 in late July 2020		Eli Lilly/Ab-Cellera (NIH Vaccines Research Center)	Defense Advanced Research Projects Agency/ Government of Canada (ISED Strategic Innovation Fund)			N/A	Sources	5/5/2020
12	Treatment	Antibodies	COVID-19 Immunoglobulin, plasma derived	Pre-clinical			CSL Behring Australia				N/A	Sources	5/10/2020
13	Treatment	Antibodies	Avastin (bevacizumab), vascular endothelial growth factor inhibitor	Clinical	Phase 2/3 studies recruiting April 2020	NCT04275414 NCT04305106 NCT04344782	Numerous trials with Chinese research sponsors; Roche				FDA-approved since 2004, approved to treat certain types of cancer	Sources	4/27/2020
14	Treatment	Antibodies	PD-1 blocking antibody; Thymosin	Clinical	Phase 2 study not yet recruiting	NCT04268537 ChiCTR2000030028	Numerous trials with Chinese research sponsors				Unknown	Sources	4/27/2020
15	Treatment	Antibodies	Opdivo (nivolumab), PD-1 blocking antibody	Clinical	Phase 2 study not yet recruiting	NCT04356508 NCT04333914	University of Hong Kong (BMS)				FDA-approved since 2014, approved to treat melanoma and squamous non-small cell lung cancer	Sources	4/27/2020
16	Treatment	Antibodies	leronlimab (PRO 140), a CCR5 antagonist	Clinical / Compassionate Use	Phase 2 trial started in April 2020; Phase 2b/3 trial starts April 2020	NCT04343651 NCT04347239	CytoDyn		CytoDyn	Treatment of HIV/AIDS, Graft versus Host Disease, Non-Alcoholic Steatohepatitis, and numerous cancers	N/A	Sources	Prior to 4/20/2020
17	Treatment	Antibodies	AiRuiKa (camrelizumab), anti-programmed cell death protein (PD-1) antibody	Clinical	No trial updates since February 2020	ChiCTR2000029806	Wuhan Jinyintan Hospital			Treatment of certain cancers	N/A	Sources	4/27/2020
18	Treatment	Antibodies	Kevzara (sarilumab), interleukin-6 receptor antagonist	Clinical	Started phase 2/3 in March 2020; preliminary Phase 2 results released April 27, 2020, trial continuing for only critical patients, Phase 3 (US) results expected June 2020, Phase 3 (ex-US) results expected 3Q 2020	NCT04315298 NCT04321993 NCT04341870 NCT04324073 NCT04327388 NCT04322773 NCT04345289 NCT02735707 NCT04357808 NCT04357860 NCT04359901	Sanofi/Regeneron; Feinstein Institutes; REMAP-CAP global trial	Biomedical Advanced Research and Development Authority (BARDA)	medRxiv (https://doi.org/10.1101/2020.04.23.20076612) Regeneron (https://newsroom.regeneron.com/index.php/news-releases/news-release-details/regeneron-and-sanofi-provide-update-us-phase-23-adaptive) ChinaXiv (http://www.chinaxiv.org/abs/202003.00026) medRxiv (https://doi.org/10.1101/2020.05.14.20094144)		FDA-approved since 2017, approved to treat rheumatoid arthritis	Sources	5/20/2020
19	Treatment	Antibodies	Actemra (tocilizumab), interleukin-6 receptor antagonist	Clinical	Roche studies could be completed May or June 2020; Phase 2 open label study in Italy active (April 2020), Phase 3 studies recruiting April 2020, some results from open label study in France released April 2020	NCT04317092 NCT04320615 NCT04310228 ChiCTR2000030894 NCT04306705 ChiCTR2000030442 ChiCTR2000029765 NCT04322773 NCT04345445 NCT04331795 NCT04332094 NCT04346355 NCT04359667 NCT04332913 NCT04335071 NCT04356937 NCT04361032 NCT04315480 NCT04339712 NCT04333914 NCT04361552 NCT04330638 NCT04331808 NCT02735707 NCT04349410 NCT04363736 NCT04372186 NCT04363853	Numerous trials with global research sponsors; Roche; REMAP-CAP	Biomedical Advanced Research and Development Authority (BARDA)	ChinaXiv (http://www.chinaxiv.org/abs/202003.00026) medRxiv (https://doi.org/10.1101/2020.04.20.20061861) medRxiv (https://doi.org/10.1101/2020.04.23.20076612) Assistance Publique Hopitaux De Paris (https://www.aphp.fr/contenu/le-tocilizumab-ameliore-significativement-le-pronostic-des-patients-avec-pneumonie-covid) PNAS (https://www.pnas.org/content/early/2020/04/27/2005615117#T1) medRxiv (https://doi.org/10.1101/2020.05.01.20078360) medRxiv (https://doi.org/10.1101/2020.05.07.20094599) medRxiv (https://doi.org/10.1101/2020.05.14.20099234) medRxiv (https://doi.org/10.1101/2020.05.13.20100404) medRxiv (https://doi.org/10.1101/2020.05.13.20100081)		FDA-approved since 2010, approved to treat various type of arthritis, including rheumatoid arthritis, and cytokine release syndrome	Sources	5/21/2020
20	Treatment	Antibodies	Gimsilumab, anti-granulocyte-macrophage colony stimulating factor monoclonal	Clinical	Phase 2 study started in April 2020	NCT04351243	Roivant Sciences				N/A	Sources	5/14/2020
21	Treatment	Antibodies	TJM2 (TJ003234), anti-granulocyte-macrophage colony stimulating factor antibody	Clinical	Phase 1/2 recruiting April 2020	NCT04341116	I-Mab Biopharma				N/A	Sources	4/27/2020
22	Treatment	Antibodies	lenzilumab, anti-granulocyte-macrophage colony stimulating factor antibody	Clinical / Compassionate Use	Phase 3 not yet recruiting April 2020	NCT04351152	Humanigen Inc.			Prevent cytokine storm with CAR-T cancer therapy; prevention/treatment of acute graft versus host disease; chronic myelomonocytic leukemia; eosinophilic asthma	N/A	Sources	4/27/2020
23	Treatment	Antibodies	Sylvant (siltuximab), interleukin-6 targeted monoclonal	Clinical / Compassionate Use	Compassionate use data shared April 2020; Phase 3 recruiting April 2020	NCT04322188 NCT04330638 NCT04329650	EUSA Pharma/The Papa Giovanni XXII Hospital; University Hospital, Ghent; Fundacion Clinic per a la Recerca Biomédica		EUSA Pharma (https://www.eusapharma.com/news/interim-analysis-data-for-siltuximab-treated-covid-19-patients-from-the-sisco-study/) medRxiv (https://doi.org/10.1101/2020.04.01.20048561) medRxiv (https://doi.org/10.1101/2020.04.23.20076612)		FDA-approved since 2014, approved to treat multicentric Castleman disease	Sources	4/28/2020
24	Treatment	Antibodies	Soliris (eculizumab), complement inhibitor	Clinical/ Expanded access	Phase 2 recruiting May 2020	NCT04288713 NCT04346797 NCT04355494	Assistance Publique - Hopitaux de Paris (Phase 2); Alexion (Expanded Access)				FDA-approved since 2007, approved to treat Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis, and Neuromyelitis Optica Spectrum Disorder	Sources	5/5/2020
25	Treatment	Antibodies	Ilaris (canakinumab), interleukin-1beta blocker	Clinical	Novartis Phase 3 to start and trial top-line results expected late summer 2020	NCT04348448 NCT04362813 NCT04365153	Novartis; other research sponsors				FDA-approved since 2009, approved to treat periodic fever syndromes and systemic juvenile idiopathic arthritis	Sources	4/30/2020
26	Treatment	Antibodies	Gamifant (emapalumab), anti-interferon gamma antibody	Clinical	Phase 2/3 recruiting April 2020	NCT04324021	Swedish Orphan Biovitrum				FDA-approved since 2018, approved to treat primary hemophagocytic lymphohistiocytosis	Sources	4/27/2020
27	Treatment	Antibodies	meplazumab, anti-CD147 antibody	Clinical	Phase 1/2 recruiting April 2020	NCT04275245	Tang-Du Hospital		medRxiv (https://doi.org/10.1101/2020.03.21.20040691)		N/A	Sources	4/27/2020
28	Treatment	Antibodies	LY3127804, anti-Angiopoietin 2 (Ang2) antibody	Clinical	Phase 2 to start in April 2020		Eli Lilly				N/A	Sources	Prior to 4/20/2020
29	Treatment	Antibodies	Ultomiris (ravulizumab-cwvz), complement inhibitor	Clinical	Phase 3 to start in May 2020	NCT04369469	Alexion Pharmaceuticals				FDA-approved since 2018, aprpoved to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome	Sources	5/5/2020
30	Treatment	Antibodies	IFX-1, anti-C5a antibody	Clinical	Phase 2/3 recruiting in April 2020	NCT04333420	InflaRx N.V.			To treat various inflammatory conditions including hidradenitis suppurativa, ANCA-associated vasculitis, and pyoderma gangraenosum	N/A	Sources	4/27/2020
31	Treatment	Antibodies	otilimab, anti-granulocyte macrophase colony-stimulating factor (GM-CSF) antibody	Clinical	Phase 2 to start end of May 2020	NCT04376684	GSK			To treat rheumatoid arthritis	N/A	Sources	5/8/2020
32	Treatment	Antibodies	Monoclonal antibody cocktail	Pre-clinical			ImmunoPrecise Antibodies				N/A	Sources	4/23/2020
33	Treatment	Antibodies	Antibody	Pre-clinical			Harbour BioMed/ Erasmus MC/ Utrecht University/ Mount Sinai Health System				N/A	Sources	5/10/2020
34	Treatment	Antibodies	Antibodies targeting the S protein from convalescent serum, humanized mice, and phage display	Pre-clinical	Phase 1 trials begin in summer 2020		AstraZeneca/ US Army Medical Research Institute of Infectious Diseases (USAMRIID)/ University of Maryland School of Medicine				N/A	Sources	Prior to 4/20/2020
35	Treatment	Antibodies	Antibody	Pre-clinical			Centivax (Distributed Bio)				N/A	Sources	5/21/2020
36	Treatment	Antibodies	Antibodies	Pre-clinical			Chelsea and Westminster Hospital, Imperial College London	UK Government			N/A	Sources	5/10/2020
37	Treatment	Antibodies	Antibody	Pre-clinical	Phase 1 trial begins in summer 2020		Vanderbilt Vaccine Center/ AstraZeneca/ IDBiologics	Defense Advanced Research Projects Agency/ Dolly Parton			N/A	Sources	5/10/2020
38	Treatment	Antibodies	Antibodies	Pre-clinical			Medicago/ Laval University's Infectious Disease Research Centre	Canadian Institutes for Health Research (CIHR)			N/A	Sources	Prior to 4/20/2020
39	Treatment	Antibodies	Antibodies	Pre-clinical			FairJourney Biologics/ Iontas				N/A	Sources	4/21/2020
40	Treatment	Antibodies	Antibodies	Pre-clinical			Prellis Biologics				N/A	Sources	5/21/2020
41	Treatment	Antibodies	Antibodies (OmniChicken platform)	Pre-clinical			Ligand Pharmaceuticals				N/A	Sources	4/23/2020
42	Treatment	Antibodies	Antibodies (OmniRat platform)	Pre-clinical			Ligand Pharmaceuticals				N/A	Sources	4/23/2020
43	Treatment	Antibodies	Monocloncal antibodies, TLR4 antagonist	Pre-clinical			Edesa Biotech/ Light Chain Bioscience (NovImmune)				N/A	Sources	4/23/2020
44	Treatment	Antibodies	Monocloncal antibodies, CXC10 antagonist	Pre-clinical			Edesa Biotech/ Light Chain Bioscience (NovImmune)				N/A	Sources	4/23/2020
45	Treatment	Antibodies	Polyclonal hyperimmune globulin (H-IG)	Pre-clinical	Phase 2 trials begin ~ August 2020		Emergent BioSolutions/ National Institute of Allergy and Infectious Diseases (NIAID)	Biomedical Advanced Research and Development Authority (BARDA)		Same human hyperimmune platform as FDA-approved anthrax treatment (Anthrasil) and smallpox vaccine complications (VIGIV) were developed	N/A	Sources	Prior to 4/20/2020
46	Treatment	Antibodies	Horse plasma product (COVID-EIG)	Pre-clinical	Phase 2 trials begin ~ August 2020		Emergent BioSolutions			Same equine hyperimmune platform as FDA-approved botulism anti-toxin (BAT) is produced	N/A	Sources	Prior to 4/20/2020
47	Treatment	Antibodies	Convalescent plasma (blood plasma from recovered patients)	Clinical / Expanded Access	Phase 2 and Phase 3 trials not yet recruiting as of April 2020	Many expanded access, observational, patient registry, plasma collection, prevention, and other studies listed in clincialtrials.gov, including: NCT04321421 NCT04292340 NCT04316728 NCT04338360 NCT04345289 NCT04349410 NCT04346589 NCT04333251 NCT04361253 NCT04323800 NCT04359810 NCT04362176 NCT04354831 NCT04360486	Multiple global research sponsors, including New York State Department of Health, Johns Hopkins University, the Feinstein Institutes	Bloomberg Philantropies and the State of Maryland (to Johns Hopkins University)/ Biomedical Advanced Research and Development Authority (BARDA) (to Mayo Clinic)	medRxiv (https://doi.org/10.1101/2020.03.16.20036145) JAMA (https://jamanetwork.com/journals/jama/fullarticle/2763983) medRxiv (https://doi.org/10.1101/2020.04.07.20056440) JAMA Network (https://jamanetwork.com/journals/jama/fullarticle/2763982) medRxiv (https://doi.org/10.1101/2020.05.08.20095471) medRxiv (https://doi.org/10.1101/2020.05.12.20099879)		N/A	Sources	5/20/2020
48	Treatment	Antibodies	Antibodies from recovered COVID-19 patients	Pre-clinical	Phase 1 trial begins Q3 2020		Tsinghua University / Third People's Hospital of Shenzhen / Brii Biosciences				N/A	Sources	Prior to 4/20/2020
49	Treatment	Antibodies	Polyclonal hyperimmune globulin (H-IG)	Pre-clinical			Grifols	Biomedical Advanced Research and Development Authority (BARDA)			N/A	Sources	Prior to 4/20/2020
50	Treatment	Antibodies	Antibodies from recovered COVID-19 patients	Pre-clinical			Grifols	Biomedical Advanced Research and Development Authority (BARDA)			N/A	Sources	Prior to 4/20/2020
51	Treatment	Antibodies	Antibodies from recovered COVID-19 patients	Pre-clinical			Amgen / Adaptive Biotechnologies				N/A	Sources	Prior to 4/20/2020
52	Treatment	Antibodies	Antibodies from recovered COVID-19 patients	Pre-clinical			Innovent Biologics				N/A	Sources	Prior to 4/20/2020
53	Treatment	Antibodies	Antibodies from recovered COVID-19 patients	Pre-clinical			Xbiotech / BioBridge Global				N/A	Sources	Prior to 4/20/2020
54	Treatment	Antibodies	Antibodies from recovered COVID-19 patients	Pre-clinical			Costa Rican Social Security Fund (CCSS)/ The University of Costa Rica (UCR)/ Clodomiro Picado Institute				N/A	Sources	Prior to 4/20/2020
55	Treatment	Antibodies	Novel IgM and IgA antibodies	Pre-clinical			Atreca/ BeiGene/ IGM Biosciences				N/A	Sources	5/4/2020
56	Treatment	Antibodies	SAB-185, Polyclonal hyperimmune globulin (H-IG)	Pre-clinical	Phase 1 starts early summer 2020		CSL Behring/ SAb Biotherapeutics	Biomedical Advanced Research and Development Authority (BARDA)/ US Department of Defense			N/A	Sources	4/30/2020
57	Treatment	Antibodies	Non-viral gene therapy to produce monoclonal antibodies	Pre-clinical			Generation Bio / Vir Biotechnology				N/A	Sources	Prior to 4/20/2020
58	Treatment	Antibodies	rCIG (recombinant anti-coronavirus 19 hyperimmune gammaglobulin), polyclonal antibodies	Pre-clinical			GigaGen				N//A	Sources	Prior to 4/20/2020
59	Treatment	Antibodies	IC14, recombinant chimeric anti-CD14 monoclonal antibody	Expanded access		NCT04346277	Implicit Bioscience			Acute Respiratory Distress Syndrome	N/A	Sources	Prior to 4/20/2020
60	Treatment	Antibodies	MEDI3506, monoclonal antibody targeting interleukin 33	Clinical	ACCORD Phase 2 trial to start May 2020		AstraZeneca; ACCORD trial	UK Government (ACCORD study)		Chronic Obstructive Pulmonary Diesase	N/A	Sources	5/10/2020
61	Treatment	Antibodies	Octagam; intravenous Immunoglobulin (IVIG)	Clinical	Phase 3 trial to start May 2020	NCT04261426 NCT04264858 NCT04350580	Multiple global research sponsors; Octapharma USA/ Sharp Memorial Hospital		Open Forum Infectious Diseases (https://academic.oup.com/ofid/article/7/3/ofaa102/5810740)		FDA-approved since 2014, approved to treat chronic immune thrombocytopenic purpura (ITP)	Sources	5/21/2020
62	Treatment	Antibodies	Purified ovine immunoglobulin from immunized sheep	Pre-clinical			Public Health England (Stuart Dowall)	UK Government			N/A	Sources	4/23/2020
63	Treatment	Antibodies	Antibodies	Pre-clinical			Ablexis/ AlivaMab Discovery Services/ Berkeley Lights Collaborate				N/A	Sources	4/28/2020
64	Treatment	Antibodies	JS016 antibody candidate	Pre-clinical	Phase 1 to start 2Q 2020		Junshi Biosciences/ Eli Lilly				N/A	Sources	5/5/2020
65	Treatment	Antibodies	Linked nanobody antibody	Pre-clinical			University of Texas at Austin/ US National Institutes of Health/ Ghent University				N/A	Sources	5/1/2020
66	Treatment	Antibodies	Single domain antibodies (sdAbs), engineered monoclonal antibody derived from camelids	Pre-clinical			Abcore				N/A	Sources	5/21/2020
67	Treatment	Antivirals	Favilavir/Favipiravir/T-705/Avigan, licensed in Japan to treat influenza	Clinical	Phase 3 trial in Japan started in March 2020; Phase 2 trial in US started April 2020; Phase 3 trial in India started May 2020 with results expected by July/August 2020 (Glenmark)	NCT04303299 NCT04310228 ChiCTR2000029548 ChiCTR2000029496 ChiCTR2000029544 ChiCTR2000030254 NCT04336904 NCT04333589 NCT04345419	Fujifilm Toyama Chemical/Zhejiang Hisun Pharmaceuticals/numerous trials with global research sponsors/ Brigham and Women's Hospital, Massachusetts General Hospital, and the University of Massachusetts Medical School/ Glenmark Pharmaceuticals		medRxiv (https://doi.org/10.1101/2020.03.17.20037432) medRxiv (https://doi.org/10.1101/2020.04.21.20066761) Kyodo News (https://english.kyodonews.net/news/2020/05/fce701d4d88d-antiflu-avigan-not-showing-apparent-efficacy-in-coronavirus-treatment.html)		N/A	Sources	5/21/2020
68	Treatment	Antivirals	Kaletra/Aluvia (lopinavir/ritonavir), HIV-1 protease inhibitor	Clinical	RECOVERY trial results expected by June 2020	NCT04303299 NCT04255017 ChiCTR2000029548 ChiCTR2000029539 EudraCT 2020-000936-23 NCT04307693 NCT04315948 NCT04252885 NCT04276688 NCT02735707 NCT04321993 2020-001113-21 NCT04286503 NCT04328012 NCT04346147	Global hospital testing (AbbVie); World Health Organization SOLIDARITY trial (studying lopinavir/ ritonavir with and without interferon beta); University of Oxford RECOVERY trial; REMAP-CAP global trial	UK Government (University of Oxford RECOVERY trial)	NEJM (https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001282?articleTools=true) medRxiv (https://doi.org/10.1101/2020.03.19.20038984) Chinese Journal of Infectious Diseases (http://rs.yiigle.com/yufabiao/1182592.htm) medRxiv (https://doi.org/10.1101/2020.03.28.20045955) medRxiv (https://doi.org/10.1101/2020.04.08.20057539) medRxiv (https://doi.org/10.1101/2020.04.21.20066761) medRxiv (https://doi.org/10.1101/2020.04.25.20079079) medRxiv (https://doi.org/10.1101/2020.04.24.20077735) The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31042-4/fulltext) medRxiv (https://doi.org/10.1101/2020.05.13.20094193)		FDA-approved since 2000, approved to treat HIV-1 infection	Sources	5/20/2020
69	Treatment	Antivirals	remdesivir, nucleotide analog	Clinical / Expanded Access / FDA issued an Emergency Use Authorization on May 1, 2020	Gilead Phase 3 trial topline results released April 2020 (severe disease) and expected May 2020 (moderate disease); NIAID trial preliminary data released April 2020, full results expected in May 2020	NCT04257656 NCT04252664 NCT04292730 NCT04292899 NCT04280705 EudraCT 2020-000936-23 NCT04315948 NCT04302766 NCT04323761 NCT04349410	Gilead; World Health Organization SOLIDARITY trial; National Institute of Allergy and Infectious Disease (NIAID)'s Adaptive COVID-19 Treatment Trial; Feinstein Institutes		NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2007016) NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2001191) Stat News (https://www.statnews.com/2020/04/16/early-peek-at-data-on-gilead-coronavirus-drug-suggests-patients-are-responding-to-treatment/) Reuters (https://www.reuters.com/article/us-health-coronavirus-gilead-sciences/gilead-disputes-report-that-coronavirus-drug-trial-flopped-idUSKCN225326) Stat (https://www.statnews.com/2020/04/23/data-on-gileads-remdesivir-released-by-accident-show-no-benefit-for-coronavirus-patients/) medRxiv (https://doi.org/10.1101/2020.04.21.20066761) Gilead (https://www.businesswire.com/news/home/20200429005424/en/Gilead-Announces-Results-Phase-3-Trial-Investigational) NIAID (https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19?utm_campaign=+42538088&utm_content=&utm_medium=email&utm_source=govdelivery&utm_term=) Lancet (https://doi.org/10.1016/S0140-6736(20)31022-9) medRxiv (https://doi.org/10.1101/2020.05.02.20088559)	Treatment of Ebola	N/A	Sources	5/20/2020
70	Treatment	Antivirals	Prezcobix (darunavir, HIV-1 protease inhibitor/cobicistat, CYP3A inhibitor)	Clinical	Phase 3 trials recruiting May 2020	ChiCTR2000029541 NCT04252274 NCT04303299 NCT04304053	Multiple global research sponsors				FDA-approved since 2015, approved to treat HIV-1 infection	Sources	5/20/2020
71	Treatment	Antivirals	galidesivir	Clinical	Phase 1b recruiting May 2020	NCT03891420	BioCryst Pharmaceuticals	National Institute of Allergy and Infectious Diseases (NIAID)		Treatment of yellow fever	N/A	Sources	5/7/2020
72	Treatment	Antivirals	Ganovo (danoprevir), hepatitis C virus NS3 protease inhibitor; ritonavir; interferon, approved in China to treat Hepatitis C	Clinical	Small open label trial completed and results released in March 2020; Larger open label trial recruiting May 2020	NCT04291729 NCT04345276	Ascletis/Chinese research sponsors		medRxiv (https://doi.org/10.1101/2020.03.22.20034041)	Treatment of Hepatitis C	N/A	Sources	5/7/2020
73	Treatment	Antivirals	ASC09, HIV protease inhibitor	Clinical	Phase 3 trial recruiting May 2020	NCT04261907 NCT04261270	Ascletis/Chinese research sponsors			Treatment of HIV/AIDS	N/A	Sources	5/7/2020
74	Treatment	Antivirals	Truvada (emtricitabine and tenofovir, both HIV-1 nucleoside analog reverse transcriptase inhibitors)	Clinical	Phase 3 trial recruiting May 2020	ChiCTR2000029468 NCT04334928	Plan Nacional sobre el Sida				FDA-approved since 2004, approved to treat and prevent HIV-1 infection	Sources	5/7/2020
75	Treatment	Antivirals	Arbidol (umifenovir), licensed in Russia and China for treatment of respiratory viral infections	Clinical	Phase 4 trials recruiting May 2020	NCT04252885 NCT04350684 NCT04286503 NCT04260594 NCT04273763	Multiple global research sponsors		medRxiv (https://doi.org/10.1101/2020.03.19.20038984) Chinese Journal of Infectious Diseases (http://rs.yiigle.com/yufabiao/1182592.htm) medRxiv (https://doi.org/10.1101/2020.03.17.20037432) medRxiv (https://doi.org/10.1101/2020.03.28.20045955) medRxiv (https://doi.org/10.1101/2020.04.08.20057539) medRxiv (https://doi.org/10.1101/2020.04.06.20042580) medRxiv (https://doi.org/10.1101/2020.04.11.20056523) medRxiv (https://doi.org/10.1101/2020.04.25.20079079)		N/A	Sources	5/7/2020
76	Treatment	Antivirals	Vicromax, broad spectrum antiviral	Pre-clinical			ViralClear Pharmaceuticals					Sources	Prior to 4/20/2020
77	Treatment	Antivirals	ISR-50	Pre-clinical			ISR Immune System Regulation				N/A	Sources	Prior to 4/20/2020
78	Treatment	Antivirals	Tamiflu (oseltamivir), neuraminidase inhibitor	Clinical	REMAP-CAP trial recruiting May 2020	NCT04303299 NCT04255017 NCT04261270 NCT02735707 NCT04338698 NCT04371601	Roche; REMAP-CAP global trial		medRxiv (https://doi.org/10.1101/2020.03.28.20045955) medRxiv (https://doi.org/10.1101/2020.04.11.20056523)		FDA-approved since 1999, approved to treat and prevent influenza	Sources	5/7/2020
79	Treatment	Antivirals	antiviral Fc conjugates	Pre-clinical			Cidara Therapeutics				N/A	Sources	Prior to 4/20/2020
80	Treatment	Antivirals	Antiviral compounds	Pre-clinical			Cocrystal Pharma				N/A	Sources	Prior to 4/20/2020
81	Treatment	Antivirals	EIDD-2801, oral ribonucleoside analog	Clinical	Phase 1 started April 2020		Ridgeback Biotherapeutics / Drug Innovation Ventures at Emory (DRIVE)				N/A	Sources	Prior to 4/20/2020
82	Treatment	Antivirals	Virazole (ribavirin for inhalation solution)	Clinical / Compassionate Use	Phase 1 recruiting May 2020	NCT04356677	Bausch Health				FDA-approved since 1985, approved to treat lower respiratory tract infections due to RSV	Sources	5/7/2020
83	Treatment	Antivirals	Antiviral drug combinations	Pre-clinical			SCORE consortium (universities of Aix-Marseille, Leuven, Utrecht, Bern, and Lubeck), the Helmholtz Centre for Infection Research, and Janssen Pharmaceutica NV	EU Commission (Horizon 2020 Program)			Unknown	Sources	Prior to 4/20/2020
84	Treatment	Antivirals	Levovir (clevudine)	Clinical	Phase 2 trial not yet recruiting	NCT04347915	Bukwang Pharm					Sources	5/7/2020
85	Treatment	Antivirals	AB001	Pre-clinical	Phase 1 to start in 2020		Agastiya Biotech				N/A	Sources	4/24/2020
86	Treatment	Antivirals	BTL-tml	Clinical	Has been used in 36 patients anecdotally		Beech Tree Labs			Treatment of herpes virus infections	N/A	Sources	5/5/2020
87	Treatment	Antivirals	DAS181, recombinant sialidase (nebulized)	Compassionate Use/ Clinical	Compassionate use finding released in May 2020; Phase 2/3 started enrolling in May 2020	NCT03808922 NCT04354389 NCT04298060 NCT04324489	Ansun Biopharma/ Renmin Hospital of Wuhan University		PR Newswire (https://www.prnewswire.com/news-releases/ansun-biopharma-announces-positive-results-from-investigator-initiated-trial-of-novel-covid-19-treatment-301033871.html)	Treatment of lower respiratory tract parainfluenza virus infections and severe influenza infections	N/A	Sources	5/5/2020
88	Treatment	Antivirals	emetine hydrochloride	Clinical	Phase 2/3 to start in Q3 2020		Acer Therapeutics/ US National Center for Advancing Translational Sciences (NCATS)			To treat viral hepatitis and varicella-virus	N/A	Sources	5/13/2020
89	Treatment	Antivirals	AT-527, oral purine nucleotide prodrug	Clinical	Phase 2 trial to start May 2020	NCT04396106	Atea Pharmaceuticals			Treatment of Hepatitis C infections	N/A	Sources	5/21/2020
90	Treatment	Cell-based therapies	PLX cell product, placenta-based cell therapy	Clinical/ Compassionate Use	Results from compassionate use released in April 2020		Pluristem Therapeutics/BIH Center for Regenerative Therapy/Berlin Center for Advanced Therapies		Pluristem Therapeutics (https://www.pluristem.com/wp-content/uploads/2020/04/PSTI-PR-Follow-up-on-Covid-19-treatments-FINAL-FOR-RELEASE.pdf)	Various conditions	N/A	Sources	5/8/2020
91	Treatment	Cell-based therapies	Mesenchymal stem cells	Clinical	Phase 1 trials ongoing May 2020; Phase 1/2 trials recruiting May 2020; Phase 2/3 trial recruiting May 2020	30 trials listed in clinicaltrials.gov ChiCTR2000029990 NCT04315987 NCT04302519 NCT04288102 NCT04313322 NCT04273646 NCT04371601 NCT04315987 NCT04252118 NCT04336254 NCT04339660 NCT04371601 NCT04366063	Numerous trials with global research sponsors		Aging and Disease (http://www.aginganddisease.org/article/0000/2152-5250/ad-0-0-216.shtml) ChinaXiv (http://chinaxiv.org/abs/202002.00084)		N/A	Sources	5/8/2020
92	Treatment	Cell-based therapies	Autologous Adipose-Tissue Derived Mesenchymal Stem Cells (ADMSCs)	Expanded access			Celltex		Celltex (https://celltexbank.com/transplantation-of-ace2-mesenchymal-stem-cells-improves-the-outcome-of-patients-with-covid-19-pneumonia/) Celltex (https://celltexbank.com/chinaxiv-reports-clinical-remission-of-a-critically-ill-covid-19-patient-treated-by-human-umbilical-cord-mesenchymal-stem-cells/)	Injuries, Pain, and Autoimmune, Vascular and Other Disease, including Inflammatory lung conditions, pneumonia, and chronic obstructive pulmonary disease (COPD)	N/A	Sources	5/13/2020
93	Treatment	Cell-based therapies	Ryoncil (remestemcel-L), allogenic mesenchymal stem cells	Clinical/ Compassionate Use/ Expanded Access	Compassionate use data shared April 2020; Phase 3 trial recruiting May 2020	NCT04366830 NCT04371393	Mesoblast/ Cardiothoracic Surgical Trials Network		Mesoblast (http://investorsmedia.mesoblast.com/static-files/337e723a-340d-493e-a4a1-0971d2c71460)	Graft versus host disease and other rare diseases, chronic obstructive pulmonary disease	N/A	Sources	5/7/2020
94	Treatment	Cell-based therapies	MultiStem, bone marrow stem cells	Clinical	Phase 2/3 trial recruiting May 2020	NCT04367077	Athersys / The University of Texas Health Science Center at Houston	Medical Technology Enterprise Consortium (MTEC)		Acute Respiratory Distress Syndrome; Stroke		Sources	5/10/2020
95	Treatment	Cell-based therapies	Allogeneic T-cell therapies	Pre-clinical			AlloVir/Baylor College of Medicine				N/A	Sources	Prior to 4/20/2020
96	Treatment	Cell-based therapies	Natural killer cell-based therapy	Pre-clinical	Begin Phase 1 by end of 2020		GC LabCell / KLEO Pharmaceuticals				N/A	Sources	Prior to 4/20/2020
97	Treatment	Cell-based therapies	CYNK-001, allogeneic, natural killer cell therapy	Clinical	Phase 1/2 study not yet recruiting May 2020	NCT04365101	Celularity/ Lung Biotechnology PBC			Various hematologic cancers and solid tumors	N/A	Sources	5/7/2020
98	Treatment	Cell-based therapies	CAP-1002, allogenic cardiosphere-derived cells	Expanded access	Expanded access trial ongoing May 2020	NCT04338347	Capricor Inc.			Duchenne muscular dystrophy	N/A	Sources	5/7/2020
99	Treatment	Cell-based therapies	haNK, natural killer cells	Clinical			ImmunityBio / NantKwest				N/A	Sources	5/21/2020
100	Treatment	Cell-based therapies	Bone marrow-derived allogenic mesenchymal stem cells (BM-Allo-MSC)	Pre-clinical	Phase 1b trial to start in Q2 2020		ImmunityBio/ NantKwest/ Be The Match BioTherapies				N/A	Sources	5/21/2020
101	Treatment	Cell-based therapies	Allogenic, adipose-derived mesenchymal stem cells (HB-adMSCs)	Clinical	Phase 2 started in April 2020	NCT04348435 NCT04349631 NCT04362189	Hope Biosciences	Hope Biosciences Stem Cell Research Foundation		Rheumatoid arthritis	N/A	Sources	4/24/2020
102	Treatment	Cell-based therapies	Astrostem-V, Allogenic, adipose-derived mesenchymal stem cells (HB-adMSCs)	Clinical	Phase 1/2a trial approved by South Korea Ministry of Food and Drug Safety in March 2020		Naturecell				N/A	Sources	5/7/2020
103	Treatment	Cell-based therapies	AmnioBoost, concentrated allogeneic MSCs and cytokines derived from amniotic fluid	Clinical	Phase 1 enrolling April 2020		Lattice Biologics				N/A	Sources	4/23/2020
104	Treatment	Cell-based therapies	Chimeric antigen receptors (CAR)/T cell receptors (TCR)-T cell therapy	Pre-clinical			Duke-NUS Medical School				N/A	Sources	4/30/2020
105	Treatment	RNA-based treatments	RNAi - testing 150 RNAis	Pre-clinical			Sirnaomics				N/A	Sources	Prior to 4/20/2020
106	Treatment	RNA-based treatments	VIR-2703 (ALN-COV) siRNA candidate	Pre-clinical	Phase 1 to start by the end of 2020		Vir Biotech / Alnylam Pharmaceuticals				N/A	Sources	5/5/2020
107	Treatment	RNA-based treatments	Ampligen; (rintatolimod)	Pre-clinical			AIM ImmunoTech/National Institute of Infectious Diseases in Japan				N/A	Sources	Prior to 4/20/2020
108	Treatment	RNA-based treatments	OT-101, a TGF-Beta antisense drug candidate	Clinical	Phase 2 study IND submitted to FDA on April 27, 2020		Mateon Therapeutics			Various cancers	N/A	Sources	5/7/2020
109	Treatment	RNA-based treatments	Inhaled mRNA	Pre-clinical	Phase 1 to start Q4 2020		Neurimmune / Ethris				N/A	Sources	Prior to 4/20/2020
110	Treatment	RNA-based treatments	Antisense oligonucleotides, peptide conjugated	Pre-clinical			Sarepta Therapeutics/ US Army Medical Research Institute of Infectious Diseases (USAMRIID)				N/A	Sources	5/1/2020
111	Treatment	Scanning compounds to repurpose	Scanning library of antiviral compounds	Pre-clinical			Janssen Pharmaceutical Companies	Biomedical Advanced Research and Development Authority (BARDA)		N/A	N/A	Sources	Prior to 4/20/2020
112	Treatment	Scanning compounds to repurpose	Scanning compounds to repurpose	Pre-clinical			Novartis			N/A	N/A	Sources	Prior to 4/20/2020
113	Treatment	Scanning compounds to repurpose	Scanning antiviral compounds previously in development	Pre-clinical	Lead candidate (protease inhibitor) to start Phase 1 trial in Q3 2020		Pfizer			N/A	N/A	Sources	Prior to 4/20/2020
114	Treatment	Scanning compounds to repurpose	Scanning compounds to repurpose	Pre-clinical			Merck			N/A	N/A	Sources	Prior to 4/20/2020
115	Treatment	Scanning compounds to repurpose	Repurposing antiviral drug candidates	Pre-clinical			Materia Medica/Cyclica			N/A	N/A	Sources	Prior to 4/20/2020
116	Treatment	Scanning compounds to repurpose	Screening new drugs + library of antiviral compounds	Pre-clinical			Enanta Pharmaceuticals			N/A	N/A	Sources	Prior to 4/20/2020
117	Treatment	Scanning compounds to repurpose	Screening drug compounds	Pre-clinical			Southwest Research Institute			N/A	N/A	Sources	Prior to 4/20/2020
118	Treatment	Scanning compounds to repurpose	Scanning compounds to repurpose	Pre-clinical			Takeda			N/A	N/A	Sources	Prior to 4/20/2020
119	Treatment	Scanning compounds to repurpose	Scanning compounds to repurpose	Pre-clinical			Queens University Belfast	UK Government		N/A	N/A	Sources	Prior to 4/20/2020
120	Treatment	Scanning compounds to repurpose	Scanning compound libraries	Pre-clinical			COVID-19 Therapeutics Accelerator (15 companies shared their compound libraries including BD, bioMérieux, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck [known as MSD outside the US and Canada], Merck KGaA, Novartis, Pfizer, and Sanofi)/ Fujifilm Diosynth Biotechnologies	Gates Foundation / Wellcome / Mastercard Impact Fund		N/A	N/A	Sources	5/1/2020
121	Treatment	Scanning compounds to repurpose	Artificial intellegence-based screening to identify repurposed drug combinations	Pre-clinical	Combinations will be ready for preclinical testing in May 2020		Healx			N/A		Sources	Prior to 4/20/2020
122	Treatment	Scanning compounds to repurpose	Identifying drugs to repurpose	Pre-clinical			The Castleman Disease Collaborative Network and the Center for Study & Treatment of Inflammatory Lymphadenopathies					Sources	Prior to 4/20/2020
123	Treatment	Scanning compounds to repurpose	Screening for antiviral drug candidates	Pre-clinical			Anixa Biosciences/ OntoChem					Sources	4/21/2020
124	Treatment	Scanning compounds to repurpose	Identifying drugs to repurpose	Pre-clinical	Identified 30 known drugs that inhibit SARS-CoV-2 replication		Sanford Burnham Prebys Medical Discovery Institute, the University of Hong Kong, Scripps Research, UC San Diego School of Medicine, the Icahn School of Medicine at Mount Sinai and UCLA		bioRxiv (https://doi.org/10.1101/2020.04.16.044016)			Sources	4/21/2020
125	Treatment	Scanning compounds to repurpose	AI-based screening to identify a peptide cocktail	Pre-clinical			Nuritas	Partnership for Advanced Computing in Europe (PACE)			N/A	Sources	4/24/2020
126	Treatment	Scanning compounds to repurpose	Identify anti-coronavirus compounds that target cellular host genes	Pre-clinical			Vir Biotechnology/ GSK				N/A	Sources	4/29/2020
127	Treatment	Scanning compounds to repurpose	Screening of drug compounds	Pre-clinical			Vanda Pharmaceuticals/ University of Illinois at Chicago				N/A	Sources	4/29/2020
128	Treatment	Scanning compounds to repurpose	Identify novel drugs	Pre-clinical			Shionogi/ Hokkaido University Research Center for Zoonosis Control				N/A	Sources	4/29/2020
129	Treatment	Other	Methylprednisolone / ciclesonide (Alvesco)/ hydrocortisone/ corticosteroids	Clinical	Primary study ends April 2020 (Peking) / June 2020 (Tongji)/ RECOVERY trial results expected by June 2020	NCT04244591 NCT04263402 NCT04273321 ChiCTR2000029656 ChiCTR2000029386 NCT02735707 NCT04330586 2020-001113-21 NCT04345445 NCT04349410 NCT04329650	Numerous trials with research sponsors globally; University of Oxford RECOVERY trial; REMAP-CAP global trial; Covis Pharma B.V.	UK Government (University of Oxford RECOVERY trial)	medRxiv (https://doi.org/10.1101/2020.03.06.20032342) medRxiv (https://doi.org/10.1101/2020.03.28.20045955) medRxiv (https://doi.org/10.1101/2020.04.07.20056390) medRxiv (https://doi.org/10.1101/2020.04.17.20064469) medRxiv (https://doi.org/10.1101/2020.04.17.20069773) medRxiv (https://doi.org/10.1101/2020.04.21.20066258) medRxiv (https://doi.org/10.1101/2020.05.04.20074609) medRxiv (https://doi.org/10.1101/2020.05.08.20094755) medRxiv (https://doi.org/10.1101/2020.05.11.20097709)		FDA-approved since at least the 1950s, approved to treat many diseases, including anti-iflammatory conditions and some cancers; asthma (ciclesconide)	Sources	5/21/2020
130	Treatment	Other	Chloroquine/ Hydroxychloroquine, antimalarial	Clinical / FDA issued an Emergency Use Authorization on March 28, 2020 (oral formulations of chloroquine phosphate and hydoxychloroquine sulfate donated to the Strategic National Stockpile to treat adolescent and adult hospitalized patients with COVID-19 when a clinical trial is not available or feasible)	Results from the University of Washington/New York University trial expected in summer 2020; RECOVERY trial results expected by June 2020	Over 50 trials registered at Clinicaltrials.gov, including: NCT04261517 NCT04303507 NCT04303299 NCT04304053 NCT04307693 NCT04316377 NCT04315948 NCT04321993 2020-001113-21 NCT04323527 NCT04333732 NCT04332991 NCT04345419 NCT04341870 NCT04345289 NCT02735707 NCT04351347 NCT04341493 NCT04332094 NCT04349410 NCT04286503 NCT04328012 NCT04346147	Numerous trials with global research sponsors; University of Minnesota; University of Washington/New York University (hydroxychloroquine); University of Oxford; IHU-Méditerranée Infection and others; World Health Organization SOLIDARITY trial (chloroquine); New York State Department of Health (hydroxychloroquine with zithromax); Mahidol Oxford Tropical Medicine Research Unit (hydroxychloroquine and chloroquine); ORCHID Trial with National Heart, Lung, and Blood Institute (NHLBI); REMAP-CAP global trial; Novartis; PRINCIPLE trial	COVID-19 Treatment Accelerator (University of Washington/New York University trial and Mahidol Oxford Tropical Medicine Research Unit trial); UK Government (University of Oxford RECOVERY trial and PRINCIPLE trial)	NCT04261517 (https://clinicaltrials.gov/ct2/show/NCT04261517?draw=5+%28prelim+outcomes%3F%29) IHU-Méditerranée Infection (https://www.mediterranee-infection.com/wp-content/uploads/2020/03/Hydroxychloroquine_final_DOI_IJAA.pdf) Journal of ZheJiang University (Medical Sciences) (http://www.zjujournals.com/med/CN/10.3785/j.issn.1008-9292.2020.03.03) medRxiv (https://doi.org/10.1101/2020.03.22.20040758) Int'l Journal of Antimicrobial Agents (https://doi.org/10.1016/j.ijantimicag.2020.105949) medRxiv (ChiCTR2000029559) (https://doi.org/10.1101/2020.04.10.20060558) medRxiv (https://doi.org/10.1101/2020.03.22.20040949) medRxiv (https://doi.org/10.1101/2020.04.02.20047050) medRxiv (https://doi.org/10.1101/2020.03.31.20048777) medRxiv (https://doi.org/10.1101/2020.03.24.20042366) medRxiv (NCT04323527) (https://doi.org/10.1101/2020.04.07.20056424) medRxiv (https://doi.org/10.1101/2020.04.08.20057539) medRxiv (https://doi.org/10.1101/2020.04.08.20054551) ScienceDirect (https://www.sciencedirect.com/science/article/pii/S0399077X20300858?via%3Dihub) ISAC (https://www.isac.world/news-and-publications/official-isac-statement) ScienceDirect (https://www.sciencedirect.com/science/article/pii/S0924857920300996) medRxiv (https://doi.org/10.1101/2020.04.10.20060699) medRxiv (ChiCTR2000029868) (https://doi.org/10.1101/2020.04.10.20060558) medRxiv (https://doi.org/10.1101/2020.04.14.20065276) medRxiv (https://doi.org/10.1101/2020.04.16.20065920) medRxiv (https://doi.org/10.1101/2020.04.16.20068205) medRxiv (https://doi.org/10.1101/2020.04.22.20075671) medRxiv (https://doi.org/10.1101/2020.04.21.20066761) medRxiv (https://doi.org/10.1101/2020.04.26.20081059) medRxiv (https://doi.org/10.1101/2020.04.27.20082180) medRxiv (https://doi.org/10.1101/2020.04.27.20073379) medRxiv (https://doi.org/10.1101/2020.04.27.20074583) NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2012410) medRxiv (https://doi.org/10.1101/2020.05.02.20080036) medRxiv (https://doi.org/10.1101/2020.05.02.20088872) JAMA (https://jamanetwork.com/journals/jama/fullarticle/2766117) medRxiv (https://doi.org/10.1101/2020.05.07.20093831) medRxiv (https://doi.org/10.1101/2020.05.07.20094326) medRxiv (https://doi.org/10.1101/2020.05.05.20088757) BMJ (https://www.bmj.com/content/369/bmj.m1849) BMJ (https://www.bmj.com/content/369/bmj.m1844) medRxiv (https://doi.org/10.1101/2020.05.14.20101774) medRxiv (https://doi.org/10.1101/2020.05.12.20099028) medRxiv (https://doi.org/10.1101/2020.05.13.20094193)		FDA-approved since 1949, approved to treat malaria (chloroquine), FDA-approved since at least 1955, approved to treat malaria, rheumatoid arthritis, and lupus (hydroxychloroquine)	Sources	5/20/2020
131	Treatment	Other	camostat mesylate, transmembrane protease serine 2 (TMPRSS2) inhibitor, approved in Japan to treat multiple conditions including pancreatitis	Clinical	Phase 1/2, Phase 2, and Phase 3 trials recruiting in May 2020	NCT04321096 NCT04353284 NCT04338906 NCT04374019 NCT04355052	Multiple global research sponsors				N/A	Sources	5/7/2020
132	Treatment	Other	Jakafi/jakavi (ruxolitinib)	Clinical / Expanded Access	Novartis/Incyte Phase 3 trial started April 2020	ChiCTR2000029580 NCT04334044 NCT04331665 NCT04337359 NCT04348071 NCT04338958 NCT04348695 NCT04355793 NCT04354714 NCT04377620 NCT04362137 NCT04366232 NCT04361903 NCT04374149 NCT04338958 NCT04359290	Novartis / Incyte, numerous researchers globally				FDA-approved since 2011, approved to treat myelofibrosis, polycythemia vera, and acute graft-versus-host disease	Sources	5/8/2020
133	Treatment	Other	interferon/peginterferon alpha-2b, PegIntron, Sylatron, IntronA, PegiHep	Clinical	Phase 2/3 enrolling May 2020	NCT04273763 NCT04349410	Zydus Cadila Group; The Camelot Foundation				PegIntron - FDA-approved since 2001, approved to treat Hepatitis C; Sylatron - FDA-approved since 2001, approved for the adjuvant treatment of melanoma; Intron A - FDA-approved since 1986, approved to treat Hepatitis C and certain cancers	Sources	5/7/2020
134	Treatment	Other	Novaferon, Nova, interferon, licensed in China for Hepatitis B	Clinical		ChiCTR2000029573 ChiCTR2000029496	Hu'nan Haiyao hongxingtang Pharmaceutical Co., Ltd (Novaferon)		medRxiv (https://doi.org/10.1101/2020.04.24.20077735)		N/A	Sources	5/7/2020
135	Treatment	Other	Traumakine (interferon beta 1-a)	Clinical	REMAP-CAP trial recruiting May 2020	NCT02735707	Faron Pharmaceuticals / REMAP-CAP global trial/ WHO SOLIDARITY trial				N/A	Sources	5/7/2020
136	Treatment	Other	Recombinant human interferon alpha-1b	Clinical	Phase 3 trial recruiting May 2020	NCT04320238	Shanghai Jiao Tong University School of Medicine		medRxiv (https://doi.org/10.1101/2020.04.11.20061473)			Sources	5/7/2020
137	Treatment	Other	SNG001, inhaled formulation of interferon beta-1a	Clinical	Phase 2 began in March 2020; initial results expected by end of June 2020		Synairgen / University of Southampton			Asthma patients with cold or flu infection; COPD patients with viral infections	N/A	Sources	5/8/2020
138	Treatment	Other	Peginterferon lambda	Clinical	Phase 2 began in April 2020	NCT04331899	Eiger BioPharmaceuticals, Inc.			Hepatitis Delta		Sources	Prior to 4/20/2020
139	Treatment	Other	Cerocal (ifenprodil), NP-120, an NDMA receptor glutamate receptor antagonist targeting Glu2NB	Pre-clinical			Algernon Pharmaceuticals			Idiopathic Pulmonary Fibrosis	N/A	Sources	Prior to 4/20/2020
140	Treatment	Other	APN01; recombinant soluble human Angiotensin Converting Enzyme 2	Clinical	Phase 2 began in April 2020		University of British Columbia/Apeiron Biologics	Austrian Government		Acute lung injury, Acute respiratory distress syndrome, Pulmonary arterial hypertension	N/A	Sources	Prior to 4/20/2020
141	Treatment	Other	Brilacidin, a defensin mimetic	Clinical			Innovation Pharmaceuticals			Oral Mucositis; Ulcerative Proctitis/Ulcerative Proctosigmoiditis; Acute Bacterial Skin and Skin Structure Infection	N/A	Sources	4/28/2020
142	Treatment	Other	BXT-25; glycoprotein	Pre-clinical			Bioxytran				N/A	Sources	Prior to 4/20/2020
143	Treatment	Other	Peptides targeting the NP protein	Pre-clinical			CEL-SCI / University of Georgia Center for Vaccines and Immunology				Unknown	Sources	Prior to 4/20/2020
144	Treatment	Other	BIO-11006, inhaled peptide	Clinical			Biomarck Pharmaceuticals			Acute Respiratory Distress Syndrome; Non-Small Cell Lung Cancer; Chronic Obstructive Pulmonary Disease (COPD)	N/A	Sources	4/24/2020
145	Treatment	Other	Gilenya (fingolimod), sphingosine 1-phosphate receptor modulator	Clinical	Phase 2 trial recruiting May 2020	NCT04280588	The First Affiliated Hospital of Fujian Medical University/Novartis				FDA-approved since 2010, approved to treat multiple sclerosis	Sources	5/7/2020
146	Treatment	Other	WP1122, glucose decoy prodrug (and related drug candidates)	Pre-clinical			Moleculin Biotech / University of Texas Medical Branch				N/A	Sources	Prior to 4/20/2020
147	Treatment	Other	Rebif (interferon beta-1a)	Clinical	Phase 3 trial recruiting May 2020	EudraCT 2020-000936-23 NCT04315948	Institut National de la Sante et de la Recherche Medicale (Merck KGaA)				FDA-approved since 2002, approved to treat multiple sclerosis	Sources	5/7/2020
148	Treatment	Other	nafamostat, approved in Japan to treat pancreatitis and other diseases	Clinical	University of Tokyo trial (IV formulation) starts April 2020; Ensysce trial will be with oral formulation		University of Tokyo/ National Center for Global Health and Medicine/ Ensysce Biosciences/ Institut Pasteur Korea				N/A	Sources	5/19/2020
149	Treatment	Other	A number of synthesized nanoviricide drug candidates	Pre-clinical			NanoViricides				N/A	Sources	Prior to 4/20/2020
150	Treatment	Other	Cozaar (losartan), angiotensin II receptor blocker (ARB)	Clinical	Phase 2 and Phase 2/3 and Phase 4 trials recruiting in May 2020	NCT04312009 NCT04311177 NCT04349410 NCT04335123 NCT04343001 NCT04328012 NCT04340557	Multiple global research sponsors	COVID-19 Treatment Accelerator			FDA-approved since 1995, approved to treat hypertension and diabetic nephropathy	Sources	5/8/2020
151	Treatment	Other	Diovan (valsartan), angiotensin II receptor blocker (ARB)	Clinical	Phase 4 trials recruiting May 2020	NCT04335786 NCT04330300	Multiple global research sponsors				FDA-approved since 1996, approved to treat hypertension, treat heart failure, and reduce cardiovascular mortality in patients after myocardial infarction	Sources	5/8/2020
152	Treatment	Other	Micardis (telmisartan)	Clinical	Phase 2 not yet recruiting as of April 2020	NCT04360551	University of Hawaii (Boehringer Ingelheim)				FDA-approved since 1998, approved to treat hypertension and reduce cardiovascular risk in patients unable to take ACE inhibitors	Sources	4/27/2020
153	Treatment	Other	Activase (alteplase), tissue plasminogen activator (tPA)	Compassionate Use			Beth Israel Deaconess, the University of Colorado Anschultz Medical Campus, and Denver Health (Genentech)				FDA-approved since 1987, approved to treat stroke, myocardial infarction, and pulmonary embolism	Sources	Prior to 4/20/2020
154	Treatment	Other	Leukine (sargramostim, rhu-Granulocyte macrophage colony stimulating factor )	Clinical		NCT04326920	Partner Therapeutics			Pulmonary conditions that affect alveolar macrophases (nebulized leukine); ARDS (IV leukine)	FDA-approved since 1991, approved to shorten the time to neutrophil recovery and reduce the incidence of infections following chemotherapy, mobilize hematopoietic progenitor cells, accelerate myeloid reconstitution following bone marrow or cell transplantation, treat delayed neutrophil recovery or graft failure after bone marrow transplantation, and increase survival of radiation	Sources	Prior to 4/20/2020
155	Treatment	Other	Kineret (anakinra), interleukin-1 receptor antagonist	Clinical		NCT04324021 NCT02735707 NCT04339712 NCT04330638 NCT04366232	Swedish Orphan Biovitrum / REMAP-CAP global trial		medRxiv (https://doi.org/10.1101/2020.04.23.20076612)		FDA-approved since 2001, approved to treat rheumatoid arthritis and cryopyrin-associated periodic syndromes	Sources	5/7/2020
156	Treatment	Other	AT-001, aldose reductase inhibitor	Clinical / Compassionate Use			Applied Therapeutics / numerous New York City hospitals			Diabetic cardiomyopathy	N/A	Sources	Prior to 4/20/2020
157	Treatment	Other	Aplidin (plitidepsin), approved in Australia to treat multiple myeloma	Clinical			PharmaMar					Sources	Prior to 4/20/2020
158	Treatment	Other	dipyridamole (Persantine), anticoagulant	Clinical			Numerous Chinese hospitals		medRxiv (https://doi.org/10.1101/2020.02.27.20027557)		FDA-approved since 1961, approved to prevent postoperative thromboembolic complications of cardiac valve replacement	Sources	Prior to 4/20/2020
159	Treatment	Other	recombinant human plasma gelsolin (rhu-pGSN)	Clinical			BioAegis Therapeutics Inc.			Community-acquired pneumonia	N/A	Sources	Prior to 4/20/2020
160	Treatment	Other	solnatide (synthetic molecule with a structure based on the lectin-like domain of human Tumour Necrosis Factor alpha)	Clinical			Apeptico	EU Commission (Horizon 2020 Program)		Pneumonia, sepsis, ARDS, Primary Graft Dysfunction, and pulmonary dysfunctions	N/A	Sources	Prior to 4/20/2020
161	Treatment	Other	Nitric oxide	Clinical		NCT04305457 NCT04312243 NCT04306393 NCT03331445	Massachusetts General Hospital; University of British Columbia				FDA-approved since 1999, approved to improve oxygenation in neonates	Sources	Prior to 4/20/2020
162	Treatment	Other	PP-001	Clinical			Panoptes Pharma GmbH			Severe eye diseases	N/A	Sources	Prior to 4/20/2020
163	Treatment	Other	ARMS-1	Clinical	Trial starts April 2020		ARMS Pharmaceutical / UH Cleveland Medical Center / Case Western Reserve University	Cleveland Foundation		Influenza prophylaxis	N/A	Sources	Prior to 4/20/2020
164	Treatment	Other	PUL-042 inhalation solution	Clinical		NCT04312997	Pulmotect			Prevent and treat respiratory complications in immunosuppressed cancer patients	N/A	Sources	Prior to 4/20/2020
165	Treatment	Other	Olumiant (baricitinib), Janus kinase (JAK) inhibitor	Clinical	NIAID trial remdesivir + baricitinib recruiting May 2020	NCT04321993 NCT04320277 NCT04340232 NCT04280705 NCT04345289 NCT04346147 NCT04358614 NCT04373044	National Institute of Allergy and Infectious Disease (NIAID)'s Adaptive COVID-19 Treatment Trial; Nova Scotia Health Authority; Hospital of Prato; University of Colorado (Eli Lilly)				FDA-approved since 2018, approved to treat rheumatoid arthritis	Sources	5/13/2020
166	Treatment	Other	Xeljanz (tofacitinib), Janus kinase (JAK) inhibitor	Clinical		NCT04332042	Pfizer				FDA-approved since 2012, approved to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis	Sources	Prior to 4/20/2020
167	Treatment	Other	colchicine	Clinical		NCT04326790 NCT04328480 NCT04322565 NCT04322682	Numerous research sponsors globally				N/A (but has been used in the US since the early 1800s, and FDA-approved in combination with probenecid, approved to treat gout)	Sources	Prior to 4/20/2020
168	Treatment	Other	heparin; low molecular weight heparin (enoxaparin), anticoagulant	Clinical		NCT04366960 NCT04360824 NCT04359277 NCT04354155 NCT04367831 NCT04345848 NCT04373707 NCT04372589 NCT04362085 NCT04344756	Multiple global research sponsors		medRxiv (https://doi.org/10.1101/2020.03.28.20046144) medRxiv (https://doi.org/10.1101/2020.04.15.20067017) medRxiv (https://doi.org/10.1101/2020.04.23.20076851) JACC (http://www.onlinejacc.org/content/early/2020/05/05/j.jacc.2020.05.001?_ga=2.52741547.2046438614.1588863110-2104341714.1587686709)		FDA-approved since at least 1993, approved to prevent blood clots and prevent/treat venous thromboembolism and myocardial infarction	Sources	5/10/2020
169	Treatment	Other	DSTAT (dociparstat sodium), glycosaminoglycan derivative of heparin	Clinical	Phase 2/3 study to start in May 2020		Chimerix			Acute myeloid leukemia	N/A	Sources	5/5/2020
170	Treatment	Other	LAU-7b (fenretinide)	Clinical	Phase 2 to start May 2020		Laurent Pharmaceuticals			Treat exaggerated inflammatory response in adult cystic fibrosis patients	N/A	Sources	5/10/2020
171	Treatment	Other	ST-001 nanoFenretinide (fenretinide)	Clinical			SciTech Development, LLC			non-Hodgkin's lymphoma	N/A	Sources	5/13/2020
172	Treatment	Other	Xpovio (selinexor), oral, selective inhibitor of nuclear export (SINE) compound	Clinical			Karyopharm Therapeutics			Treat various cancers	FDA-approved since 2019, approved to treat multiple myeloma	Sources	Prior to 4/20/2020
173	Treatment	Other	BLD-2660, synthetic small molecule inhibitor of calpain (CAPN) 1, 2, and 9	Clinical		NCT04334460	Blade Therapeutics				N/A	Sources	Prior to 4/20/2020
174	Treatment	Other	Calquence (acalabrutinib), Bruton's tyrosine kinase (BTK) inhibitor	Clinical	ACCORD Phase 2 trial to start May 2020	NCT04346199 NCT04380688	AstraZeneca; ACCORD study	UK Government (ACCORD study)			FDA-approved since 2017, approved to treat mantle cell lymphoma and chronic lymphocytic leukemia	Sources	5/10/2020
175	Treatment	Other	CD24Fc, biological immunomodulator (nonpolymorphic regions of CD24 attached to the Fc region of human IgG1)	Clinical	Phase 3 trial started in April 2020	NCT04317040	OncoImmune			Graft versus Host Disease	N/A	Sources	4/24/2020
176	Treatment	Other	Aviptadil, synthetic form of Vasoactive Intestinal Polypeptide	Clinical	Phase 2 trial started in April 2020	NCT04311697	NeuroRx/ Relief Therapeutics/ Thomas Jefferson University Hospital/ NYU Langone Health			Sarcoid, Pulmonary Fibrosis, Bronchospasm, Erectile Dysfunction, and Acute Respiratory Distress Syndrome (ARDS)	N/A	Sources	5/10/2020
177	Treatment	Other	vazegepant, CGRP receptor antagonist	Clinical	Phase 2 to start April 2020		Biohaven / Thomas Jefferson University			Acute migraine		Sources	Prior to 4/20/2020
178	Treatment	Other	CM4620-IE, calcium release-activated calcium (CRAC) channel inhibtor	Clinical	Phase 2 started in April 2020	NCT04345614	CalciMedica			Pancreatitis		Sources	Prior to 4/20/2020
179	Treatment	Other	ivermectin	Clinical		NCT04343092 NCT04345419 NCT04351347	MedinCell/ University of Utah/ Surgisphere Corp; University of Baghdad; Tanta University				FDA-approved since 1996, approved to treat intestinal parasites and head lice infestations	Sources	4/23/2020
180	Treatment	Other	nitazoxanide, antiprotozoal	Clinical		NCT04351347 NCT04348409 NCT04343248 NCT04341493 NCT04345419	Romark Laboratories; various researchers globally				FDA-approved since 2002, approved to treat diarrhea caused by Giardia lamblia or Cryptosporidum parvum	Sources	4/23/2020
181	Treatment	Other	EPAspire, oral formulation of highly purified eicosapentaenoic acid free fatty acid (EPA-FFA) in gastro-resistant capsules	Clinical			KD Pharma / SLA Pharma			Familial adenomatous polyposis	N/A	Sources	Prior to 4/20/2020
182	Treatment	Other	niclosamide	Clinical		NCT04345419	Union Therapeutics/ Institut Pasteur Korea/ Daewoong Therapeutics			Atopic Dermatitis	N/A	Sources	4/24/2020
183	Treatment	Other	ADX-629, orally available reactive aldehyde species (RASP) inhibitor	Clinical	IND submission to FDA in June 2020		Aldeyra Therapeutics			Systemic immune-mediated diseases	N/A	Sources	5/21/2020
184	Treatment	Other	ADX-1612, HSP 90 inhibitor	Clinical	IND submission to FDA in Q3 2020		Aldeyra Therapeutics			Various cancers	N/A	Sources	5/21/2020
185	Treatment	Other	N-803, IL-15 "superagonist"	Clinical			ImmunityBio / NantKwest			Bladder Carcinoma In Situ	N/A	Sources	Prior to 4/20/2020
186	Treatment	Other	piclidenoson, A3 adenosine receptor agonist	Clinical	Pre-IND meeting request filed with FDA in May 2020	NCT04333472	Can-Fite BioPharma			Rheumatoid arthritis; psoriasis	N/A	Sources	5/21/2020
187	Treatment	Other	Ryanodex (dantrolene sodium), skeletal muscle relaxant	Clinical			Eagle Pharmaceuticals / Amneal Pharmaceuticals / Alcami Corporation / Hackensack University Medical Center				FDA-approved since 2014, approved to prevent and treat malignant hyperthermia	Sources	4/21/2020
188	Treatment	Other	Veyonda (idronoxil)	Clinical			Noxopharm			Prostate cancer	N/A	Sources	4/23/2020
189	Treatment	Other	MRx-4DP0004, strain of Bifidobacterium breve isolated from the gut microbiome of a healthy human	Clinical	UK approval to start Phase 2 study in April 2020		4D Pharma			Asthma	N/A	Sources	4/23/2020
190	Treatment	Other	EDP1815, oral single strain of microbe	Clinical	Phase 2 to start and data expected 2H 2020		Evelo Biosciences/ Rutgers University/ Robert Wood Johnson University Hospital			Psoriasis and Atopic Dermatitis		Sources	5/10/2020
191	Treatment	Other	roscovitine seliciclib, cyclin-dependent kinase (CDK)2/9 inhibitor	Clinical			Cyclacel Pharmaceuticals/ University of Edinburgh	LifeArc		Rheumatoid arthritis	N/A	Sources	4/23/2020
192	Treatment	Other	fadraciclib (CYC065), cyclin-dependent kinase (CDK)2/9 inhibitor	Clinical			Cyclacel Pharmaceuticals/ University of Edinburgh	LifeArc		Various cancers	N/A	Sources	4/23/2020
193	Treatment	Other	ATYR1923, fusion protein (immuno-modulatory domain of histidyl tRNA synthetase fused to the Fc region of a human antibody) modulator of neuropilin-2	Clinical	Phase 2 study ~ April/May 2020		aTyr			Pulmonary sarcoidosis	N/A	Sources	4/24/2020
194	Treatment	Other	Farxiga (dapagliflozin), sodium-glucose cotransporter 2 (SGLTs) inhibitor	Clinical	Phase 3 study started in April 2020	NCT04350593	AstraZeneca/ Saint Luke's Mid America Heart Institute			Heart failure; Chronic kidney disease	FDA-approved since 2014, approved to improve glycemic controls in adults with type 2 diabetes and reduce the risk of hospitalization for heart failure in adults with type 2 diabetes	Sources	4/24/2020
195	Treatment	Other	Ruconest (recombinant human C1 esterase inhibitor)	Compassionate Use			Pharming		Pharming (https://www.pharming.com/sites/default/files/imce/Press%20releases/Ruconest%20Covid%20compassionate%20use%2021%20April%202020.pdf)		FDA-approved since 2014, approved to treat hereditary angioedema	Sources	4/24/2020
196	Treatment	Other	DIBI, iron-binding polymer	Pre-clinical			Chelation Partners				N/A	Sources	4/28/2020
197	Treatment	Other	brensocatib, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1)	Clinical	Phase 2 study to begin enrollment in May 2020		Insmed Inc.			Bronchiectasis and other inflammatory diseases	N/A	Sources	4/28/2020
198	Treatment	Other	Pepcid (famotidine), histamine-2 (H2) receptor antagonist	Clinical	Phase 2 study underway in April 2020		Feinstein Institutes for Medical Research at Northwell Health/ Alchem		medRxiv (https://doi.org/10.1101/2020.05.01.20086694)		FDA-approved since 1986, approved to treat ulcers, gastroesophageal reflux disease, erosive esophagitis, pathological hypersecretory conditions, and to reduce the risk of duodenal ulcer recurrence	Sources	5/10/2020
199	Treatment	Other	tradipitant, a neurokinin-1 receptor antagonist	Clinical	Phase 3 trial started in April 2020	NCT04326426	Vanda Pharmaceuticals/ Feinstein Institutes for Medical Research at Northwell Health			Gastroparesis, motion sickness, and atopic dermatitis	N/A	Sources	4/29/2020
200	Treatment	Other	GP1681, small molecule inhibitor of cytokine release	Pre-clinical	Phase 1/2 to start in 2020		Quotient Sciences/ CytoAgents				N/A	Sources	5/21/2020
201	Treatment	Other	Metablok, peptide	Clinical			Arch Biopartners			Lung and Kidney Inflammation	N/A	Sources	4/30/2020
202	Treatment	Other	pacritinib, oral kinase inhibitor with specificity for JAK2, IRAK1 and CSFIR	Clinical	Phase 3 to start in May 2020, results expected by the end of 2020		CTI Biopharma			Myelofibrosis	N/A	Sources	4/30/2020
203	Treatment	Other	Microbiome therapeutic	Pre-clinical	Clinical trials to start in 2020		Persephone Biosciences				N/A	Sources	4/30/2020
204	Treatment	Other	pH barrier, transepithelial nebulized alkaline treatment	Pre-clinical			pHbarrier				N/A	Sources	4/30/2020
205	Treatment	Other	Coronzot, a novel family of drugs, sequestration of the labile iron	Pre-clinical			Silkim Pharma				N/A	Sources	5/1/2020
206	Treatment	Other	Neumifil, multivalent carbohydrate binding molecules	Pre-clinical			Pneumagen Ltd.				N/A	Sources	5/1/2020
207	Treatment	Other	bemcentinib, selective AXL kinase inhibitor	Clinical	Phase 2 top line data expected July-August 2020; ACCORD trial to start May 2020		BerGenBio; ACCORD study	UK Government (ACCORD study)		Various cancers	N/A	Sources	5/10/2020
208	Treatment	Other	Otezla (apremilast), inhibitor of phosphodiesterase 4 (PDE4)	Clinical			Amgen				FDA-approved since 2014, approved to treat psoriatic arthritis, severe plaque psoriasis, and oral ulcers associated with Behcet's Disease	Sources	5/4/2020
209	Treatment	Other	MN-166 (ibudilast), orally bioavailable, small molecule macrophase migration inhibitory factor (MIF) inhibitor and phosphodiesterase (PDE) -4 and -10 inhibitor	Clinical			MediciNova/ Yale			Treatment of numerous neurodegenerative diseases and substance dependence	N/A	Sources	5/5/2020
210	Treatment	Other	Yeliva (opaganib, ABC294640), oral sphingosine kinase-2 (SK2) selective inhibitor	Clinical/ Compassionate Use	Preliminary data from compassionate use released in April 2020		RedHill Biopharma		RedHill Biopharma (https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=15258) RedHill Biopharma (https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=15257) RedHill Biopharma (https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=15261)	Various oncology indications	N/A	Sources	5/8/2020
211	Treatment	Other	RHB-107 (upamostat, WX-671), serine protease inhibitor	Clinical			RedHill Biopharma/ NIAID			Various oncology indications	N/A	Sources	5/8/2020
212	Treatment	Other	ST266, cell-free biologic made from anti-inflammatory proteins secreted by placental cells	Clinical	Phase 1/2 to start in 4Q 2020		Noveome Biotherapeutics	Commonwealth of Pennsylvania		Multiple ophthalmic indications	N/A	Sources	5/10/2020
213	Treatment	Other	Lysteda/Cyklokapron (tranexamic acid), an antifibrinolytic	Clinical	Phase 2 not yet recruiting May 2020	NCT04338074 NCT04338126	University of Alabama at Birmingham				FDA-approved since 1986, approved to treat cyclic heavy menstrual bleeding	Sources	5/13/2020
214	Treatment	Other	senicapoc	Clinical			Aarhus University	The Danish Government		Sickle cell anemia; Alzheimer's disease	N/A	Sources	5/14/2020
215	Treatment	Other	Luvox (fluvoxamine), a selective serotonin reuptake inhibitor	Clinical	Phase 2 trial recruiting May 2020	NCT04342663	Washington University School of Medicine in St. Louis				FDA-approved since 1994, approved to treat obsessive compulsive disorder	Sources	5/14/2020
216	Treatment	Other	Gleevac (imatinib), kinase inhibitor	Clinical	Phase 2 trial recruiting May 2020	NCT04346147 NCT04357613 NCT04356495	Exvastat Ltd/ Global sponsors	Innovative Medicines Initiative			FDA-approved since 2001, approved to treat various cancers	Sources	5/14/2020
217	Treatment	Other	ABX464	Clinical	Phase 2b/3 trial cleared by French regulatory agency in May 2020		Abivax	Bpifrance		Ulcerative colitis; rheumatoid arthritis; hepatocellular carcinoma	N/A	Sources	5/19/2020
218	Treatment	Other	IMU-838, selective oral dihydroorotate dehydrogenase (DHODH) inhibitor	Clinical	Phase 2 trial cleared by German regulatory agency in May 2020		Immunic, Inc.			Ulcerative colitis; remitting multiple sclerosis	N/A	Sources	5/19/2020
219	Treatment	Other	sPIF (synthetic pre implantation factor)	Pre-clinical	Preparing for a Phase 1/2a trial in May 2020		BioIncept				N/A	Sources	5/20/2020
220	Treatment	Device	CytoSorb (blood purification device, extracorporeal cytokine adsorber))	FDA issued an Emergency Use Authorization on April 10, 2020 / Clinical / Compassionate Use		NCT04324528 ChiCTR2000030475 NCT04344080 DRKS00021447 (CytoSorbents), https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00021447	CytoSorbents Corporation				N/A	Sources	5/10/2020
221	Treatment	Device	Extracorporeal blood purification (EBP) devices	FDA issued an Emergency Use Authorization on April 9, 2020			Terumo BCT Inc / Marker Therapeutics AG					Sources	Prior to 4/20/2020
222	Treatment	Device	Seraph100MicrobindAffinity Blood Filter (Seraphy 100), approved in the EU for pathogen reduction	Clinical/ FDA issued an Emergency Use Authorization on April 17, 2020			ExThera Medical				N/A	Sources	4/21/2020
223	Treatment	Device	Oxiris Blood Purification Filter	FDA issued an Emergency Use Authorization on April 23, 2020			Baxter				N/A	Sources	4/24/2020
224	Treatment	Device	INOpulse	Compassionate Use			Bellerophon					Sources	Prior to 4/20/2020
225	Treatment	Device	Hemolung Respiratory Assist System	FDA issued an Emergency Use Authorization on April 24, 2020			ALung Technologies			Acute Exacerbation of Chronic Obstructive Pulmonary Disease; Acute Respiratory Distress Syndrome (ARDS)	N/A	Sources	4/28/2020
226	Treatment	Device	MultiFiltrate PRO System and multiBic/multiPlus Solutions, continuous renal replacement therapy (CRRT)	FDA issued an Emergency Use Authorization on April 30, 2020			Fresenius Medical				N/A	Sources	5/8/2020
227	#ff3333	Dormant / Discontinued	Washed microbiota transplantation	Clinical		NCT04251767	The Second Hospital of Nanjing Medical University		Study stopped before recruitment		Unknown	Sources	Prior to 4/20/2020
228		Dormant / Discontinued	Recombinant ACE2 (angiotensin-converting enzyme 2)	Clinical		NCT04287686	The First Affiliated Hospital of Guangzhou Medical University		Study stopped before recruitment		Unknown	Sources	Prior to 4/20/2020
229		Dormant / Discontinued	Combination of ebastine, lopinavir, and interferon alpha	Clinical	Chinese trial site last updated March 30, 2020	ChiCTR2000030535	Mianyang Central Hospital				N/A	Sources	5/7/2020
230		Dormant / Discontinued	Xofluza (baloxavir marboxil), polymerase acidic endonuclease inhibitor	Clinical	Chinese trial site last updated February 12, 2020	ChiCTR2000029544 ChiCTR2000029548	Roche/the First Hospital Affiliated to Zhejiang University's Medical School		medRxiv (https://doi.org/10.1101/2020.04.29.20085761) (ChiCTR2000029544)		FDA-approved since 2018, approved to treat influenza	Sources	5/10/2020
231		Dormant / Discontinued	azvudine, reverse transcriptase inhibitor	Clinical	Chinese trial site last updated February 16, 2020 - March 4, 2020 for various trials	ChiCTR2000030487 ChiCTR2000030424 ChiCTR2000029853	Numerous trials with Chinese research sponsors				N/A	Sources	5/7/2020
232	Vaccine	DNA-based	DNA plasmid vaccine with electroporation; INO-4800	Clinical	Phase 1 initial data expected June 2020; Phase 2/3 trials start July/August 2020	NCT04336410	Inovio Pharmaceuticals/Beijing Advaccine Biotechnology/VGXI Inc./ Richter-Helm BioLogics/Ology Bioservices	Coalition for Epidemic Preparedness (CEPI) / Gates Foundation / US Department of Defense		Same platform as vaccine candidates for Lassa, Nipah, HIV, Filovirus, HPV, cancer indications, Zika, and Hepatitis B	N/A	Sources	5/21/2020
233	Vaccine	DNA-based	DNA	Pre-clinical	Animal results released in May 2020; Phase 1 to start in fall 2020		Takis / Applied DNA Sciences / Evvivax				N/A	Sources	5/10/2020
234	Vaccine	DNA-based	DNA with electroporation	Pre-clinical	Phase 1 to start in 2020		OPENCORONA - Cobra Biologics / Karolinska Institute	European Commission (Horizon 2020 Program)			N/A	Sources	5/19/2020
235	Vaccine	DNA-based	DNA plasmid	Pre-clinical			Osaka University / AnGes / Takara Bio				N/A	Sources	Prior to 4/20/2020
236	Vaccine	DNA-based	DNA plasmid	Pre-clinical			Zydus Cadila				N/A	Sources	Prior to 4/20/2020
237	Vaccine	DNA-based	DNA plasmid, needle-free delivery	Pre-clinical			Immunomic Therapeutics / EpiVax / PharmaJet			Same platform as vaccine candidates for SARS	N/A	Sources	Prior to 4/20/2020
238	Vaccine	DNA-based	DNA	Pre-clinical			BioNet Asia				N/A	Sources	4/20/2020
239	Vaccine	DNA-based	DNA	Pre-clinical			University of Waterloo				N/A	Sources	4/20/2020
240	Vaccine	DNA-based	DNA	Pre-clinical			Entos Pharmaceuticals				N/A	Sources	5/4/2020
241	Vaccine	DNA-based	DNA	Pre-clinical	Phase 1 to start in Q1 2021		Scancell/ University of Nottingham			Same platform as vaccine candidates for cancer	N/A	Sources	4/28/2020
242	Vaccine	DNA-based	bacTRL-Spike	Pre-clinical			Symvivo				N/A	Sources	5/12/2020
243	Vaccine	Inactivated virus	Inactivated	Pre-clinical			Institute of Medical Biology, Chinese Academy of Medical Sciences				N/A	Sources	5/4/2020
244	Vaccine	Inactivated virus	Inactivated (inactivated + alum); PiCoVacc	Clinical	Phase 1/2 started April 2020	NCT04352608	Sinovac			Same platform as vaccine candidates for SARS	N/A	Sources	5/21/2020
245	Vaccine	Inactivated virus	Inactivated (inactivated + CpG 1018)	Pre-clinical			Sinovac/ Dynavax				N/A	Sources	4/28/2020
246	Vaccine	Inactivated virus	Inactivated	Clinical	Phase 1 started in May 2020	ChiCTR2000031809	Wuhan Institute of Biological Products/ Sinopharm				N/A	Sources	5/4/2020
247	Vaccine	Inactivated virus	Inactivated	Clinical	Phase 1 to start in May 2020	ChiCTR2000032459	Beijing Institute of Biological Products/ Sinopharm				N/A	Sources	5/19/2020
248	Vaccine	Inactivated virus	Inactivated	Pre-clinical			Osaka University / BIKEN / NIBIOHN				N/A	Sources	Prior to 4/20/2020
249	Vaccine	Inactivated virus	VLA2001, Inactivated + CpG 1018	Pre-clinical			Valneva/ Dynavax			Same platform as vaccine candidates for Japanese Encephalitis	N/A	Sources	5/12/2020
250	Vaccine	Inactivated virus	Inactivated	Pre-clinical			Research Institute for Biological Safety Problems, Republic of Kazakhstan					Sources	5/19/2020
251	Vaccine	Live attenuated virus	Codon deoptimized live attenuated virus	Pre-clinical	Animal data in summer 2020		Codagenix / Serum Institute of India			Same platform as vaccine candidates for HAV, InfA, ZIKV, FMD, SIV, RSV, DENV	N/A	Sources	4/28/2020
252	Vaccine	Live attenuated virus	Codon deoptimized live attenuated virus	Pre-clinical			Indian Immunologicals Ltd/ Griffith University				N/A	Sources	4/28/2020
253	Vaccine	Live attenuated virus	Live attenuated virus, measles virus (S, N targets)	Pre-clinical			DZIF - German Center for Infection Research			Same platform as vaccine candidates for Zika, H7N9, CHIKV	N/A	Sources	5/12/2020
254	Vaccine	Non-replicating viral vector	Non-replicating viral vector; MVA encoded VLP	Pre-clinical			GeoVax / BravoVax			Same platform as vaccine candidates for LASV, EBOV, MARV, HIV	N/A	Sources	Prior to 4/20/2020
255	Vaccine	Non-replicating viral vector	Non-replicating viral vector; Ad26 (alone or with MVA boost)	Pre-clinical	Start Phase 1 in September 2020		Janssen Pharmaceutical Companies/Beth Israel Deaconess Medical Center / Emergent BioSolutions/ Catalent	Biomedical Advanced Research and Development Authority (BARDA)		Same platform as vaccine candidates for Ebola, HIV, RSV	N/A	Sources	4/30/2020
256	Vaccine	Non-replicating viral vector	Non-replicating viral vector; replication defective simian adenovirus (GRAd) encoding SARS-CoV-2 S	Pre-clinical	Start Phase 1 in summer 2020		ReiThera/ Leukocare/ Univercells				N/A	Sources	5/19/2020
257	Vaccine	Non-replicating viral vector	Non-replicating viral vector; Ad5	Pre-clinical			ImmunityBio / NantKwest				N/A	Sources	Prior to 4/20/2020
258	Vaccine	Non-replicating viral vector	Non-replicating viral vector; ChAdOx1	Clinical	Phase 1/2 began April 2020, data expected in May 2020; Phase 2/3 trials expected to start by the middle of 2020*	NCT04324606	Consortium of the Jenner Institute, Oxford Biomedica, University of Oxford, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., Merck KGaA, the Serum Institute, Vaccitech, and AstraZeneca	Coalition for Epidemic Preparedness (CEPI) / UK Government		Same platform as vaccine candidates for influenza, TB, Chikungunya, Zika, MenB, plague	N/A	Sources	5/20/2020
259	Vaccine	Non-replicating viral vector	Non-replicating viral vector; MVA-S encoded	Pre-clinical			DZIF - German Center for Infection Research			Same platform as vaccine candidates for many pathogens	N/A	Sources	4/20/2020
260	Vaccine	Non-replicating viral vector	AdCOVID; single-dose, intranasal vaccine; non replicating viral vector; adenovirus-based NasoVAX expressing spike protein	Pre-clinical	Phase 1 trial to begin Q3 2020		Altimmune / University of Alabama at Birmingham			Same platform as vaccine candidates for influenza	N/A	Sources	Prior to 4/20/2020
261	Vaccine	Non-replicating viral vector	Non-replicating viral vector; Ad5 S (GREVAX™ platform)	Pre-clinical			Greffex			Same platform as vaccine candidates for MERS	N/A	Sources	Prior to 4/20/2020
262	Vaccine	Non-replicating viral vector	Oral Ad5 S	Pre-clinical			Stabilitech Biopharma Ltd				N/A	Sources	5/4/2020
263	Vaccine	Non-replicating viral vector	Adenovirus-based + HLA-matched peptides (Pan-Corona)	Pre-clinical			Valo Therapeutics Ltd				N/A	Sources	5/4/2020
264	Vaccine	Non-replicating viral vector	Non-replicating viral vector; Oral Vaccine platform	Pre-clinical	Phase 1 trial to begin in the second half of 2020		Vaxart / Emergent BioSolutions			Same platform as vaccine candidates for InfA, CHIKV, LASV, NORV, EBOV, RVF, HBV, VEE	N/A	Sources	Prior to 4/20/2020
265	Vaccine	Non-replicating viral vector	Non-replicating viral vector, MVA expressing structural proteins	Pre-clinical			Centro Nacional Biotecnologia (CNB-CSIC), Spain			Same platform as vaccine candidates for HIV, HCV, CHIKV, EBOV, Zika, Malaria, Leishmania	N/A	Sources	Prior to 4/20/2020
266	Vaccine	Non-replicating viral vector	Non-replicating viral vector; dendritic cell-based vaccine	Pre-clinical			University of Manitoba				N/A	Sources	4/20/2020
267	Vaccine	Non-replicating viral vector	Non-replicating viral vector; parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein	Pre-clincial			University of Georgia/ University of Iowa			Same platform as vaccine candidates for MERS	N/A	Sources	4/28/2020
268	Vaccine	Non-replicating viral vector	Non-replicating viral vector; Adenovirus Type 5 vector (Ad5-nCoV)	Clinical	Phase 2 started April 2020	NCT04313127 ChiCTR2000030906 ChiCTR2000031781	CanSino Biologics/Beijing Institute of Biotechnology/ Canada's National Research Council			Same platform as vaccine candidates for EBOV	N/A	Sources	5/20/2020
269	Vaccine	Non-replicating viral vector	Recombinant deactivated rabies virus containing S1	Pre-clinical			Bharat Biotech/ Thomas Jefferson University				N/A	Sources	5/4/2020
270	Vaccine	Protein subunit	Protein subunit, capsid-like particle (CLP)	Pre-clinical	Phase 1 to begin by February 2021		PREVENT-nCoV consortium (AdaptVac, Institute for Tropical Medicine at University of Tubingen, Leiden University Medical Center, University of Copenhagen, ExpreS2ion Biotechnologies, Wageningen University)/ Bavarian Nordic	European Commission (Horizon 2020 Program)		Same platform as vaccine candidates for HPV	N/A	Sources	5/14/2020
271	Vaccine	Protein subunit	Protein subunit, drosophila S2 insect cell expression system VLPs	Pre-clinical			ExpreS2ion				N/A	Sources	Prior to 4/20/2020
272	Vaccine	Protein subunit	Protein subunit; S protein	Pre-clinical			WRAIR / USAMRIID				N/A	Sources	Prior to 4/20/2020
273	Vaccine	Protein subunit	Protein subunit, S protein + adjuvant	Pre-clinical			National Institute of Infectious Disease, Japan			Same platform as vaccine candidates for Influenza	N/A	Sources	Prior to 4/20/2020
274	Vaccine	Protein subunit	Protein subunit, VLP-recombinant protein + adjuvant	Pre-clinical			Osaka University / BIKEN / National Institutes of Biomedical Innovation, Japan				N/A	Sources	Prior to 4/20/2020
275	Vaccine	Protein subunit	Protein subunit, native like trimeric subunit spike protein	Pre-clinical	Phase 1 to start by mid-2020		Clover Biopharmaceuticals Inc. / GSK / Dynavax	Coalition for Epidemic Preparedness (CEPI)		Same platform as vaccine candidates for HIV, RSV, Influenza	N/A	Sources	5/12/2020
276	Vaccine	Protein subunit	Protein subunit; peptide	Pre-clinical			Vaxil Bio				N/A	Sources	Prior to 4/20/2020
277	Vaccine	Protein subunit	Protein subunit; adjuvanted protein subunit (RBD)	Pre-clinical			Biological E Ltd				N/A	Sources	Prior to 4/20/2020
278	Vaccine	Protein subunit	Protein subunit; S protein	Pre-clinical			AJ Vaccines				N/A	Sources	Prior to 4/20/2020
279	Vaccine	Protein subunit	Protein subunit; recombinant spike protein with Advax adjuvant	Pre-clinical			Vaxine Pty Ltd / Flinders University / Oracle				N/A	Sources	4/28/2020
280	Vaccine	Protein subunit	Protein subunit; Ii-Key peptide	Pre-clinical			Generex / EpiVax			Same platform as vaccine candidates for HIV, SARS-CoV, Influenza	N/A	Sources	Prior to 4/20/2020
281	Vaccine	Protein subunit	Protein subunit; S protein	Pre-clinical			EpiVax / University of Georgia			Same platform as vaccine candidates for Inf H7N9	N/A	Sources	Prior to 4/20/2020
282	Vaccine	Protein subunit	PittCoVacc, Protein subunit, microneedle arrays S1 subunit	Pre-clinical	Phase 1 to start as early as June 2020		University of Pittsburgh			Same platform as vaccine candidates for MERS	N/A	Sources	Prior to 4/20/2020
283	Vaccine	Protein subunit	Protein subunit; S protein	Pre-clinical	Phase 1 to start as early as June 2020		University of Cambridge / DIOSynVax			Influenza, Ebola	N/A	Sources	Prior to 4/20/2020
284	Vaccine	Protein subunit	Protein subunit; COVID-19 XWG-03 truncated Spike proteins	Pre-clinical			Innovax / Xiamen University / GSK			Same platform as vaccine candidates for HPV	N/A	Sources	Prior to 4/20/2020
285	Vaccine	Protein subunit	Protein subunit; S protein, baculovirus production	Pre-clinical	Phase 1/2 to start in September 2020		Sanofi Pasteur / GSK	Biomedical Advanced Research and Development Authority (BARDA)		Same platform as vaccine candidates for Influenza, SARS-CoV (FDA approved vaccine)	N/A	Sources	5/8/2020
286	Vaccine	Protein subunit	Protein subunit; recombinant protein vaccine, utilizing baculovirus expression vector system technology	Pre-clincial	Phase 1 to start by end of 2020		UMN Pharma (Shionogi)	Japan Agency for Medical Research and Development			N/A	Sources	5/10/2020
287	Vaccine	Protein subunit	Protein subunit; NVX-CoV2373; Full length recombinant SARS COV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M	Pre-clinical	Start Phase 1/2 May 2020; top-line data expected July 2020		Novavax / Emergent BioSolutions	Coalition for Epidemic Preparedness (CEPI)		Same platform as vaccine candidates for RSV, CCHF, HPV, VZV, EBOV	N/A	Sources	5/13/2020
288	Vaccine	Protein subunit	Protein subunit (gp-96 backbone)	Pre-clinical			Heat Biologics (Zolovax) / University of Miami			Same platform as vaccine candidates for cancer (NSCLC), HIV, malaria, Zika	N/A	Sources	Prior to 4/20/2020
289	Vaccine	Protein subunit	Protein subunit; molecular clamp stabilized Spike protein	Pre-clinical			University of Queensland / GSK / Dynavax	Coalition for Epidemic Preparedness (CEPI)/Queensland Government/Federal Government (Australia)/Paul Ramsay Foundation		Same platform as vaccine candidates for Nipah, influenza, Ebola, Lassa	N/A	Sources	Prior to 4/20/2020
290	Vaccine	Protein subunit	Protein subunit; peptide vaccine	Pre-clinical			FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo			Same platform as vaccine candidates for Ebola	N/A	Sources	Prior to 4/20/2020
291	Vaccine	Protein subunit	Protein subunit; subunit vaccine	Pre-clincial			FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo				N/A	Sources	4/28/2020
292	Vaccine	Protein subunit	Protein subunit; S1 or RBD protein	Pre-clinical			Baylor College of Medicine			Same platform as vaccine candidates for SARS	N/A	Sources	Prior to 4/20/2020
293	Vaccine	Protein subunit	Protein subunit; Subunit protein, plant produced	Pre-clinical			iBio / CC-Pharming				N/A	Sources	Prior to 4/20/2020
294	Vaccine	Protein subunit	Protein subunit, recombinant protein, nanoparticles (based on S-protein and other epitopes)	Pre-clinical			St. Petersburg Scientific Research Institute of Vaccines and Serums				N/A	Sources	Prior to 4/20/2020
295	Vaccine	Protein subunit	Protein subunit, adjuvanted microsphere peptide	Pre-clinical	Animal testing results expected in April 2020		VIDO-InterVac, University of Saskatchewan	The Government of Saskatchewan and the Canadian Federal Government			N/A	Sources	Prior to 4/20/2020
296	Vaccine	Protein subunit	Protein subunit, peptide	Pre-clinical			Flow Pharma			Same platform as vaccine candidates for Ebola, Marburg, HIV, Zika, Influenza, HPV therapeutic vaccine, Breast Cancer	N/A	Sources	Prior to 4/20/2020
297	Vaccine	Protein subunit	Protein subunit, synthetic long peptide vaccine candidate for S and M proteins	Pre-clinical			OncoGen				N/A	Sources	Prior to 4/20/2020
298	Vaccine	Protein subunit	Protein subunit; oral E. coli-based protein expression system of S and N proteins	Pre-clinical			MIGAL Galilee Research Institute				N/A	Sources	Prior to 4/20/2020
299	Vaccine	Protein subunit	Protein subunit, nanoparticle vaccine	Pre-clinical			LakePharma, Inc.					Sources	5/4/2020
300	Vaccine	Protein subunit	Protein subunit; spike based	Pre-clinical			University of Alberta			Same platform as vaccine candidates for Hepatitis C	N/A	Sources	Prior to 4/20/2020
301	Vaccine	Protein subunit	Protein subunit, recombinant S1-Fc fusion protein	Pre-clinical			AnyGo Technology				N/A	Sources	5/4/2020
302	Vaccine	Protein subunit	Protein subunit, recombinant protein	Pre-clinical			Yisheng Biopharma				N/A	Sources	5/4/2020
303	Vaccine	Protein subunit	Protein subunit, recombinant S protein in IC-BEVS	Pre-clinical			Vabiotech				N/A	Sources	5/4/2020
304	Vaccine	Protein subunit	Protein subunit; DPX-COVID-19, protein subunit, peptide antigens formulated in LNP	Pre-clinical	Start Phase 1 testing by summer 2020		IMV, Inc. / Canadian Center for Vaccinology at Dalhousie University / Izaak Walton Killam Health Center/ Nova Scotia Health Authority; Canadian Immunization Research Network / University of Laval / Global Urgent and Advanced Research and Development in Canada			Same platform as vaccine candidates for cancer and infectious diseases, including malaria and anthrax	N/A	Sources	5/21/2020
305	Vaccine	Protein subunit	Protein subunit; plant virus nanotechnology formulated as injectable and microneedle patch	Pre-clinical			University of California, San Diego	National Science Foundation (Rapid Response Research [RAPID] grant)			N/A	Sources	4/28/2020
306	Vaccine	Protein subunit	OMV-based vaccine	Pre-clinical			Quadram Institute Biosciences			Same platform as vaccine candidates for Flu A, plaque	N/A	Sources	5/12/2020
307	Vaccine	Protein subunit	OMV-based vaccine	Pre-clinical			BiOMVis Srl/ University of Trento				N/A	Sources	5/12/2020
308	Vaccine	Protein subunit	Orally delivered, heat stable subunit	Pre-clinical			Applied Biotechnology Institute, Inc.				N/A	Sources	5/12/2020
309	Vaccine	Protein subunit	S-2 P protein + CpG 1018	Pre-clinical			Medigen Vaccine Biologics Corp/ NIAID/ Dynavax				N/A	Sources	5/12/2020
310	Vaccine	Protein subunit	Peptides derived from Spike protein	Pre-clinical			Axon Neuroscience SE				N/A	Sources	5/12/2020
311	Vaccine	Protein subunit	Adjuvanted recombinant protein (RBD-Dimer)	Pre-clinical			Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology, Chinese Academy of Sciences				N/A	Sources	5/19/2020
312	Vaccine	Protein subunit	RBD-based	Pre-clinical			Neovii/Tel Aviv University				N/A	Sources	5/19/2020
313	Vaccine	Protein subunit	Outer Membrane Vesicle (OMV)-peptide	Pre-clinical			Intravacc/Epivax				N/A	Sources	5/19/2020
314	Vaccine	Replicating viral vector	Replicating viral vector; YF17D Vector	Pre-clinical			KU Leuven				N/A	Sources	5/4/2020
315	Vaccine	Replicating viral vector	Replicating viral vector; measles vector	Pre-clinical			Zydus Cadila				N/A	Sources	Prior to 4/20/2020
316	Vaccine	Replicating viral vector	Replicating viral vector; measles vector	Pre-clinical	Start animal testing in April 2020		Institut Pasteur / Themis / University of Pittsburgh	Coalition for Epidemic Preparedness (CEPI)		Same platform as vaccine candidates for West nile, CHIKV, Ebola, Lassa, Zika, MERS	N/A	Sources	Prior to 4/20/2020
317	Vaccine	Replicating viral vector	Replicating viral vector; measles vector	Pre-clinical			FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo				N/A	Sources	4/28/2020
318	Vaccine	Replicating viral vector	Replicating viral vector; horsepox vector expressing S protein; TNX-1800	Pre-clinical			Tonix Pharma / Southern Research			Same platform as vaccine candidates for smallpox, monkeypox	N/A	Sources	5/19/2020
319	Vaccine	Replicating viral vector	Replicating viral vector, live viral vectored vaccine based on attenuated influenza virus backbone (intranasal)	Pre-clinical			BIOCAD / IEM				N/A	Sources	Prior to 4/20/2020
320	Vaccine	Replicating viral vector	Replicating viral vector, recombinant vaccine based on Influenza A virus, for the prevention of COVID-19 (intranasal)	Pre-clincial			FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo			Same platform as vaccine candidates for influenza	N/A	Sources	4/28/2020
321	Vaccine	Replicating viral vector	Replicating viral vector, replication-competent VSV chimeric virus technology (VSVdeltaG) delivering the SARS-CoV-2 Spike (S) glycoprotein	Pre-clinical			IAVI / Batavia			Same platform as vaccine candidates for Ebola, Marburg, Lassa	N/A	Sources	4/28/2020
322	Vaccine	Replicating viral vector	Replicating viral vector, influenza vector expressing RBD	Pre-clinical			The University of Hong Kong	Coalition for Epidemic Preparedness (CEPI)		Same platform as vaccine candidates for MERS	N/A	Sources	Prior to 4/20/2020
323	Vaccine	Replicating viral vector	Replicating viral vector; VSV-S	Pre-clinical			University of Western Ontario			Same platform as vaccine candidates for HIV, MERS	N/A	Sources	Prior to 4/20/2020
324	Vaccine	Replicating viral vector	Replicating viral vector; VSV vector	Pre-clinical			FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo				N/A	Sources	4/28/2020
325	Vaccine	Replicating viral vector	M2-deficient single replication (M2SR) influenza vector	Pre-clinical	Start Phase 1 trial in fall 2020		University of Wisconsin-Madison / FluGen/ Bharat Biotech			Same platform as vaccine candidates for influenza	N/A	Sources	5/4/2020
326	Vaccine	Replicating viral vector	Newcastle disease virus vector (NDV-SARS-CoV-2/Spike)	Pre-clinical			Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ.				N/A	Sources	5/19/2020
327	Vaccine	Replicating viral vector	Avian paramyxovirus vector (APMV)	Pre-clinical			The Lancaster University, UK				N/A	Sources	5/19/2020
328	Vaccine	RNA-based vaccine	RNA; LNP-encapsulated mRNA cocktail encoding VLP	Pre-clinical			Fudan University / Shanghai JiaoTong University / RNACure Biopharma				N/A	Sources	Prior to 4/20/2020
329	Vaccine	RNA-based vaccine	RNA; LNP-encapsulated mRNA cocktail encoding RBD	Pre-clinical			Fudan University / Shanghai JiaoTong University / RNACure Biopharma				N/A	Sources	Prior to 4/20/2020
330	Vaccine	RNA-based vaccine	RNA; Replicating defective SARS-CoV-2 derived RNAs	Pre-clinical			Centro Nacional Biotecnologia (CNB-CSIC), Spain				N/A	Sources	Prior to 4/20/2020
331	Vaccine	RNA-based vaccine	RNA; LNP-encapsulated mRNA	Pre-clinical			University of Tokyo / Daiichi-Sankyo			Same platform as vaccine candidates for MERS	N/A	Sources	Prior to 4/20/2020
332	Vaccine	RNA-based vaccine	RNA; several mRNA candidates	Pre-clinical			RNAimmune, Inc.				N/A	Sources	5/4/2020
333	Vaccine	RNA-based vaccine	RNA; mRNA	Pre-clincial			FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo				N/A	Sources	4/28/2020
334	Vaccine	RNA-based vaccine	RNA; mRNA	Pre-clinical			China CDC / Tongji University / Stermina				N/A	Sources	Prior to 4/20/2020
335	Vaccine	RNA-based vaccine	RNA; mRNA lipid nanoparticle (mRNA-LNP)	Pre-clinical			CanSino Biologics/Precision Nanosystems				N/A	Sources	5/21/2020
336	Vaccine	RNA-based vaccine	RNA; LNP-encapsulated mRNA (mRNA 1273)	Clinical	Phase 1 ongoing; Phase 2 to start May 2020; Phase 3 to start early summer 2020; FDA granted fast track designation May 2020; initial phase 1 data released May 18, 2020	NCT04283461	Moderna/NIAID/Lonza	Coalition for Epidemic Preparedness (CEPI)/ Biomedical Advanced Research and Development Authority (BARDA)	Moderna (https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-interim-phase-1-data-its-mrna-vaccine)	Same platform as vaccine candidates for multiple candidates	N/A	Sources	5/19/2020
337	Vaccine	RNA-based vaccine	LUNAR-COV19; RNA; mRNA	Pre-clinical	Start Phase 1 in summer 2020		Arcturus/Duke-NUS/ Catalent			Same platform as vaccine candidates for multiple candidates	N/A	Sources	5/5/2020
338	Vaccine	RNA-based vaccine	RNA; saRNA	Pre-clinical	Start Phase 1 in summer 2020		Imperial College London	UK Government		Same platform as vaccine candidates for EBOV, LASV, MARV, Inf (H7N9), RABV	N/A	Sources	4/23/2020
339	Vaccine	RNA-based vaccine	RNA; mRNA	Pre-clinical	Start Phase 1/2a trial June 2020		CureVac	Coalition for Epidemic Preparedness (CEPI); European Commission; Gates Foundation; Defense Advanced Research Projects Agency (DARPA)		Same platform as vaccine candidates for RABV, LASV, YFV, MERS, InfA, ZIKV, DengV, NIPV	N/A	Sources	5/19/2020
340	Vaccine	RNA-based vaccine	3 LNP-mRNAs; BNT162	Clinical	Phase 1/2 started April 2020; first data expected end of June or July 2020	EudraCT 2020-001038-36 NCT04368728	BioNTech / Fosun Pharma / Pfizer				N/A	Sources	5/19/2020
341	Vaccine	RNA-based vaccine	RNA; liposome-encapsulated mRNA	Pre-clinical	Animal studies begin in April 2020		BIOCAD			Same platform as vaccine candidates for cancer	N/A	Sources	Prior to 4/20/2020
342	Vaccine	RNA-based vaccine	LNP-mRNA	Pre-clinical			Sanofi Pasteur / Translate Bio				N/A	Sources	5/12/2020
343	Vaccine	RNA-based vaccine	RNA; mRNA in an intranasal delivery system (cross-strain protective COV-2 mRNA) vaccine for high-risk populations	Pre-clinical	Start Phase 1 early 2021		eTheRNA Immunotherapies / EpiVax/ Nexelis/ REPROCELL / Centre for the Evaluation of Vaccination of the University of Antwerp				N/A	Sources	5/4/2020
344	Vaccine	RNA-based vaccine	RNA	Pre-clinical			GeneOne Life Science / Houston Methodist				N/A	Sources	Prior to 4/20/2020
345	Vaccine	RNA-based vaccine	RNA; ZIP-1642, vaccine consists of a combination of mRNA molecules, encoding multiple SARS-CoV-2 antigens	Pre-clincial			Ziphius Therapeutics/ Ghent University				N/A	Sources	4/28/2020
346	Vaccine	RNA-based vaccine	mRNA	Pre-clinical			Greenlight Biosciences				N/A	Sources	5/12/2020
347	Vaccine	Virus-like particle	VLP; virus-like particle, based on RBD displayed on virus-like particle	Pre-clinical			Saiba GmbH				N/A	Sources	Prior to 4/20/2020
348	Vaccine	Virus-like particle	VLP; plant-derived VLP	Pre-clinical	Start Phase 1 in July/August 2020; Phase 2 by the end of 2020		Medicago Inc.			Same platform as vaccine candidates for flu, rotavirus, norovirus, West Nile virus, and cancer	N/A	Sources	5/21/2020
349	Vaccine	Virus-like particle	VLP; ADDomerTM multiepitope display	Pre-clinical			Imophoron Ltd / Bristol University's Max Planck Centre				N/A	Sources	Prior to 4/20/2020
350	Vaccine	Virus-like particle	VLP	Pre-clinical			Doherty Institute				N/A	Sources	Prior to 4/20/2020
351	Vaccine	Virus-like particle	VLP (COVID-19 and SARS1)	Pre-clincial			OSIVAX				N/A	Sources	5/4/2020
352	Vaccine	Virus-like particle	VLP; eVLP	Pre-clinical			ARTES Biotechnology			Same platform as vaccine candidates for malaria	N/A	Sources	5/4/2020
353	Vaccine	Virus-like particle	VLPs peptides/whole virus	Pre-clinical			University of Sao Paulo					Sources	5/19/2020
354	Vaccine	Virus-like particle	Enveloped virus-like particle (eVLP): Pan-coronavirus vaccine candidate, targeting COVID-19, SARS, and MERS, spike protein	Pre-clinical	Start Phase 1 testing by end of 2020		VBI Vaccines / National Research Council of Canada			Same platform as vaccine candidates for glioblastoma, cytomegalovirus, and Zika	N/A	Sources	4/28/2020
355	Vaccine	Unknown	Gene-encoded antibody vaccine, non-viral nanoparticle delivery	Pre-clinical			SmartPharm Therapeutics / Sorrento Therapeutics				N/A	Sources	Prior to 4/20/2020
356	Vaccine	Unknown	Self-assembling vaccine (fusion protein of a heat shock protein and Avidin, with biotinylated immunogenic peptides)	Pre-clinical	Animal study results by October 2020		HaloVax (Voltron Therapeutics) / The Vaccine & Immunotherapy Center at the Massachusetts General Hospital	Analog Devices Foundation			N/A	Sources	4/21/2020
357	Vaccine	Unknown	LV-SMENP-DC Dendritic cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins; administered with antigen-specific cytotoxic T lymphocytes	Pre-clinical		NCT04276896	Shenzhen Geno-Immune Medical Institute				N/A	Sources	5/12/2020
358	Vaccine	Unknown	Artificial antigen-presenting cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins	Pre-clinical		NCT04299724	Shenzhen Geno-Immune Medical Institute				N/A	Sources	5/12/2020
359	Vaccine	Unknown	ISR-50	Pre-clinical	Animal study results expected in Q2 2020, Phase 1 begins Q4 2020		ISR Immune System Regulation				N/A	Sources	Prior to 4/20/2020
360	Vaccine	Unknown	Unknown	Pre-clinical			ImmunoPrecise				N/A	Sources	Prior to 4/20/2020
361	Vaccine	Unknown	Unknown	Pre-clinical			Tulane University				N/A	Sources	Prior to 4/20/2020
362	Vaccine	Unknown	Unknown	Pre-clinical	Phase 1 begins as early as September 2020		SK Biosciences				N/A	Sources	Prior to 4/20/2020
363	Vaccine	Unknown	Unknown	Pre-clinical			Vir Biotechnology / GSK				N/A	Sources	Prior to 4/20/2020
364	Vaccine	Unknown	Unknown	Pre-clinical			Precision Vaccines Program at Boston Children's Hospital				N/A	Sources	Prior to 4/20/2020
365	Vaccine	Unknown	Unknown, tobacco plant technology	Pre-clinical			Kentucky BioProcessing (British American Tobacco)				N/A	Sources	Prior to 4/20/2020
366	Vaccine	Unknown	Unknown	Pre-clinical			Universite Laval				N/A	Sources	Prior to 4/20/2020
367	Vaccine	Unknown	Unknown	Pre-clinical	Phase 1 to start in summer 2020		Covaxx				N/A	Sources	4/21/2020
368	Vaccine	Unknown	Unknown	Pre-clinical			Catholic University/ Millennium Institute of Immunology and Immunotherapy/ Technological Consortium in Clinical Molecular Biomedicine, Chile				N/A	Sources	4/23/2020
369	Vaccine	Unknown	Unknown	Pre-clinical			Emergex Vaccines/ George Mason University's National Center for Biodefense and Infectious Diseases (NCBID)				N/A	Sources	4/24/2020
370	Vaccine	Unknown	TerraCoV2	Pre-clinical	Start Phase 1 in late 2020 or early 2021		Oragenics (Noachis Terra)/ Aragen Bioscience				N/A	Sources	5/21/2020
371	Vaccine	Unknown	AVI-205	Pre-clinical			AbVision				N/A	Sources	5/13/2020
372	Vaccine	Replicating bacterial vector	Recombinant LVS ΔcapB – vectored vaccine expressing multiple SARS-CoV-2 antigens	Pre-clinical			University of California, Los Angeles (Horwitz Lab)			Same platform as vaccines against select agents and emerging pathogens	N/A	Sources	5/10/2020

	B	C	D	E	F	G	H	I	J	K	L	M
1			0 Best Practices - Expand the formula bar so that you don't miss the additional info found in some of the cells. Reference the image to the right for more help. - Use filters to explore and organize the information for your own use. When accessing through this view-only link, filters are temporary to that search/find. - This document is also available for download under the File tab. - To find the latest additions or updates to the tracker, command+F or control+F and search for an asterisk. All cells with new information have an added at the end.						Last Update: May 21, 2020 \| 12:37 pm ET © 2020 Milken Institute00 2020
2	Product Category	Product Description	Stage of Development	Anticipated Next Steps	Clinical Trials for COVID-19	Developer / Researcher	Funder	Published Results	Clinical Trials for Other Diseases (T only)	FDA-Approved Indications	Sources	Date Last Updated

3	Antibodies	Polyclonal hyperimmune globulin (H-IG), unbranded	Pre-clinical	Phase 1 trials start in summer 2020. To patients between December 2020 and December 2021		CoVIg-19 Plasma Alliance (Takeda, CSL Behring, Biotest AG, Bio Products Laboratory, LFB, and Octapharma, ADMA Biologics, BioPharma Plasma, GC Pharma, Sanquin)/ National Institute of Allergy and Infectious Disease (NIAID)/ Microsoft (CoVIg-19 PlasmaBot)				N/A	Sources	5/10/2020
4	Antibodies	Antibodies from mice, REGN3048-3051, against the spike protein	Pre-clinical	Start Phase 1 June 2020		Regeneron	Biomedical Advanced Research and Development Authority (BARDA)			N/A	Sources	Prior to 4/20/2020
5	Antibodies	CT-P59; Antibodies from recovered COVID-19 patients	Pre-clinical	Start Phase 1 in July 2020		Celltrion	The Korea Health Industry Development Institute			N/A	Sources	5/14/2020
6	Antibodies	Super-antibody or antibody cocktail to target potential mutations of SARS-CoV-2	Pre-clinical			Celltrion				N/A	Sources	Prior to 4/20/2020
7	Antibodies	COVI-SHIELD antibody cocktail that binds to three different epitopes	Pre-clinical	Start Phase 2 trial 3Q 2020		Sorrento Therapeutics/ Mount Sinai Health System				N/A	Sources	5/20/2020
8	Antibodies	Antibodies from recovered COVID-19 patients	Pre-clinical			Kamada/ Kedrion Biopharma				N/A	Sources	5/4/2020
9	Antibodies	VIR-7831 and VIR-7832, antibodies from recovered SARS patients	Pre-clinical	Start Phase 2 ~ July-September 2020		Vir Biotechnology/GSK/ Samsung/WuXi Biologics/Biogen				N/A	Sources	5/20/2020
10	Antibodies	Antibodies from recovered COVID-19 patients	Pre-clinical	Start Phase 1 in late July 2020		Eli Lilly/Ab-Cellera (NIH Vaccines Research Center)	Defense Advanced Research Projects Agency/ Government of Canada (ISED Strategic Innovation Fund)			N/A	Sources	5/5/2020
11	Antibodies	COVID-19 Immunoglobulin, plasma derived	Pre-clinical			CSL Behring Australia				N/A	Sources	5/10/2020
12	Antibodies	Avastin (bevacizumab), vascular endothelial growth factor inhibitor	Clinical	Phase 2/3 studies recruiting April 2020	NCT04275414 NCT04305106 NCT04344782	Numerous trials with Chinese research sponsors; Roche				FDA-approved since 2004, approved to treat certain types of cancer	Sources	4/27/2020
13	Antibodies	PD-1 blocking antibody; Thymosin	Clinical	Phase 2 study not yet recruiting	NCT04268537 ChiCTR2000030028	Numerous trials with Chinese research sponsors				Unknown	Sources	4/27/2020
14	Antibodies	Opdivo (nivolumab), PD-1 blocking antibody	Clinical	Phase 2 study not yet recruiting	NCT04356508 NCT04333914	University of Hong Kong (BMS)				FDA-approved since 2014, approved to treat melanoma and squamous non-small cell lung cancer	Sources	4/27/2020
15	Antibodies	leronlimab (PRO 140), a CCR5 antagonist	Clinical / Compassionate Use	Phase 2 trial started in April 2020; Phase 2b/3 trial starts April 2020	NCT04343651 NCT04347239	CytoDyn		CytoDyn	Treatment of HIV/AIDS, Graft versus Host Disease, Non-Alcoholic Steatohepatitis, and numerous cancers	N/A	Sources	Prior to 4/20/2020
16	Antibodies	AiRuiKa (camrelizumab), anti-programmed cell death protein (PD-1) antibody	Clinical	No trial updates since February 2020	ChiCTR2000029806	Wuhan Jinyintan Hospital			Treatment of certain cancers	N/A	Sources	4/27/2020
17	Antibodies	Kevzara (sarilumab), interleukin-6 receptor antagonist	Clinical	Started phase 2/3 in March 2020; preliminary Phase 2 results released April 27, 2020, trial continuing for only critical patients, Phase 3 (US) results expected June 2020, Phase 3 (ex-US) results expected 3Q 2020	NCT04315298 NCT04321993 NCT04341870 NCT04324073 NCT04327388 NCT04322773 NCT04345289 NCT02735707 NCT04357808 NCT04357860 NCT04359901	Sanofi/Regeneron; Feinstein Institutes; REMAP-CAP global trial	Biomedical Advanced Research and Development Authority (BARDA)	medRxiv (https://doi.org/10.1101/2020.04.23.20076612) Regeneron (https://newsroom.regeneron.com/index.php/news-releases/news-release-details/regeneron-and-sanofi-provide-update-us-phase-23-adaptive) ChinaXiv (http://www.chinaxiv.org/abs/202003.00026) medRxiv (https://doi.org/10.1101/2020.05.14.20094144)		FDA-approved since 2017, approved to treat rheumatoid arthritis	Sources	5/20/2020
18	Antibodies	Actemra (tocilizumab), interleukin-6 receptor antagonist	Clinical	Roche studies could be completed May or June 2020; Phase 2 open label study in Italy active (April 2020), Phase 3 studies recruiting April 2020, some results from open label study in France released April 2020	NCT04317092 NCT04320615 NCT04310228 ChiCTR2000030894 NCT04306705 ChiCTR2000030442 ChiCTR2000029765 NCT04322773 NCT04345445 NCT04331795 NCT04332094 NCT04346355 NCT04359667 NCT04332913 NCT04335071 NCT04356937 NCT04361032 NCT04315480 NCT04339712 NCT04333914 NCT04361552 NCT04330638 NCT04331808 NCT02735707 NCT04349410 NCT04363736 NCT04372186 NCT04363853	Numerous trials with global research sponsors; Roche; REMAP-CAP	Biomedical Advanced Research and Development Authority (BARDA)	ChinaXiv (http://www.chinaxiv.org/abs/202003.00026) medRxiv (https://doi.org/10.1101/2020.04.20.20061861) medRxiv (https://doi.org/10.1101/2020.04.23.20076612) Assistance Publique Hopitaux De Paris (https://www.aphp.fr/contenu/le-tocilizumab-ameliore-significativement-le-pronostic-des-patients-avec-pneumonie-covid) PNAS (https://www.pnas.org/content/early/2020/04/27/2005615117#T1) medRxiv (https://doi.org/10.1101/2020.05.01.20078360) medRxiv (https://doi.org/10.1101/2020.05.07.20094599) medRxiv (https://doi.org/10.1101/2020.05.14.20099234) medRxiv (https://doi.org/10.1101/2020.05.13.20100404) medRxiv (https://doi.org/10.1101/2020.05.13.20100081)		FDA-approved since 2010, approved to treat various type of arthritis, including rheumatoid arthritis, and cytokine release syndrome	Sources	5/21/2020
19	Antibodies	Gimsilumab, anti-granulocyte-macrophage colony stimulating factor monoclonal	Clinical	Phase 2 study started in April 2020	NCT04351243	Roivant Sciences				N/A	Sources	5/14/2020
20	Antibodies	TJM2 (TJ003234), anti-granulocyte-macrophage colony stimulating factor antibody	Clinical	Phase 1/2 recruiting April 2020	NCT04341116	I-Mab Biopharma				N/A	Sources	4/27/2020
21	Antibodies	lenzilumab, anti-granulocyte-macrophage colony stimulating factor antibody	Clinical / Compassionate Use	Phase 3 not yet recruiting April 2020	NCT04351152	Humanigen Inc.			Prevent cytokine storm with CAR-T cancer therapy; prevention/treatment of acute graft versus host disease; chronic myelomonocytic leukemia; eosinophilic asthma	N/A	Sources	4/27/2020
22	Antibodies	Sylvant (siltuximab), interleukin-6 targeted monoclonal	Clinical / Compassionate Use	Compassionate use data shared April 2020; Phase 3 recruiting April 2020	NCT04322188 NCT04330638 NCT04329650	EUSA Pharma/The Papa Giovanni XXII Hospital; University Hospital, Ghent; Fundacion Clinic per a la Recerca Biomédica		EUSA Pharma (https://www.eusapharma.com/news/interim-analysis-data-for-siltuximab-treated-covid-19-patients-from-the-sisco-study/) medRxiv (https://doi.org/10.1101/2020.04.01.20048561) medRxiv (https://doi.org/10.1101/2020.04.23.20076612)		FDA-approved since 2014, approved to treat multicentric Castleman disease	Sources	4/28/2020
23	Antibodies	Soliris (eculizumab), complement inhibitor	Clinical/ Expanded access	Phase 2 recruiting May 2020	NCT04288713 NCT04346797 NCT04355494	Assistance Publique - Hopitaux de Paris (Phase 2); Alexion (Expanded Access)				FDA-approved since 2007, approved to treat Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis, and Neuromyelitis Optica Spectrum Disorder	Sources	5/5/2020
24	Antibodies	Ilaris (canakinumab), interleukin-1beta blocker	Clinical	Novartis Phase 3 to start and trial top-line results expected late summer 2020	NCT04348448 NCT04362813 NCT04365153	Novartis; other research sponsors				FDA-approved since 2009, approved to treat periodic fever syndromes and systemic juvenile idiopathic arthritis	Sources	4/30/2020
25	Antibodies	Gamifant (emapalumab), anti-interferon gamma antibody	Clinical	Phase 2/3 recruiting April 2020	NCT04324021	Swedish Orphan Biovitrum				FDA-approved since 2018, approved to treat primary hemophagocytic lymphohistiocytosis	Sources	4/27/2020
26	Antibodies	meplazumab, anti-CD147 antibody	Clinical	Phase 1/2 recruiting April 2020	NCT04275245	Tang-Du Hospital		medRxiv (https://doi.org/10.1101/2020.03.21.20040691)		N/A	Sources	4/27/2020
27	Antibodies	LY3127804, anti-Angiopoietin 2 (Ang2) antibody	Clinical	Phase 2 to start in April 2020		Eli Lilly				N/A	Sources	Prior to 4/20/2020
28	Antibodies	Ultomiris (ravulizumab-cwvz), complement inhibitor	Clinical	Phase 3 to start in May 2020	NCT04369469	Alexion Pharmaceuticals				FDA-approved since 2018, aprpoved to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome	Sources	5/5/2020
29	Antibodies	IFX-1, anti-C5a antibody	Clinical	Phase 2/3 recruiting in April 2020	NCT04333420	InflaRx N.V.			To treat various inflammatory conditions including hidradenitis suppurativa, ANCA-associated vasculitis, and pyoderma gangraenosum	N/A	Sources	4/27/2020
30	Antibodies	otilimab, anti-granulocyte macrophase colony-stimulating factor (GM-CSF) antibody	Clinical	Phase 2 to start end of May 2020	NCT04376684	GSK			To treat rheumatoid arthritis	N/A	Sources	5/8/2020
31	Antibodies	Monoclonal antibody cocktail	Pre-clinical			ImmunoPrecise Antibodies				N/A	Sources	4/23/2020
32	Antibodies	Antibody	Pre-clinical			Harbour BioMed/ Erasmus MC/ Utrecht University/ Mount Sinai Health System				N/A	Sources	5/10/2020
33	Antibodies	Antibodies targeting the S protein from convalescent serum, humanized mice, and phage display	Pre-clinical	Phase 1 trials begin in summer 2020		AstraZeneca/ US Army Medical Research Institute of Infectious Diseases (USAMRIID)/ University of Maryland School of Medicine				N/A	Sources	Prior to 4/20/2020
34	Antibodies	Antibody	Pre-clinical			Centivax (Distributed Bio)				N/A	Sources	5/21/2020
35	Antibodies	Antibodies	Pre-clinical			Chelsea and Westminster Hospital, Imperial College London	UK Government			N/A	Sources	5/10/2020
36	Antibodies	Antibody	Pre-clinical	Phase 1 trial begins in summer 2020		Vanderbilt Vaccine Center/ AstraZeneca/ IDBiologics	Defense Advanced Research Projects Agency/ Dolly Parton			N/A	Sources	5/10/2020
37	Antibodies	Antibodies	Pre-clinical			Medicago/ Laval University's Infectious Disease Research Centre	Canadian Institutes for Health Research (CIHR)			N/A	Sources	Prior to 4/20/2020
38	Antibodies	Antibodies	Pre-clinical			FairJourney Biologics/ Iontas				N/A	Sources	4/21/2020
39	Antibodies	Antibodies	Pre-clinical			Prellis Biologics				N/A	Sources	5/21/2020
40	Antibodies	Antibodies (OmniChicken platform)	Pre-clinical			Ligand Pharmaceuticals				N/A	Sources	4/23/2020
41	Antibodies	Antibodies (OmniRat platform)	Pre-clinical			Ligand Pharmaceuticals				N/A	Sources	4/23/2020
42	Antibodies	Monocloncal antibodies, TLR4 antagonist	Pre-clinical			Edesa Biotech/ Light Chain Bioscience (NovImmune)				N/A	Sources	4/23/2020
43	Antibodies	Monocloncal antibodies, CXC10 antagonist	Pre-clinical			Edesa Biotech/ Light Chain Bioscience (NovImmune)				N/A	Sources	4/23/2020
44	Antibodies	Polyclonal hyperimmune globulin (H-IG)	Pre-clinical	Phase 2 trials begin ~ August 2020		Emergent BioSolutions/ National Institute of Allergy and Infectious Diseases (NIAID)	Biomedical Advanced Research and Development Authority (BARDA)		Same human hyperimmune platform as FDA-approved anthrax treatment (Anthrasil) and smallpox vaccine complications (VIGIV) were developed	N/A	Sources	Prior to 4/20/2020
45	Antibodies	Horse plasma product (COVID-EIG)	Pre-clinical	Phase 2 trials begin ~ August 2020		Emergent BioSolutions			Same equine hyperimmune platform as FDA-approved botulism anti-toxin (BAT) is produced	N/A	Sources	Prior to 4/20/2020
46	Antibodies	Convalescent plasma (blood plasma from recovered patients)	Clinical / Expanded Access	Phase 2 and Phase 3 trials not yet recruiting as of April 2020	Many expanded access, observational, patient registry, plasma collection, prevention, and other studies listed in clincialtrials.gov, including: NCT04321421 NCT04292340 NCT04316728 NCT04338360 NCT04345289 NCT04349410 NCT04346589 NCT04333251 NCT04361253 NCT04323800 NCT04359810 NCT04362176 NCT04354831 NCT04360486	Multiple global research sponsors, including New York State Department of Health, Johns Hopkins University, the Feinstein Institutes	Bloomberg Philantropies and the State of Maryland (to Johns Hopkins University)/ Biomedical Advanced Research and Development Authority (BARDA) (to Mayo Clinic)	medRxiv (https://doi.org/10.1101/2020.03.16.20036145) JAMA (https://jamanetwork.com/journals/jama/fullarticle/2763983) medRxiv (https://doi.org/10.1101/2020.04.07.20056440) JAMA Network (https://jamanetwork.com/journals/jama/fullarticle/2763982) medRxiv (https://doi.org/10.1101/2020.05.08.20095471) medRxiv (https://doi.org/10.1101/2020.05.12.20099879)		N/A	Sources	5/20/2020
47	Antibodies	Antibodies from recovered COVID-19 patients	Pre-clinical	Phase 1 trial begins Q3 2020		Tsinghua University / Third People's Hospital of Shenzhen / Brii Biosciences				N/A	Sources	Prior to 4/20/2020
48	Antibodies	Polyclonal hyperimmune globulin (H-IG)	Pre-clinical			Grifols	Biomedical Advanced Research and Development Authority (BARDA)			N/A	Sources	Prior to 4/20/2020
49	Antibodies	Antibodies from recovered COVID-19 patients	Pre-clinical			Grifols	Biomedical Advanced Research and Development Authority (BARDA)			N/A	Sources	Prior to 4/20/2020
50	Antibodies	Antibodies from recovered COVID-19 patients	Pre-clinical			Amgen / Adaptive Biotechnologies				N/A	Sources	Prior to 4/20/2020
51	Antibodies	Antibodies from recovered COVID-19 patients	Pre-clinical			Innovent Biologics				N/A	Sources	Prior to 4/20/2020
52	Antibodies	Antibodies from recovered COVID-19 patients	Pre-clinical			Xbiotech / BioBridge Global				N/A	Sources	Prior to 4/20/2020
53	Antibodies	Antibodies from recovered COVID-19 patients	Pre-clinical			Costa Rican Social Security Fund (CCSS)/ The University of Costa Rica (UCR)/ Clodomiro Picado Institute				N/A	Sources	Prior to 4/20/2020
54	Antibodies	Novel IgM and IgA antibodies	Pre-clinical			Atreca/ BeiGene/ IGM Biosciences				N/A	Sources	5/4/2020
55	Antibodies	SAB-185, Polyclonal hyperimmune globulin (H-IG)	Pre-clinical	Phase 1 starts early summer 2020		CSL Behring/ SAb Biotherapeutics	Biomedical Advanced Research and Development Authority (BARDA)/ US Department of Defense			N/A	Sources	4/30/2020
56	Antibodies	Non-viral gene therapy to produce monoclonal antibodies	Pre-clinical			Generation Bio / Vir Biotechnology				N/A	Sources	Prior to 4/20/2020
57	Antibodies	rCIG (recombinant anti-coronavirus 19 hyperimmune gammaglobulin), polyclonal antibodies	Pre-clinical			GigaGen				N//A	Sources	Prior to 4/20/2020
58	Antibodies	IC14, recombinant chimeric anti-CD14 monoclonal antibody	Expanded access		NCT04346277	Implicit Bioscience			Acute Respiratory Distress Syndrome	N/A	Sources	Prior to 4/20/2020
59	Antibodies	MEDI3506, monoclonal antibody targeting interleukin 33	Clinical	ACCORD Phase 2 trial to start May 2020		AstraZeneca; ACCORD trial	UK Government (ACCORD study)		Chronic Obstructive Pulmonary Diesase	N/A	Sources	5/10/2020
60	Antibodies	Octagam; intravenous Immunoglobulin (IVIG)	Clinical	Phase 3 trial to start May 2020	NCT04261426 NCT04264858 NCT04350580	Multiple global research sponsors; Octapharma USA/ Sharp Memorial Hospital		Open Forum Infectious Diseases (https://academic.oup.com/ofid/article/7/3/ofaa102/5810740)		FDA-approved since 2014, approved to treat chronic immune thrombocytopenic purpura (ITP)	Sources	5/21/2020
61	Antibodies	Purified ovine immunoglobulin from immunized sheep	Pre-clinical			Public Health England (Stuart Dowall)	UK Government			N/A	Sources	4/23/2020
62	Antibodies	Antibodies	Pre-clinical			Ablexis/ AlivaMab Discovery Services/ Berkeley Lights Collaborate				N/A	Sources	4/28/2020
63	Antibodies	JS016 antibody candidate	Pre-clinical	Phase 1 to start 2Q 2020		Junshi Biosciences/ Eli Lilly				N/A	Sources	5/5/2020
64	Antibodies	Linked nanobody antibody	Pre-clinical			University of Texas at Austin/ US National Institutes of Health/ Ghent University				N/A	Sources	5/1/2020
65	Antibodies	Single domain antibodies (sdAbs), engineered monoclonal antibody derived from camelids	Pre-clinical			Abcore				N/A	Sources	5/21/2020
66	Antivirals	Favilavir/Favipiravir/T-705/Avigan, licensed in Japan to treat influenza	Clinical	Phase 3 trial in Japan started in March 2020; Phase 2 trial in US started April 2020; Phase 3 trial in India started May 2020 with results expected by July/August 2020 (Glenmark)	NCT04303299 NCT04310228 ChiCTR2000029548 ChiCTR2000029496 ChiCTR2000029544 ChiCTR2000030254 NCT04336904 NCT04333589 NCT04345419	Fujifilm Toyama Chemical/Zhejiang Hisun Pharmaceuticals/numerous trials with global research sponsors/ Brigham and Women's Hospital, Massachusetts General Hospital, and the University of Massachusetts Medical School/ Glenmark Pharmaceuticals		medRxiv (https://doi.org/10.1101/2020.03.17.20037432) medRxiv (https://doi.org/10.1101/2020.04.21.20066761) Kyodo News (https://english.kyodonews.net/news/2020/05/fce701d4d88d-antiflu-avigan-not-showing-apparent-efficacy-in-coronavirus-treatment.html)		N/A	Sources	5/21/2020
67	Antivirals	Kaletra/Aluvia (lopinavir/ritonavir), HIV-1 protease inhibitor	Clinical	RECOVERY trial results expected by June 2020	NCT04303299 NCT04255017 ChiCTR2000029548 ChiCTR2000029539 EudraCT 2020-000936-23 NCT04307693 NCT04315948 NCT04252885 NCT04276688 NCT02735707 NCT04321993 2020-001113-21 NCT04286503 NCT04328012 NCT04346147	Global hospital testing (AbbVie); World Health Organization SOLIDARITY trial (studying lopinavir/ ritonavir with and without interferon beta); University of Oxford RECOVERY trial; REMAP-CAP global trial	UK Government (University of Oxford RECOVERY trial)	NEJM (https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001282?articleTools=true) medRxiv (https://doi.org/10.1101/2020.03.19.20038984) Chinese Journal of Infectious Diseases (http://rs.yiigle.com/yufabiao/1182592.htm) medRxiv (https://doi.org/10.1101/2020.03.28.20045955) medRxiv (https://doi.org/10.1101/2020.04.08.20057539) medRxiv (https://doi.org/10.1101/2020.04.21.20066761) medRxiv (https://doi.org/10.1101/2020.04.25.20079079) medRxiv (https://doi.org/10.1101/2020.04.24.20077735) The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31042-4/fulltext) medRxiv (https://doi.org/10.1101/2020.05.13.20094193)		FDA-approved since 2000, approved to treat HIV-1 infection	Sources	5/20/2020
68	Antivirals	remdesivir, nucleotide analog	Clinical / Expanded Access / FDA issued an Emergency Use Authorization on May 1, 2020	Gilead Phase 3 trial topline results released April 2020 (severe disease) and expected May 2020 (moderate disease); NIAID trial preliminary data released April 2020, full results expected in May 2020	NCT04257656 NCT04252664 NCT04292730 NCT04292899 NCT04280705 EudraCT 2020-000936-23 NCT04315948 NCT04302766 NCT04323761 NCT04349410	Gilead; World Health Organization SOLIDARITY trial; National Institute of Allergy and Infectious Disease (NIAID)'s Adaptive COVID-19 Treatment Trial; Feinstein Institutes		NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2007016) NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2001191) Stat News (https://www.statnews.com/2020/04/16/early-peek-at-data-on-gilead-coronavirus-drug-suggests-patients-are-responding-to-treatment/) Reuters (https://www.reuters.com/article/us-health-coronavirus-gilead-sciences/gilead-disputes-report-that-coronavirus-drug-trial-flopped-idUSKCN225326) Stat (https://www.statnews.com/2020/04/23/data-on-gileads-remdesivir-released-by-accident-show-no-benefit-for-coronavirus-patients/) medRxiv (https://doi.org/10.1101/2020.04.21.20066761) Gilead (https://www.businesswire.com/news/home/20200429005424/en/Gilead-Announces-Results-Phase-3-Trial-Investigational) NIAID (https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19?utm_campaign=+42538088&utm_content=&utm_medium=email&utm_source=govdelivery&utm_term=) Lancet (https://doi.org/10.1016/S0140-6736(20)31022-9) medRxiv (https://doi.org/10.1101/2020.05.02.20088559)	Treatment of Ebola	N/A	Sources	5/20/2020
69	Antivirals	Prezcobix (darunavir, HIV-1 protease inhibitor/cobicistat, CYP3A inhibitor)	Clinical	Phase 3 trials recruiting May 2020	ChiCTR2000029541 NCT04252274 NCT04303299 NCT04304053	Multiple global research sponsors				FDA-approved since 2015, approved to treat HIV-1 infection	Sources	5/20/2020
70	Antivirals	galidesivir	Clinical	Phase 1b recruiting May 2020	NCT03891420	BioCryst Pharmaceuticals	National Institute of Allergy and Infectious Diseases (NIAID)		Treatment of yellow fever	N/A	Sources	5/7/2020
71	Antivirals	Ganovo (danoprevir), hepatitis C virus NS3 protease inhibitor; ritonavir; interferon, approved in China to treat Hepatitis C	Clinical	Small open label trial completed and results released in March 2020; Larger open label trial recruiting May 2020	NCT04291729 NCT04345276	Ascletis/Chinese research sponsors		medRxiv (https://doi.org/10.1101/2020.03.22.20034041)	Treatment of Hepatitis C	N/A	Sources	5/7/2020
72	Antivirals	ASC09, HIV protease inhibitor	Clinical	Phase 3 trial recruiting May 2020	NCT04261907 NCT04261270	Ascletis/Chinese research sponsors			Treatment of HIV/AIDS	N/A	Sources	5/7/2020
73	Antivirals	Truvada (emtricitabine and tenofovir, both HIV-1 nucleoside analog reverse transcriptase inhibitors)	Clinical	Phase 3 trial recruiting May 2020	ChiCTR2000029468 NCT04334928	Plan Nacional sobre el Sida				FDA-approved since 2004, approved to treat and prevent HIV-1 infection	Sources	5/7/2020
74	Antivirals	Arbidol (umifenovir), licensed in Russia and China for treatment of respiratory viral infections	Clinical	Phase 4 trials recruiting May 2020	NCT04252885 NCT04350684 NCT04286503 NCT04260594 NCT04273763	Multiple global research sponsors		medRxiv (https://doi.org/10.1101/2020.03.19.20038984) Chinese Journal of Infectious Diseases (http://rs.yiigle.com/yufabiao/1182592.htm) medRxiv (https://doi.org/10.1101/2020.03.17.20037432) medRxiv (https://doi.org/10.1101/2020.03.28.20045955) medRxiv (https://doi.org/10.1101/2020.04.08.20057539) medRxiv (https://doi.org/10.1101/2020.04.06.20042580) medRxiv (https://doi.org/10.1101/2020.04.11.20056523) medRxiv (https://doi.org/10.1101/2020.04.25.20079079)		N/A	Sources	5/7/2020
75	Antivirals	Vicromax, broad spectrum antiviral	Pre-clinical			ViralClear Pharmaceuticals					Sources	Prior to 4/20/2020
76	Antivirals	ISR-50	Pre-clinical			ISR Immune System Regulation				N/A	Sources	Prior to 4/20/2020
77	Antivirals	Tamiflu (oseltamivir), neuraminidase inhibitor	Clinical	REMAP-CAP trial recruiting May 2020	NCT04303299 NCT04255017 NCT04261270 NCT02735707 NCT04338698 NCT04371601	Roche; REMAP-CAP global trial		medRxiv (https://doi.org/10.1101/2020.03.28.20045955) medRxiv (https://doi.org/10.1101/2020.04.11.20056523)		FDA-approved since 1999, approved to treat and prevent influenza	Sources	5/7/2020
78	Antivirals	antiviral Fc conjugates	Pre-clinical			Cidara Therapeutics				N/A	Sources	Prior to 4/20/2020
79	Antivirals	Antiviral compounds	Pre-clinical			Cocrystal Pharma				N/A	Sources	Prior to 4/20/2020
80	Antivirals	EIDD-2801, oral ribonucleoside analog	Clinical	Phase 1 started April 2020		Ridgeback Biotherapeutics / Drug Innovation Ventures at Emory (DRIVE)				N/A	Sources	Prior to 4/20/2020
81	Antivirals	Virazole (ribavirin for inhalation solution)	Clinical / Compassionate Use	Phase 1 recruiting May 2020	NCT04356677	Bausch Health				FDA-approved since 1985, approved to treat lower respiratory tract infections due to RSV	Sources	5/7/2020
82	Antivirals	Antiviral drug combinations	Pre-clinical			SCORE consortium (universities of Aix-Marseille, Leuven, Utrecht, Bern, and Lubeck), the Helmholtz Centre for Infection Research, and Janssen Pharmaceutica NV	EU Commission (Horizon 2020 Program)			Unknown	Sources	Prior to 4/20/2020
83	Antivirals	Levovir (clevudine)	Clinical	Phase 2 trial not yet recruiting	NCT04347915	Bukwang Pharm					Sources	5/7/2020
84	Antivirals	AB001	Pre-clinical	Phase 1 to start in 2020		Agastiya Biotech				N/A	Sources	4/24/2020
85	Antivirals	BTL-tml	Clinical	Has been used in 36 patients anecdotally		Beech Tree Labs			Treatment of herpes virus infections	N/A	Sources	5/5/2020
86	Antivirals	DAS181, recombinant sialidase (nebulized)	Compassionate Use/ Clinical	Compassionate use finding released in May 2020; Phase 2/3 started enrolling in May 2020	NCT03808922 NCT04354389 NCT04298060 NCT04324489	Ansun Biopharma/ Renmin Hospital of Wuhan University		PR Newswire (https://www.prnewswire.com/news-releases/ansun-biopharma-announces-positive-results-from-investigator-initiated-trial-of-novel-covid-19-treatment-301033871.html)	Treatment of lower respiratory tract parainfluenza virus infections and severe influenza infections	N/A	Sources	5/5/2020
87	Antivirals	emetine hydrochloride	Clinical	Phase 2/3 to start in Q3 2020		Acer Therapeutics/ US National Center for Advancing Translational Sciences (NCATS)			To treat viral hepatitis and varicella-virus	N/A	Sources	5/13/2020
88	Antivirals	AT-527, oral purine nucleotide prodrug	Clinical	Phase 2 trial to start May 2020	NCT04396106	Atea Pharmaceuticals			Treatment of Hepatitis C infections	N/A	Sources	5/21/2020
89	Cell-based therapies	PLX cell product, placenta-based cell therapy	Clinical/ Compassionate Use	Results from compassionate use released in April 2020		Pluristem Therapeutics/BIH Center for Regenerative Therapy/Berlin Center for Advanced Therapies		Pluristem Therapeutics (https://www.pluristem.com/wp-content/uploads/2020/04/PSTI-PR-Follow-up-on-Covid-19-treatments-FINAL-FOR-RELEASE.pdf)	Various conditions	N/A	Sources	5/8/2020
90	Cell-based therapies	Mesenchymal stem cells	Clinical	Phase 1 trials ongoing May 2020; Phase 1/2 trials recruiting May 2020; Phase 2/3 trial recruiting May 2020	30 trials listed in clinicaltrials.gov ChiCTR2000029990 NCT04315987 NCT04302519 NCT04288102 NCT04313322 NCT04273646 NCT04371601 NCT04315987 NCT04252118 NCT04336254 NCT04339660 NCT04371601 NCT04366063	Numerous trials with global research sponsors		Aging and Disease (http://www.aginganddisease.org/article/0000/2152-5250/ad-0-0-216.shtml) ChinaXiv (http://chinaxiv.org/abs/202002.00084)		N/A	Sources	5/8/2020
91	Cell-based therapies	Autologous Adipose-Tissue Derived Mesenchymal Stem Cells (ADMSCs)	Expanded access			Celltex		Celltex (https://celltexbank.com/transplantation-of-ace2-mesenchymal-stem-cells-improves-the-outcome-of-patients-with-covid-19-pneumonia/) Celltex (https://celltexbank.com/chinaxiv-reports-clinical-remission-of-a-critically-ill-covid-19-patient-treated-by-human-umbilical-cord-mesenchymal-stem-cells/)	Injuries, Pain, and Autoimmune, Vascular and Other Disease, including Inflammatory lung conditions, pneumonia, and chronic obstructive pulmonary disease (COPD)	N/A	Sources	5/13/2020
92	Cell-based therapies	Ryoncil (remestemcel-L), allogenic mesenchymal stem cells	Clinical/ Compassionate Use/ Expanded Access	Compassionate use data shared April 2020; Phase 3 trial recruiting May 2020	NCT04366830 NCT04371393	Mesoblast/ Cardiothoracic Surgical Trials Network		Mesoblast (http://investorsmedia.mesoblast.com/static-files/337e723a-340d-493e-a4a1-0971d2c71460)	Graft versus host disease and other rare diseases, chronic obstructive pulmonary disease	N/A	Sources	5/7/2020
93	Cell-based therapies	MultiStem, bone marrow stem cells	Clinical	Phase 2/3 trial recruiting May 2020	NCT04367077	Athersys / The University of Texas Health Science Center at Houston	Medical Technology Enterprise Consortium (MTEC)		Acute Respiratory Distress Syndrome; Stroke		Sources	5/10/2020
94	Cell-based therapies	Allogeneic T-cell therapies	Pre-clinical			AlloVir/Baylor College of Medicine				N/A	Sources	Prior to 4/20/2020
95	Cell-based therapies	Natural killer cell-based therapy	Pre-clinical	Begin Phase 1 by end of 2020		GC LabCell / KLEO Pharmaceuticals				N/A	Sources	Prior to 4/20/2020
96	Cell-based therapies	CYNK-001, allogeneic, natural killer cell therapy	Clinical	Phase 1/2 study not yet recruiting May 2020	NCT04365101	Celularity/ Lung Biotechnology PBC			Various hematologic cancers and solid tumors	N/A	Sources	5/7/2020
97	Cell-based therapies	CAP-1002, allogenic cardiosphere-derived cells	Expanded access	Expanded access trial ongoing May 2020	NCT04338347	Capricor Inc.			Duchenne muscular dystrophy	N/A	Sources	5/7/2020
98	Cell-based therapies	haNK, natural killer cells	Clinical			ImmunityBio / NantKwest				N/A	Sources	5/21/2020
99	Cell-based therapies	Bone marrow-derived allogenic mesenchymal stem cells (BM-Allo-MSC)	Pre-clinical	Phase 1b trial to start in Q2 2020		ImmunityBio/ NantKwest/ Be The Match BioTherapies				N/A	Sources	5/21/2020
100	Cell-based therapies	Allogenic, adipose-derived mesenchymal stem cells (HB-adMSCs)	Clinical	Phase 2 started in April 2020	NCT04348435 NCT04349631 NCT04362189	Hope Biosciences	Hope Biosciences Stem Cell Research Foundation		Rheumatoid arthritis	N/A	Sources	4/24/2020
101	Cell-based therapies	Astrostem-V, Allogenic, adipose-derived mesenchymal stem cells (HB-adMSCs)	Clinical	Phase 1/2a trial approved by South Korea Ministry of Food and Drug Safety in March 2020		Naturecell				N/A	Sources	5/7/2020
102	Cell-based therapies	AmnioBoost, concentrated allogeneic MSCs and cytokines derived from amniotic fluid	Clinical	Phase 1 enrolling April 2020		Lattice Biologics				N/A	Sources	4/23/2020
103	Cell-based therapies	Chimeric antigen receptors (CAR)/T cell receptors (TCR)-T cell therapy	Pre-clinical			Duke-NUS Medical School				N/A	Sources	4/30/2020
104	RNA-based treatments	RNAi - testing 150 RNAis	Pre-clinical			Sirnaomics				N/A	Sources	Prior to 4/20/2020
105	RNA-based treatments	VIR-2703 (ALN-COV) siRNA candidate	Pre-clinical	Phase 1 to start by the end of 2020		Vir Biotech / Alnylam Pharmaceuticals				N/A	Sources	5/5/2020
106	RNA-based treatments	Ampligen; (rintatolimod)	Pre-clinical			AIM ImmunoTech/National Institute of Infectious Diseases in Japan				N/A	Sources	Prior to 4/20/2020
107	RNA-based treatments	OT-101, a TGF-Beta antisense drug candidate	Clinical	Phase 2 study IND submitted to FDA on April 27, 2020		Mateon Therapeutics			Various cancers	N/A	Sources	5/7/2020
108	RNA-based treatments	Inhaled mRNA	Pre-clinical	Phase 1 to start Q4 2020		Neurimmune / Ethris				N/A	Sources	Prior to 4/20/2020
109	RNA-based treatments	Antisense oligonucleotides, peptide conjugated	Pre-clinical			Sarepta Therapeutics/ US Army Medical Research Institute of Infectious Diseases (USAMRIID)				N/A	Sources	5/1/2020
110	Scanning compounds to repurpose	Scanning library of antiviral compounds	Pre-clinical			Janssen Pharmaceutical Companies	Biomedical Advanced Research and Development Authority (BARDA)		N/A	N/A	Sources	Prior to 4/20/2020
111	Scanning compounds to repurpose	Scanning compounds to repurpose	Pre-clinical			Novartis			N/A	N/A	Sources	Prior to 4/20/2020
112	Scanning compounds to repurpose	Scanning antiviral compounds previously in development	Pre-clinical	Lead candidate (protease inhibitor) to start Phase 1 trial in Q3 2020		Pfizer			N/A	N/A	Sources	Prior to 4/20/2020
113	Scanning compounds to repurpose	Scanning compounds to repurpose	Pre-clinical			Merck			N/A	N/A	Sources	Prior to 4/20/2020
114	Scanning compounds to repurpose	Repurposing antiviral drug candidates	Pre-clinical			Materia Medica/Cyclica			N/A	N/A	Sources	Prior to 4/20/2020
115	Scanning compounds to repurpose	Screening new drugs + library of antiviral compounds	Pre-clinical			Enanta Pharmaceuticals			N/A	N/A	Sources	Prior to 4/20/2020
116	Scanning compounds to repurpose	Screening drug compounds	Pre-clinical			Southwest Research Institute			N/A	N/A	Sources	Prior to 4/20/2020
117	Scanning compounds to repurpose	Scanning compounds to repurpose	Pre-clinical			Takeda			N/A	N/A	Sources	Prior to 4/20/2020
118	Scanning compounds to repurpose	Scanning compounds to repurpose	Pre-clinical			Queens University Belfast	UK Government		N/A	N/A	Sources	Prior to 4/20/2020
119	Scanning compounds to repurpose	Scanning compound libraries	Pre-clinical			COVID-19 Therapeutics Accelerator (15 companies shared their compound libraries including BD, bioMérieux, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck [known as MSD outside the US and Canada], Merck KGaA, Novartis, Pfizer, and Sanofi)/ Fujifilm Diosynth Biotechnologies	Gates Foundation / Wellcome / Mastercard Impact Fund		N/A	N/A	Sources	5/1/2020
120	Scanning compounds to repurpose	Artificial intellegence-based screening to identify repurposed drug combinations	Pre-clinical	Combinations will be ready for preclinical testing in May 2020		Healx			N/A		Sources	Prior to 4/20/2020
121	Scanning compounds to repurpose	Identifying drugs to repurpose	Pre-clinical			The Castleman Disease Collaborative Network and the Center for Study & Treatment of Inflammatory Lymphadenopathies					Sources	Prior to 4/20/2020
122	Scanning compounds to repurpose	Screening for antiviral drug candidates	Pre-clinical			Anixa Biosciences/ OntoChem					Sources	4/21/2020
123	Scanning compounds to repurpose	Identifying drugs to repurpose	Pre-clinical	Identified 30 known drugs that inhibit SARS-CoV-2 replication		Sanford Burnham Prebys Medical Discovery Institute, the University of Hong Kong, Scripps Research, UC San Diego School of Medicine, the Icahn School of Medicine at Mount Sinai and UCLA		bioRxiv (https://doi.org/10.1101/2020.04.16.044016)			Sources	4/21/2020
124	Scanning compounds to repurpose	AI-based screening to identify a peptide cocktail	Pre-clinical			Nuritas	Partnership for Advanced Computing in Europe (PACE)			N/A	Sources	4/24/2020
125	Scanning compounds to repurpose	Identify anti-coronavirus compounds that target cellular host genes	Pre-clinical			Vir Biotechnology/ GSK				N/A	Sources	4/29/2020
126	Scanning compounds to repurpose	Screening of drug compounds	Pre-clinical			Vanda Pharmaceuticals/ University of Illinois at Chicago				N/A	Sources	4/29/2020
127	Scanning compounds to repurpose	Identify novel drugs	Pre-clinical			Shionogi/ Hokkaido University Research Center for Zoonosis Control				N/A	Sources	4/29/2020
128	Other	Methylprednisolone / ciclesonide (Alvesco)/ hydrocortisone/ corticosteroids	Clinical	Primary study ends April 2020 (Peking) / June 2020 (Tongji)/ RECOVERY trial results expected by June 2020	NCT04244591 NCT04263402 NCT04273321 ChiCTR2000029656 ChiCTR2000029386 NCT02735707 NCT04330586 2020-001113-21 NCT04345445 NCT04349410 NCT04329650	Numerous trials with research sponsors globally; University of Oxford RECOVERY trial; REMAP-CAP global trial; Covis Pharma B.V.	UK Government (University of Oxford RECOVERY trial)	medRxiv (https://doi.org/10.1101/2020.03.06.20032342) medRxiv (https://doi.org/10.1101/2020.03.28.20045955) medRxiv (https://doi.org/10.1101/2020.04.07.20056390) medRxiv (https://doi.org/10.1101/2020.04.17.20064469) medRxiv (https://doi.org/10.1101/2020.04.17.20069773) medRxiv (https://doi.org/10.1101/2020.04.21.20066258) medRxiv (https://doi.org/10.1101/2020.05.04.20074609) medRxiv (https://doi.org/10.1101/2020.05.08.20094755) medRxiv (https://doi.org/10.1101/2020.05.11.20097709)		FDA-approved since at least the 1950s, approved to treat many diseases, including anti-iflammatory conditions and some cancers; asthma (ciclesconide)	Sources	5/21/2020
129	Other	Chloroquine/ Hydroxychloroquine, antimalarial	Clinical / FDA issued an Emergency Use Authorization on March 28, 2020 (oral formulations of chloroquine phosphate and hydoxychloroquine sulfate donated to the Strategic National Stockpile to treat adolescent and adult hospitalized patients with COVID-19 when a clinical trial is not available or feasible)	Results from the University of Washington/New York University trial expected in summer 2020; RECOVERY trial results expected by June 2020	Over 50 trials registered at Clinicaltrials.gov, including: NCT04261517 NCT04303507 NCT04303299 NCT04304053 NCT04307693 NCT04316377 NCT04315948 NCT04321993 2020-001113-21 NCT04323527 NCT04333732 NCT04332991 NCT04345419 NCT04341870 NCT04345289 NCT02735707 NCT04351347 NCT04341493 NCT04332094 NCT04349410 NCT04286503 NCT04328012 NCT04346147	Numerous trials with global research sponsors; University of Minnesota; University of Washington/New York University (hydroxychloroquine); University of Oxford; IHU-Méditerranée Infection and others; World Health Organization SOLIDARITY trial (chloroquine); New York State Department of Health (hydroxychloroquine with zithromax); Mahidol Oxford Tropical Medicine Research Unit (hydroxychloroquine and chloroquine); ORCHID Trial with National Heart, Lung, and Blood Institute (NHLBI); REMAP-CAP global trial; Novartis; PRINCIPLE trial	COVID-19 Treatment Accelerator (University of Washington/New York University trial and Mahidol Oxford Tropical Medicine Research Unit trial); UK Government (University of Oxford RECOVERY trial and PRINCIPLE trial)	NCT04261517 (https://clinicaltrials.gov/ct2/show/NCT04261517?draw=5+%28prelim+outcomes%3F%29) IHU-Méditerranée Infection (https://www.mediterranee-infection.com/wp-content/uploads/2020/03/Hydroxychloroquine_final_DOI_IJAA.pdf) Journal of ZheJiang University (Medical Sciences) (http://www.zjujournals.com/med/CN/10.3785/j.issn.1008-9292.2020.03.03) medRxiv (https://doi.org/10.1101/2020.03.22.20040758) Int'l Journal of Antimicrobial Agents (https://doi.org/10.1016/j.ijantimicag.2020.105949) medRxiv (ChiCTR2000029559) (https://doi.org/10.1101/2020.04.10.20060558) medRxiv (https://doi.org/10.1101/2020.03.22.20040949) medRxiv (https://doi.org/10.1101/2020.04.02.20047050) medRxiv (https://doi.org/10.1101/2020.03.31.20048777) medRxiv (https://doi.org/10.1101/2020.03.24.20042366) medRxiv (NCT04323527) (https://doi.org/10.1101/2020.04.07.20056424) medRxiv (https://doi.org/10.1101/2020.04.08.20057539) medRxiv (https://doi.org/10.1101/2020.04.08.20054551) ScienceDirect (https://www.sciencedirect.com/science/article/pii/S0399077X20300858?via%3Dihub) ISAC (https://www.isac.world/news-and-publications/official-isac-statement) ScienceDirect (https://www.sciencedirect.com/science/article/pii/S0924857920300996) medRxiv (https://doi.org/10.1101/2020.04.10.20060699) medRxiv (ChiCTR2000029868) (https://doi.org/10.1101/2020.04.10.20060558) medRxiv (https://doi.org/10.1101/2020.04.14.20065276) medRxiv (https://doi.org/10.1101/2020.04.16.20065920) medRxiv (https://doi.org/10.1101/2020.04.16.20068205) medRxiv (https://doi.org/10.1101/2020.04.22.20075671) medRxiv (https://doi.org/10.1101/2020.04.21.20066761) medRxiv (https://doi.org/10.1101/2020.04.26.20081059) medRxiv (https://doi.org/10.1101/2020.04.27.20082180) medRxiv (https://doi.org/10.1101/2020.04.27.20073379) medRxiv (https://doi.org/10.1101/2020.04.27.20074583) NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2012410) medRxiv (https://doi.org/10.1101/2020.05.02.20080036) medRxiv (https://doi.org/10.1101/2020.05.02.20088872) JAMA (https://jamanetwork.com/journals/jama/fullarticle/2766117) medRxiv (https://doi.org/10.1101/2020.05.07.20093831) medRxiv (https://doi.org/10.1101/2020.05.07.20094326) medRxiv (https://doi.org/10.1101/2020.05.05.20088757) BMJ (https://www.bmj.com/content/369/bmj.m1849) BMJ (https://www.bmj.com/content/369/bmj.m1844) medRxiv (https://doi.org/10.1101/2020.05.14.20101774) medRxiv (https://doi.org/10.1101/2020.05.12.20099028) medRxiv (https://doi.org/10.1101/2020.05.13.20094193)		FDA-approved since 1949, approved to treat malaria (chloroquine), FDA-approved since at least 1955, approved to treat malaria, rheumatoid arthritis, and lupus (hydroxychloroquine)	Sources	5/20/2020
130	Other	camostat mesylate, transmembrane protease serine 2 (TMPRSS2) inhibitor, approved in Japan to treat multiple conditions including pancreatitis	Clinical	Phase 1/2, Phase 2, and Phase 3 trials recruiting in May 2020	NCT04321096 NCT04353284 NCT04338906 NCT04374019 NCT04355052	Multiple global research sponsors				N/A	Sources	5/7/2020
131	Other	Jakafi/jakavi (ruxolitinib)	Clinical / Expanded Access	Novartis/Incyte Phase 3 trial started April 2020	ChiCTR2000029580 NCT04334044 NCT04331665 NCT04337359 NCT04348071 NCT04338958 NCT04348695 NCT04355793 NCT04354714 NCT04377620 NCT04362137 NCT04366232 NCT04361903 NCT04374149 NCT04338958 NCT04359290	Novartis / Incyte, numerous researchers globally				FDA-approved since 2011, approved to treat myelofibrosis, polycythemia vera, and acute graft-versus-host disease	Sources	5/8/2020
132	Other	interferon/peginterferon alpha-2b, PegIntron, Sylatron, IntronA, PegiHep	Clinical	Phase 2/3 enrolling May 2020	NCT04273763 NCT04349410	Zydus Cadila Group; The Camelot Foundation				PegIntron - FDA-approved since 2001, approved to treat Hepatitis C; Sylatron - FDA-approved since 2001, approved for the adjuvant treatment of melanoma; Intron A - FDA-approved since 1986, approved to treat Hepatitis C and certain cancers	Sources	5/7/2020
133	Other	Novaferon, Nova, interferon, licensed in China for Hepatitis B	Clinical		ChiCTR2000029573 ChiCTR2000029496	Hu'nan Haiyao hongxingtang Pharmaceutical Co., Ltd (Novaferon)		medRxiv (https://doi.org/10.1101/2020.04.24.20077735)		N/A	Sources	5/7/2020
134	Other	Traumakine (interferon beta 1-a)	Clinical	REMAP-CAP trial recruiting May 2020	NCT02735707	Faron Pharmaceuticals / REMAP-CAP global trial/ WHO SOLIDARITY trial				N/A	Sources	5/7/2020
135	Other	Recombinant human interferon alpha-1b	Clinical	Phase 3 trial recruiting May 2020	NCT04320238	Shanghai Jiao Tong University School of Medicine		medRxiv (https://doi.org/10.1101/2020.04.11.20061473)			Sources	5/7/2020
136	Other	SNG001, inhaled formulation of interferon beta-1a	Clinical	Phase 2 began in March 2020; initial results expected by end of June 2020		Synairgen / University of Southampton			Asthma patients with cold or flu infection; COPD patients with viral infections	N/A	Sources	5/8/2020
137	Other	Peginterferon lambda	Clinical	Phase 2 began in April 2020	NCT04331899	Eiger BioPharmaceuticals, Inc.			Hepatitis Delta		Sources	Prior to 4/20/2020
138	Other	Cerocal (ifenprodil), NP-120, an NDMA receptor glutamate receptor antagonist targeting Glu2NB	Pre-clinical			Algernon Pharmaceuticals			Idiopathic Pulmonary Fibrosis	N/A	Sources	Prior to 4/20/2020
139	Other	APN01; recombinant soluble human Angiotensin Converting Enzyme 2	Clinical	Phase 2 began in April 2020		University of British Columbia/Apeiron Biologics	Austrian Government		Acute lung injury, Acute respiratory distress syndrome, Pulmonary arterial hypertension	N/A	Sources	Prior to 4/20/2020
140	Other	Brilacidin, a defensin mimetic	Clinical			Innovation Pharmaceuticals			Oral Mucositis; Ulcerative Proctitis/Ulcerative Proctosigmoiditis; Acute Bacterial Skin and Skin Structure Infection	N/A	Sources	4/28/2020
141	Other	BXT-25; glycoprotein	Pre-clinical			Bioxytran				N/A	Sources	Prior to 4/20/2020
142	Other	Peptides targeting the NP protein	Pre-clinical			CEL-SCI / University of Georgia Center for Vaccines and Immunology				Unknown	Sources	Prior to 4/20/2020
143	Other	BIO-11006, inhaled peptide	Clinical			Biomarck Pharmaceuticals			Acute Respiratory Distress Syndrome; Non-Small Cell Lung Cancer; Chronic Obstructive Pulmonary Disease (COPD)	N/A	Sources	4/24/2020
144	Other	Gilenya (fingolimod), sphingosine 1-phosphate receptor modulator	Clinical	Phase 2 trial recruiting May 2020	NCT04280588	The First Affiliated Hospital of Fujian Medical University/Novartis				FDA-approved since 2010, approved to treat multiple sclerosis	Sources	5/7/2020
145	Other	WP1122, glucose decoy prodrug (and related drug candidates)	Pre-clinical			Moleculin Biotech / University of Texas Medical Branch				N/A	Sources	Prior to 4/20/2020
146	Other	Rebif (interferon beta-1a)	Clinical	Phase 3 trial recruiting May 2020	EudraCT 2020-000936-23 NCT04315948	Institut National de la Sante et de la Recherche Medicale (Merck KGaA)				FDA-approved since 2002, approved to treat multiple sclerosis	Sources	5/7/2020
147	Other	nafamostat, approved in Japan to treat pancreatitis and other diseases	Clinical	University of Tokyo trial (IV formulation) starts April 2020; Ensysce trial will be with oral formulation		University of Tokyo/ National Center for Global Health and Medicine/ Ensysce Biosciences/ Institut Pasteur Korea				N/A	Sources	5/19/2020
148	Other	A number of synthesized nanoviricide drug candidates	Pre-clinical			NanoViricides				N/A	Sources	Prior to 4/20/2020
149	Other	Cozaar (losartan), angiotensin II receptor blocker (ARB)	Clinical	Phase 2 and Phase 2/3 and Phase 4 trials recruiting in May 2020	NCT04312009 NCT04311177 NCT04349410 NCT04335123 NCT04343001 NCT04328012 NCT04340557	Multiple global research sponsors	COVID-19 Treatment Accelerator			FDA-approved since 1995, approved to treat hypertension and diabetic nephropathy	Sources	5/8/2020
150	Other	Diovan (valsartan), angiotensin II receptor blocker (ARB)	Clinical	Phase 4 trials recruiting May 2020	NCT04335786 NCT04330300	Multiple global research sponsors				FDA-approved since 1996, approved to treat hypertension, treat heart failure, and reduce cardiovascular mortality in patients after myocardial infarction	Sources	5/8/2020
151	Other	Micardis (telmisartan)	Clinical	Phase 2 not yet recruiting as of April 2020	NCT04360551	University of Hawaii (Boehringer Ingelheim)				FDA-approved since 1998, approved to treat hypertension and reduce cardiovascular risk in patients unable to take ACE inhibitors	Sources	4/27/2020
152	Other	Activase (alteplase), tissue plasminogen activator (tPA)	Compassionate Use			Beth Israel Deaconess, the University of Colorado Anschultz Medical Campus, and Denver Health (Genentech)				FDA-approved since 1987, approved to treat stroke, myocardial infarction, and pulmonary embolism	Sources	Prior to 4/20/2020
153	Other	Leukine (sargramostim, rhu-Granulocyte macrophage colony stimulating factor )	Clinical		NCT04326920	Partner Therapeutics			Pulmonary conditions that affect alveolar macrophases (nebulized leukine); ARDS (IV leukine)	FDA-approved since 1991, approved to shorten the time to neutrophil recovery and reduce the incidence of infections following chemotherapy, mobilize hematopoietic progenitor cells, accelerate myeloid reconstitution following bone marrow or cell transplantation, treat delayed neutrophil recovery or graft failure after bone marrow transplantation, and increase survival of radiation	Sources	Prior to 4/20/2020
154	Other	Kineret (anakinra), interleukin-1 receptor antagonist	Clinical		NCT04324021 NCT02735707 NCT04339712 NCT04330638 NCT04366232	Swedish Orphan Biovitrum / REMAP-CAP global trial		medRxiv (https://doi.org/10.1101/2020.04.23.20076612)		FDA-approved since 2001, approved to treat rheumatoid arthritis and cryopyrin-associated periodic syndromes	Sources	5/7/2020
155	Other	AT-001, aldose reductase inhibitor	Clinical / Compassionate Use			Applied Therapeutics / numerous New York City hospitals			Diabetic cardiomyopathy	N/A	Sources	Prior to 4/20/2020
156	Other	Aplidin (plitidepsin), approved in Australia to treat multiple myeloma	Clinical			PharmaMar					Sources	Prior to 4/20/2020
157	Other	dipyridamole (Persantine), anticoagulant	Clinical			Numerous Chinese hospitals		medRxiv (https://doi.org/10.1101/2020.02.27.20027557)		FDA-approved since 1961, approved to prevent postoperative thromboembolic complications of cardiac valve replacement	Sources	Prior to 4/20/2020
158	Other	recombinant human plasma gelsolin (rhu-pGSN)	Clinical			BioAegis Therapeutics Inc.			Community-acquired pneumonia	N/A	Sources	Prior to 4/20/2020
159	Other	solnatide (synthetic molecule with a structure based on the lectin-like domain of human Tumour Necrosis Factor alpha)	Clinical			Apeptico	EU Commission (Horizon 2020 Program)		Pneumonia, sepsis, ARDS, Primary Graft Dysfunction, and pulmonary dysfunctions	N/A	Sources	Prior to 4/20/2020
160	Other	Nitric oxide	Clinical		NCT04305457 NCT04312243 NCT04306393 NCT03331445	Massachusetts General Hospital; University of British Columbia				FDA-approved since 1999, approved to improve oxygenation in neonates	Sources	Prior to 4/20/2020
161	Other	PP-001	Clinical			Panoptes Pharma GmbH			Severe eye diseases	N/A	Sources	Prior to 4/20/2020
162	Other	ARMS-1	Clinical	Trial starts April 2020		ARMS Pharmaceutical / UH Cleveland Medical Center / Case Western Reserve University	Cleveland Foundation		Influenza prophylaxis	N/A	Sources	Prior to 4/20/2020
163	Other	PUL-042 inhalation solution	Clinical		NCT04312997	Pulmotect			Prevent and treat respiratory complications in immunosuppressed cancer patients	N/A	Sources	Prior to 4/20/2020
164	Other	Olumiant (baricitinib), Janus kinase (JAK) inhibitor	Clinical	NIAID trial remdesivir + baricitinib recruiting May 2020	NCT04321993 NCT04320277 NCT04340232 NCT04280705 NCT04345289 NCT04346147 NCT04358614 NCT04373044	National Institute of Allergy and Infectious Disease (NIAID)'s Adaptive COVID-19 Treatment Trial; Nova Scotia Health Authority; Hospital of Prato; University of Colorado (Eli Lilly)				FDA-approved since 2018, approved to treat rheumatoid arthritis	Sources	5/13/2020
165	Other	Xeljanz (tofacitinib), Janus kinase (JAK) inhibitor	Clinical		NCT04332042	Pfizer				FDA-approved since 2012, approved to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis	Sources	Prior to 4/20/2020
166	Other	colchicine	Clinical		NCT04326790 NCT04328480 NCT04322565 NCT04322682	Numerous research sponsors globally				N/A (but has been used in the US since the early 1800s, and FDA-approved in combination with probenecid, approved to treat gout)	Sources	Prior to 4/20/2020
167	Other	heparin; low molecular weight heparin (enoxaparin), anticoagulant	Clinical		NCT04366960 NCT04360824 NCT04359277 NCT04354155 NCT04367831 NCT04345848 NCT04373707 NCT04372589 NCT04362085 NCT04344756	Multiple global research sponsors		medRxiv (https://doi.org/10.1101/2020.03.28.20046144) medRxiv (https://doi.org/10.1101/2020.04.15.20067017) medRxiv (https://doi.org/10.1101/2020.04.23.20076851) JACC (http://www.onlinejacc.org/content/early/2020/05/05/j.jacc.2020.05.001?_ga=2.52741547.2046438614.1588863110-2104341714.1587686709)		FDA-approved since at least 1993, approved to prevent blood clots and prevent/treat venous thromboembolism and myocardial infarction	Sources	5/10/2020
168	Other	DSTAT (dociparstat sodium), glycosaminoglycan derivative of heparin	Clinical	Phase 2/3 study to start in May 2020		Chimerix			Acute myeloid leukemia	N/A	Sources	5/5/2020
169	Other	LAU-7b (fenretinide)	Clinical	Phase 2 to start May 2020		Laurent Pharmaceuticals			Treat exaggerated inflammatory response in adult cystic fibrosis patients	N/A	Sources	5/10/2020
170	Other	ST-001 nanoFenretinide (fenretinide)	Clinical			SciTech Development, LLC			non-Hodgkin's lymphoma	N/A	Sources	5/13/2020
171	Other	Xpovio (selinexor), oral, selective inhibitor of nuclear export (SINE) compound	Clinical			Karyopharm Therapeutics			Treat various cancers	FDA-approved since 2019, approved to treat multiple myeloma	Sources	Prior to 4/20/2020
172	Other	BLD-2660, synthetic small molecule inhibitor of calpain (CAPN) 1, 2, and 9	Clinical		NCT04334460	Blade Therapeutics				N/A	Sources	Prior to 4/20/2020
173	Other	Calquence (acalabrutinib), Bruton's tyrosine kinase (BTK) inhibitor	Clinical	ACCORD Phase 2 trial to start May 2020	NCT04346199 NCT04380688	AstraZeneca; ACCORD study	UK Government (ACCORD study)			FDA-approved since 2017, approved to treat mantle cell lymphoma and chronic lymphocytic leukemia	Sources	5/10/2020
174	Other	CD24Fc, biological immunomodulator (nonpolymorphic regions of CD24 attached to the Fc region of human IgG1)	Clinical	Phase 3 trial started in April 2020	NCT04317040	OncoImmune			Graft versus Host Disease	N/A	Sources	4/24/2020
175	Other	Aviptadil, synthetic form of Vasoactive Intestinal Polypeptide	Clinical	Phase 2 trial started in April 2020	NCT04311697	NeuroRx/ Relief Therapeutics/ Thomas Jefferson University Hospital/ NYU Langone Health			Sarcoid, Pulmonary Fibrosis, Bronchospasm, Erectile Dysfunction, and Acute Respiratory Distress Syndrome (ARDS)	N/A	Sources	5/10/2020
176	Other	vazegepant, CGRP receptor antagonist	Clinical	Phase 2 to start April 2020		Biohaven / Thomas Jefferson University			Acute migraine		Sources	Prior to 4/20/2020
177	Other	CM4620-IE, calcium release-activated calcium (CRAC) channel inhibtor	Clinical	Phase 2 started in April 2020	NCT04345614	CalciMedica			Pancreatitis		Sources	Prior to 4/20/2020
178	Other	ivermectin	Clinical		NCT04343092 NCT04345419 NCT04351347	MedinCell/ University of Utah/ Surgisphere Corp; University of Baghdad; Tanta University				FDA-approved since 1996, approved to treat intestinal parasites and head lice infestations	Sources	4/23/2020
179	Other	nitazoxanide, antiprotozoal	Clinical		NCT04351347 NCT04348409 NCT04343248 NCT04341493 NCT04345419	Romark Laboratories; various researchers globally				FDA-approved since 2002, approved to treat diarrhea caused by Giardia lamblia or Cryptosporidum parvum	Sources	4/23/2020
180	Other	EPAspire, oral formulation of highly purified eicosapentaenoic acid free fatty acid (EPA-FFA) in gastro-resistant capsules	Clinical			KD Pharma / SLA Pharma			Familial adenomatous polyposis	N/A	Sources	Prior to 4/20/2020
181	Other	niclosamide	Clinical		NCT04345419	Union Therapeutics/ Institut Pasteur Korea/ Daewoong Therapeutics			Atopic Dermatitis	N/A	Sources	4/24/2020
182	Other	ADX-629, orally available reactive aldehyde species (RASP) inhibitor	Clinical	IND submission to FDA in June 2020		Aldeyra Therapeutics			Systemic immune-mediated diseases	N/A	Sources	5/21/2020
183	Other	ADX-1612, HSP 90 inhibitor	Clinical	IND submission to FDA in Q3 2020		Aldeyra Therapeutics			Various cancers	N/A	Sources	5/21/2020
184	Other	N-803, IL-15 "superagonist"	Clinical			ImmunityBio / NantKwest			Bladder Carcinoma In Situ	N/A	Sources	Prior to 4/20/2020
185	Other	piclidenoson, A3 adenosine receptor agonist	Clinical	Pre-IND meeting request filed with FDA in May 2020	NCT04333472	Can-Fite BioPharma			Rheumatoid arthritis; psoriasis	N/A	Sources	5/21/2020
186	Other	Ryanodex (dantrolene sodium), skeletal muscle relaxant	Clinical			Eagle Pharmaceuticals / Amneal Pharmaceuticals / Alcami Corporation / Hackensack University Medical Center				FDA-approved since 2014, approved to prevent and treat malignant hyperthermia	Sources	4/21/2020
187	Other	Veyonda (idronoxil)	Clinical			Noxopharm			Prostate cancer	N/A	Sources	4/23/2020
188	Other	MRx-4DP0004, strain of Bifidobacterium breve isolated from the gut microbiome of a healthy human	Clinical	UK approval to start Phase 2 study in April 2020		4D Pharma			Asthma	N/A	Sources	4/23/2020
189	Other	EDP1815, oral single strain of microbe	Clinical	Phase 2 to start and data expected 2H 2020		Evelo Biosciences/ Rutgers University/ Robert Wood Johnson University Hospital			Psoriasis and Atopic Dermatitis		Sources	5/10/2020
190	Other	roscovitine seliciclib, cyclin-dependent kinase (CDK)2/9 inhibitor	Clinical			Cyclacel Pharmaceuticals/ University of Edinburgh	LifeArc		Rheumatoid arthritis	N/A	Sources	4/23/2020
191	Other	fadraciclib (CYC065), cyclin-dependent kinase (CDK)2/9 inhibitor	Clinical			Cyclacel Pharmaceuticals/ University of Edinburgh	LifeArc		Various cancers	N/A	Sources	4/23/2020
192	Other	ATYR1923, fusion protein (immuno-modulatory domain of histidyl tRNA synthetase fused to the Fc region of a human antibody) modulator of neuropilin-2	Clinical	Phase 2 study ~ April/May 2020		aTyr			Pulmonary sarcoidosis	N/A	Sources	4/24/2020
193	Other	Farxiga (dapagliflozin), sodium-glucose cotransporter 2 (SGLTs) inhibitor	Clinical	Phase 3 study started in April 2020	NCT04350593	AstraZeneca/ Saint Luke's Mid America Heart Institute			Heart failure; Chronic kidney disease	FDA-approved since 2014, approved to improve glycemic controls in adults with type 2 diabetes and reduce the risk of hospitalization for heart failure in adults with type 2 diabetes	Sources	4/24/2020
194	Other	Ruconest (recombinant human C1 esterase inhibitor)	Compassionate Use			Pharming		Pharming (https://www.pharming.com/sites/default/files/imce/Press%20releases/Ruconest%20Covid%20compassionate%20use%2021%20April%202020.pdf)		FDA-approved since 2014, approved to treat hereditary angioedema	Sources	4/24/2020
195	Other	DIBI, iron-binding polymer	Pre-clinical			Chelation Partners				N/A	Sources	4/28/2020
196	Other	brensocatib, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1)	Clinical	Phase 2 study to begin enrollment in May 2020		Insmed Inc.			Bronchiectasis and other inflammatory diseases	N/A	Sources	4/28/2020
197	Other	Pepcid (famotidine), histamine-2 (H2) receptor antagonist	Clinical	Phase 2 study underway in April 2020		Feinstein Institutes for Medical Research at Northwell Health/ Alchem		medRxiv (https://doi.org/10.1101/2020.05.01.20086694)		FDA-approved since 1986, approved to treat ulcers, gastroesophageal reflux disease, erosive esophagitis, pathological hypersecretory conditions, and to reduce the risk of duodenal ulcer recurrence	Sources	5/10/2020
198	Other	tradipitant, a neurokinin-1 receptor antagonist	Clinical	Phase 3 trial started in April 2020	NCT04326426	Vanda Pharmaceuticals/ Feinstein Institutes for Medical Research at Northwell Health			Gastroparesis, motion sickness, and atopic dermatitis	N/A	Sources	4/29/2020
199	Other	GP1681, small molecule inhibitor of cytokine release	Pre-clinical	Phase 1/2 to start in 2020		Quotient Sciences/ CytoAgents				N/A	Sources	5/21/2020
200	Other	Metablok, peptide	Clinical			Arch Biopartners			Lung and Kidney Inflammation	N/A	Sources	4/30/2020
201	Other	pacritinib, oral kinase inhibitor with specificity for JAK2, IRAK1 and CSFIR	Clinical	Phase 3 to start in May 2020, results expected by the end of 2020		CTI Biopharma			Myelofibrosis	N/A	Sources	4/30/2020
202	Other	Microbiome therapeutic	Pre-clinical	Clinical trials to start in 2020		Persephone Biosciences				N/A	Sources	4/30/2020
203	Other	pH barrier, transepithelial nebulized alkaline treatment	Pre-clinical			pHbarrier				N/A	Sources	4/30/2020
204	Other	Coronzot, a novel family of drugs, sequestration of the labile iron	Pre-clinical			Silkim Pharma				N/A	Sources	5/1/2020
205	Other	Neumifil, multivalent carbohydrate binding molecules	Pre-clinical			Pneumagen Ltd.				N/A	Sources	5/1/2020
206	Other	bemcentinib, selective AXL kinase inhibitor	Clinical	Phase 2 top line data expected July-August 2020; ACCORD trial to start May 2020		BerGenBio; ACCORD study	UK Government (ACCORD study)		Various cancers	N/A	Sources	5/10/2020
207	Other	Otezla (apremilast), inhibitor of phosphodiesterase 4 (PDE4)	Clinical			Amgen				FDA-approved since 2014, approved to treat psoriatic arthritis, severe plaque psoriasis, and oral ulcers associated with Behcet's Disease	Sources	5/4/2020
208	Other	MN-166 (ibudilast), orally bioavailable, small molecule macrophase migration inhibitory factor (MIF) inhibitor and phosphodiesterase (PDE) -4 and -10 inhibitor	Clinical			MediciNova/ Yale			Treatment of numerous neurodegenerative diseases and substance dependence	N/A	Sources	5/5/2020
209	Other	Yeliva (opaganib, ABC294640), oral sphingosine kinase-2 (SK2) selective inhibitor	Clinical/ Compassionate Use	Preliminary data from compassionate use released in April 2020		RedHill Biopharma		RedHill Biopharma (https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=15258) RedHill Biopharma (https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=15257) RedHill Biopharma (https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=15261)	Various oncology indications	N/A	Sources	5/8/2020
210	Other	RHB-107 (upamostat, WX-671), serine protease inhibitor	Clinical			RedHill Biopharma/ NIAID			Various oncology indications	N/A	Sources	5/8/2020
211	Other	ST266, cell-free biologic made from anti-inflammatory proteins secreted by placental cells	Clinical	Phase 1/2 to start in 4Q 2020		Noveome Biotherapeutics	Commonwealth of Pennsylvania		Multiple ophthalmic indications	N/A	Sources	5/10/2020
212	Other	Lysteda/Cyklokapron (tranexamic acid), an antifibrinolytic	Clinical	Phase 2 not yet recruiting May 2020	NCT04338074 NCT04338126	University of Alabama at Birmingham				FDA-approved since 1986, approved to treat cyclic heavy menstrual bleeding	Sources	5/13/2020
213	Other	senicapoc	Clinical			Aarhus University	The Danish Government		Sickle cell anemia; Alzheimer's disease	N/A	Sources	5/14/2020
214	Other	Luvox (fluvoxamine), a selective serotonin reuptake inhibitor	Clinical	Phase 2 trial recruiting May 2020	NCT04342663	Washington University School of Medicine in St. Louis				FDA-approved since 1994, approved to treat obsessive compulsive disorder	Sources	5/14/2020
215	Other	Gleevac (imatinib), kinase inhibitor	Clinical	Phase 2 trial recruiting May 2020	NCT04346147 NCT04357613 NCT04356495	Exvastat Ltd/ Global sponsors	Innovative Medicines Initiative			FDA-approved since 2001, approved to treat various cancers	Sources	5/14/2020
216	Other	ABX464	Clinical	Phase 2b/3 trial cleared by French regulatory agency in May 2020		Abivax	Bpifrance		Ulcerative colitis; rheumatoid arthritis; hepatocellular carcinoma	N/A	Sources	5/19/2020
217	Other	IMU-838, selective oral dihydroorotate dehydrogenase (DHODH) inhibitor	Clinical	Phase 2 trial cleared by German regulatory agency in May 2020		Immunic, Inc.			Ulcerative colitis; remitting multiple sclerosis	N/A	Sources	5/19/2020
218	Other	sPIF (synthetic pre implantation factor)	Pre-clinical	Preparing for a Phase 1/2a trial in May 2020		BioIncept				N/A	Sources	5/20/2020
219	Device	CytoSorb (blood purification device, extracorporeal cytokine adsorber))	FDA issued an Emergency Use Authorization on April 10, 2020 / Clinical / Compassionate Use		NCT04324528 ChiCTR2000030475 NCT04344080 DRKS00021447 (CytoSorbents), https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00021447	CytoSorbents Corporation				N/A	Sources	5/10/2020
220	Device	Extracorporeal blood purification (EBP) devices	FDA issued an Emergency Use Authorization on April 9, 2020			Terumo BCT Inc / Marker Therapeutics AG					Sources	Prior to 4/20/2020
221	Device	Seraph100MicrobindAffinity Blood Filter (Seraphy 100), approved in the EU for pathogen reduction	Clinical/ FDA issued an Emergency Use Authorization on April 17, 2020			ExThera Medical				N/A	Sources	4/21/2020
222	Device	Oxiris Blood Purification Filter	FDA issued an Emergency Use Authorization on April 23, 2020			Baxter				N/A	Sources	4/24/2020
223	Device	INOpulse	Compassionate Use			Bellerophon					Sources	Prior to 4/20/2020
224	Device	Hemolung Respiratory Assist System	FDA issued an Emergency Use Authorization on April 24, 2020			ALung Technologies			Acute Exacerbation of Chronic Obstructive Pulmonary Disease; Acute Respiratory Distress Syndrome (ARDS)	N/A	Sources	4/28/2020
225	Device	MultiFiltrate PRO System and multiBic/multiPlus Solutions, continuous renal replacement therapy (CRRT)	FDA issued an Emergency Use Authorization on April 30, 2020			Fresenius Medical				N/A	Sources	5/8/2020
226	Dormant / Discontinued	Washed microbiota transplantation	Clinical		NCT04251767	The Second Hospital of Nanjing Medical University		Study stopped before recruitment		Unknown	Sources	Prior to 4/20/2020
227	Dormant / Discontinued	Recombinant ACE2 (angiotensin-converting enzyme 2)	Clinical		NCT04287686	The First Affiliated Hospital of Guangzhou Medical University		Study stopped before recruitment		Unknown	Sources	Prior to 4/20/2020
228	Dormant / Discontinued	Combination of ebastine, lopinavir, and interferon alpha	Clinical	Chinese trial site last updated March 30, 2020	ChiCTR2000030535	Mianyang Central Hospital				N/A	Sources	5/7/2020
229	Dormant / Discontinued	Xofluza (baloxavir marboxil), polymerase acidic endonuclease inhibitor	Clinical	Chinese trial site last updated February 12, 2020	ChiCTR2000029544 ChiCTR2000029548	Roche/the First Hospital Affiliated to Zhejiang University's Medical School		medRxiv (https://doi.org/10.1101/2020.04.29.20085761) (ChiCTR2000029544)		FDA-approved since 2018, approved to treat influenza	Sources	5/10/2020
230	Dormant / Discontinued	azvudine, reverse transcriptase inhibitor	Clinical	Chinese trial site last updated February 16, 2020 - March 4, 2020 for various trials	ChiCTR2000030487 ChiCTR2000030424 ChiCTR2000029853	Numerous trials with Chinese research sponsors				N/A	Sources	5/7/2020
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918

	C	D	E	F	G	H	I	J	K	L	M	N
1			0 Best Practices - Expand the formula bar so that you don't miss the additional info found in some of the cells. Reference the image to the right for more help. - Use filters to explore and organize the information for your own use. When accessing through this view-only link, filters are temporary to that search/find. - This document is also available for download under the File tab. - To find the latest additions or updates to the tracker, command+F or control+F and search for an asterisk. All cells with new information have an added at the end.						Last Update: May 21, 2020 \| 12:37 pm ET © 2020 Milken Institute00 2020
2	Product Category	Product Description	Stage of Development	Anticipated Next Steps	Clinical Trials for COVID-19	Developer / Researcher	Funder	Published Results	Related Use / Platform (V Only)	FDA-Approved Indications	Sources	Date Last Updated

3	DNA-based	DNA plasmid vaccine with electroporation; INO-4800	Clinical	Phase 1 initial data expected June 2020; Phase 2/3 trials start July/August 2020	NCT04336410	Inovio Pharmaceuticals/Beijing Advaccine Biotechnology/VGXI Inc./ Richter-Helm BioLogics/Ology Bioservices	Coalition for Epidemic Preparedness (CEPI) / Gates Foundation / US Department of Defense		Same platform as vaccine candidates for Lassa, Nipah, HIV, Filovirus, HPV, cancer indications, Zika, and Hepatitis B	N/A	Sources	5/21/2020
4	DNA-based	DNA	Pre-clinical	Animal results released in May 2020; Phase 1 to start in fall 2020		Takis / Applied DNA Sciences / Evvivax				N/A	Sources	5/10/2020
5	DNA-based	DNA with electroporation	Pre-clinical	Phase 1 to start in 2020		OPENCORONA - Cobra Biologics / Karolinska Institute	European Commission (Horizon 2020 Program)			N/A	Sources	5/19/2020
6	DNA-based	DNA plasmid	Pre-clinical			Osaka University / AnGes / Takara Bio				N/A	Sources	Prior to 4/20/2020
7	DNA-based	DNA plasmid	Pre-clinical			Zydus Cadila				N/A	Sources	Prior to 4/20/2020
8	DNA-based	DNA plasmid, needle-free delivery	Pre-clinical			Immunomic Therapeutics / EpiVax / PharmaJet			Same platform as vaccine candidates for SARS	N/A	Sources	Prior to 4/20/2020
9	DNA-based	DNA	Pre-clinical			BioNet Asia				N/A	Sources	4/20/2020
10	DNA-based	DNA	Pre-clinical			University of Waterloo				N/A	Sources	4/20/2020
11	DNA-based	DNA	Pre-clinical			Entos Pharmaceuticals				N/A	Sources	5/4/2020
12	DNA-based	DNA	Pre-clinical	Phase 1 to start in Q1 2021		Scancell/ University of Nottingham			Same platform as vaccine candidates for cancer	N/A	Sources	4/28/2020
13	DNA-based	bacTRL-Spike	Pre-clinical			Symvivo				N/A	Sources	5/12/2020
14	Inactivated virus	Inactivated	Pre-clinical			Institute of Medical Biology, Chinese Academy of Medical Sciences				N/A	Sources	5/4/2020
15	Inactivated virus	Inactivated (inactivated + alum); PiCoVacc	Clinical	Phase 1/2 started April 2020	NCT04352608	Sinovac			Same platform as vaccine candidates for SARS	N/A	Sources	5/21/2020
16	Inactivated virus	Inactivated (inactivated + CpG 1018)	Pre-clinical			Sinovac/ Dynavax				N/A	Sources	4/28/2020
17	Inactivated virus	Inactivated	Clinical	Phase 1 started in May 2020	ChiCTR2000031809	Wuhan Institute of Biological Products/ Sinopharm				N/A	Sources	5/4/2020
18	Inactivated virus	Inactivated	Clinical	Phase 1 to start in May 2020	ChiCTR2000032459	Beijing Institute of Biological Products/ Sinopharm				N/A	Sources	5/19/2020
19	Inactivated virus	Inactivated	Pre-clinical			Osaka University / BIKEN / NIBIOHN				N/A	Sources	Prior to 4/20/2020
20	Inactivated virus	VLA2001, Inactivated + CpG 1018	Pre-clinical			Valneva/ Dynavax			Same platform as vaccine candidates for Japanese Encephalitis	N/A	Sources	5/12/2020
21	Inactivated virus	Inactivated	Pre-clinical			Research Institute for Biological Safety Problems, Republic of Kazakhstan					Sources	5/19/2020
22	Live attenuated virus	Codon deoptimized live attenuated virus	Pre-clinical	Animal data in summer 2020		Codagenix / Serum Institute of India			Same platform as vaccine candidates for HAV, InfA, ZIKV, FMD, SIV, RSV, DENV	N/A	Sources	4/28/2020
23	Live attenuated virus	Codon deoptimized live attenuated virus	Pre-clinical			Indian Immunologicals Ltd/ Griffith University				N/A	Sources	4/28/2020
24	Live attenuated virus	Live attenuated virus, measles virus (S, N targets)	Pre-clinical			DZIF - German Center for Infection Research			Same platform as vaccine candidates for Zika, H7N9, CHIKV	N/A	Sources	5/12/2020
25	Non-replicating viral vector	Non-replicating viral vector; MVA encoded VLP	Pre-clinical			GeoVax / BravoVax			Same platform as vaccine candidates for LASV, EBOV, MARV, HIV	N/A	Sources	Prior to 4/20/2020
26	Non-replicating viral vector	Non-replicating viral vector; Ad26 (alone or with MVA boost)	Pre-clinical	Start Phase 1 in September 2020		Janssen Pharmaceutical Companies/Beth Israel Deaconess Medical Center / Emergent BioSolutions/ Catalent	Biomedical Advanced Research and Development Authority (BARDA)		Same platform as vaccine candidates for Ebola, HIV, RSV	N/A	Sources	4/30/2020
27	Non-replicating viral vector	Non-replicating viral vector; replication defective simian adenovirus (GRAd) encoding SARS-CoV-2 S	Pre-clinical	Start Phase 1 in summer 2020		ReiThera/ Leukocare/ Univercells				N/A	Sources	5/19/2020
28	Non-replicating viral vector	Non-replicating viral vector; Ad5	Pre-clinical			ImmunityBio / NantKwest				N/A	Sources	Prior to 4/20/2020
29	Non-replicating viral vector	Non-replicating viral vector; ChAdOx1	Clinical	Phase 1/2 began April 2020, data expected in May 2020; Phase 2/3 trials expected to start by the middle of 2020*	NCT04324606	Consortium of the Jenner Institute, Oxford Biomedica, University of Oxford, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., Merck KGaA, the Serum Institute, Vaccitech, and AstraZeneca	Coalition for Epidemic Preparedness (CEPI) / UK Government		Same platform as vaccine candidates for influenza, TB, Chikungunya, Zika, MenB, plague	N/A	Sources	5/20/2020
30	Non-replicating viral vector	Non-replicating viral vector; MVA-S encoded	Pre-clinical			DZIF - German Center for Infection Research			Same platform as vaccine candidates for many pathogens	N/A	Sources	4/20/2020
31	Non-replicating viral vector	AdCOVID; single-dose, intranasal vaccine; non replicating viral vector; adenovirus-based NasoVAX expressing spike protein	Pre-clinical	Phase 1 trial to begin Q3 2020		Altimmune / University of Alabama at Birmingham			Same platform as vaccine candidates for influenza	N/A	Sources	Prior to 4/20/2020
32	Non-replicating viral vector	Non-replicating viral vector; Ad5 S (GREVAX™ platform)	Pre-clinical			Greffex			Same platform as vaccine candidates for MERS	N/A	Sources	Prior to 4/20/2020
33	Non-replicating viral vector	Oral Ad5 S	Pre-clinical			Stabilitech Biopharma Ltd				N/A	Sources	5/4/2020
34	Non-replicating viral vector	Adenovirus-based + HLA-matched peptides (Pan-Corona)	Pre-clinical			Valo Therapeutics Ltd				N/A	Sources	5/4/2020
35	Non-replicating viral vector	Non-replicating viral vector; Oral Vaccine platform	Pre-clinical	Phase 1 trial to begin in the second half of 2020		Vaxart / Emergent BioSolutions			Same platform as vaccine candidates for InfA, CHIKV, LASV, NORV, EBOV, RVF, HBV, VEE	N/A	Sources	Prior to 4/20/2020
36	Non-replicating viral vector	Non-replicating viral vector, MVA expressing structural proteins	Pre-clinical			Centro Nacional Biotecnologia (CNB-CSIC), Spain			Same platform as vaccine candidates for HIV, HCV, CHIKV, EBOV, Zika, Malaria, Leishmania	N/A	Sources	Prior to 4/20/2020
37	Non-replicating viral vector	Non-replicating viral vector; dendritic cell-based vaccine	Pre-clinical			University of Manitoba				N/A	Sources	4/20/2020
38	Non-replicating viral vector	Non-replicating viral vector; parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein	Pre-clincial			University of Georgia/ University of Iowa			Same platform as vaccine candidates for MERS	N/A	Sources	4/28/2020
39	Non-replicating viral vector	Non-replicating viral vector; Adenovirus Type 5 vector (Ad5-nCoV)	Clinical	Phase 2 started April 2020	NCT04313127 ChiCTR2000030906 ChiCTR2000031781	CanSino Biologics/Beijing Institute of Biotechnology/ Canada's National Research Council			Same platform as vaccine candidates for EBOV	N/A	Sources	5/20/2020
40	Non-replicating viral vector	Recombinant deactivated rabies virus containing S1	Pre-clinical			Bharat Biotech/ Thomas Jefferson University				N/A	Sources	5/4/2020
41	Protein subunit	Protein subunit, capsid-like particle (CLP)	Pre-clinical	Phase 1 to begin by February 2021		PREVENT-nCoV consortium (AdaptVac, Institute for Tropical Medicine at University of Tubingen, Leiden University Medical Center, University of Copenhagen, ExpreS2ion Biotechnologies, Wageningen University)/ Bavarian Nordic	European Commission (Horizon 2020 Program)		Same platform as vaccine candidates for HPV	N/A	Sources	5/14/2020
42	Protein subunit	Protein subunit, drosophila S2 insect cell expression system VLPs	Pre-clinical			ExpreS2ion				N/A	Sources	Prior to 4/20/2020
43	Protein subunit	Protein subunit; S protein	Pre-clinical			WRAIR / USAMRIID				N/A	Sources	Prior to 4/20/2020
44	Protein subunit	Protein subunit, S protein + adjuvant	Pre-clinical			National Institute of Infectious Disease, Japan			Same platform as vaccine candidates for Influenza	N/A	Sources	Prior to 4/20/2020
45	Protein subunit	Protein subunit, VLP-recombinant protein + adjuvant	Pre-clinical			Osaka University / BIKEN / National Institutes of Biomedical Innovation, Japan				N/A	Sources	Prior to 4/20/2020
46	Protein subunit	Protein subunit, native like trimeric subunit spike protein	Pre-clinical	Phase 1 to start by mid-2020		Clover Biopharmaceuticals Inc. / GSK / Dynavax	Coalition for Epidemic Preparedness (CEPI)		Same platform as vaccine candidates for HIV, RSV, Influenza	N/A	Sources	5/12/2020
47	Protein subunit	Protein subunit; peptide	Pre-clinical			Vaxil Bio				N/A	Sources	Prior to 4/20/2020
48	Protein subunit	Protein subunit; adjuvanted protein subunit (RBD)	Pre-clinical			Biological E Ltd				N/A	Sources	Prior to 4/20/2020
49	Protein subunit	Protein subunit; S protein	Pre-clinical			AJ Vaccines				N/A	Sources	Prior to 4/20/2020
50	Protein subunit	Protein subunit; recombinant spike protein with Advax adjuvant	Pre-clinical			Vaxine Pty Ltd / Flinders University / Oracle				N/A	Sources	4/28/2020
51	Protein subunit	Protein subunit; Ii-Key peptide	Pre-clinical			Generex / EpiVax			Same platform as vaccine candidates for HIV, SARS-CoV, Influenza	N/A	Sources	Prior to 4/20/2020
52	Protein subunit	Protein subunit; S protein	Pre-clinical			EpiVax / University of Georgia			Same platform as vaccine candidates for Inf H7N9	N/A	Sources	Prior to 4/20/2020
53	Protein subunit	PittCoVacc, Protein subunit, microneedle arrays S1 subunit	Pre-clinical	Phase 1 to start as early as June 2020		University of Pittsburgh			Same platform as vaccine candidates for MERS	N/A	Sources	Prior to 4/20/2020
54	Protein subunit	Protein subunit; S protein	Pre-clinical	Phase 1 to start as early as June 2020		University of Cambridge / DIOSynVax			Influenza, Ebola	N/A	Sources	Prior to 4/20/2020
55	Protein subunit	Protein subunit; COVID-19 XWG-03 truncated Spike proteins	Pre-clinical			Innovax / Xiamen University / GSK			Same platform as vaccine candidates for HPV	N/A	Sources	Prior to 4/20/2020
56	Protein subunit	Protein subunit; S protein, baculovirus production	Pre-clinical	Phase 1/2 to start in September 2020		Sanofi Pasteur / GSK	Biomedical Advanced Research and Development Authority (BARDA)		Same platform as vaccine candidates for Influenza, SARS-CoV (FDA approved vaccine)	N/A	Sources	5/8/2020
57	Protein subunit	Protein subunit; recombinant protein vaccine, utilizing baculovirus expression vector system technology	Pre-clincial	Phase 1 to start by end of 2020		UMN Pharma (Shionogi)	Japan Agency for Medical Research and Development			N/A	Sources	5/10/2020
58	Protein subunit	Protein subunit; NVX-CoV2373; Full length recombinant SARS COV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M	Pre-clinical	Start Phase 1/2 May 2020; top-line data expected July 2020		Novavax / Emergent BioSolutions	Coalition for Epidemic Preparedness (CEPI)		Same platform as vaccine candidates for RSV, CCHF, HPV, VZV, EBOV	N/A	Sources	5/13/2020
59	Protein subunit	Protein subunit (gp-96 backbone)	Pre-clinical			Heat Biologics (Zolovax) / University of Miami			Same platform as vaccine candidates for cancer (NSCLC), HIV, malaria, Zika	N/A	Sources	Prior to 4/20/2020
60	Protein subunit	Protein subunit; molecular clamp stabilized Spike protein	Pre-clinical			University of Queensland / GSK / Dynavax	Coalition for Epidemic Preparedness (CEPI)/Queensland Government/Federal Government (Australia)/Paul Ramsay Foundation		Same platform as vaccine candidates for Nipah, influenza, Ebola, Lassa	N/A	Sources	Prior to 4/20/2020
61	Protein subunit	Protein subunit; peptide vaccine	Pre-clinical			FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo			Same platform as vaccine candidates for Ebola	N/A	Sources	Prior to 4/20/2020
62	Protein subunit	Protein subunit; subunit vaccine	Pre-clincial			FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo				N/A	Sources	4/28/2020
63	Protein subunit	Protein subunit; S1 or RBD protein	Pre-clinical			Baylor College of Medicine			Same platform as vaccine candidates for SARS	N/A	Sources	Prior to 4/20/2020
64	Protein subunit	Protein subunit; Subunit protein, plant produced	Pre-clinical			iBio / CC-Pharming				N/A	Sources	Prior to 4/20/2020
65	Protein subunit	Protein subunit, recombinant protein, nanoparticles (based on S-protein and other epitopes)	Pre-clinical			St. Petersburg Scientific Research Institute of Vaccines and Serums				N/A	Sources	Prior to 4/20/2020
66	Protein subunit	Protein subunit, adjuvanted microsphere peptide	Pre-clinical	Animal testing results expected in April 2020		VIDO-InterVac, University of Saskatchewan	The Government of Saskatchewan and the Canadian Federal Government			N/A	Sources	Prior to 4/20/2020
67	Protein subunit	Protein subunit, peptide	Pre-clinical			Flow Pharma			Same platform as vaccine candidates for Ebola, Marburg, HIV, Zika, Influenza, HPV therapeutic vaccine, Breast Cancer	N/A	Sources	Prior to 4/20/2020
68	Protein subunit	Protein subunit, synthetic long peptide vaccine candidate for S and M proteins	Pre-clinical			OncoGen				N/A	Sources	Prior to 4/20/2020
69	Protein subunit	Protein subunit; oral E. coli-based protein expression system of S and N proteins	Pre-clinical			MIGAL Galilee Research Institute				N/A	Sources	Prior to 4/20/2020
70	Protein subunit	Protein subunit, nanoparticle vaccine	Pre-clinical			LakePharma, Inc.					Sources	5/4/2020
71	Protein subunit	Protein subunit; spike based	Pre-clinical			University of Alberta			Same platform as vaccine candidates for Hepatitis C	N/A	Sources	Prior to 4/20/2020
72	Protein subunit	Protein subunit, recombinant S1-Fc fusion protein	Pre-clinical			AnyGo Technology				N/A	Sources	5/4/2020
73	Protein subunit	Protein subunit, recombinant protein	Pre-clinical			Yisheng Biopharma				N/A	Sources	5/4/2020
74	Protein subunit	Protein subunit, recombinant S protein in IC-BEVS	Pre-clinical			Vabiotech				N/A	Sources	5/4/2020
75	Protein subunit	Protein subunit; DPX-COVID-19, protein subunit, peptide antigens formulated in LNP	Pre-clinical	Start Phase 1 testing by summer 2020		IMV, Inc. / Canadian Center for Vaccinology at Dalhousie University / Izaak Walton Killam Health Center/ Nova Scotia Health Authority; Canadian Immunization Research Network / University of Laval / Global Urgent and Advanced Research and Development in Canada			Same platform as vaccine candidates for cancer and infectious diseases, including malaria and anthrax	N/A	Sources	5/21/2020
76	Protein subunit	Protein subunit; plant virus nanotechnology formulated as injectable and microneedle patch	Pre-clinical			University of California, San Diego	National Science Foundation (Rapid Response Research [RAPID] grant)			N/A	Sources	4/28/2020
77	Protein subunit	OMV-based vaccine	Pre-clinical			Quadram Institute Biosciences			Same platform as vaccine candidates for Flu A, plaque	N/A	Sources	5/12/2020
78	Protein subunit	OMV-based vaccine	Pre-clinical			BiOMVis Srl/ University of Trento				N/A	Sources	5/12/2020
79	Protein subunit	Orally delivered, heat stable subunit	Pre-clinical			Applied Biotechnology Institute, Inc.				N/A	Sources	5/12/2020
80	Protein subunit	S-2 P protein + CpG 1018	Pre-clinical			Medigen Vaccine Biologics Corp/ NIAID/ Dynavax				N/A	Sources	5/12/2020
81	Protein subunit	Peptides derived from Spike protein	Pre-clinical			Axon Neuroscience SE				N/A	Sources	5/12/2020
82	Protein subunit	Adjuvanted recombinant protein (RBD-Dimer)	Pre-clinical			Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology, Chinese Academy of Sciences				N/A	Sources	5/19/2020
83	Protein subunit	RBD-based	Pre-clinical			Neovii/Tel Aviv University				N/A	Sources	5/19/2020
84	Protein subunit	Outer Membrane Vesicle (OMV)-peptide	Pre-clinical			Intravacc/Epivax				N/A	Sources	5/19/2020
85	Replicating viral vector	Replicating viral vector; YF17D Vector	Pre-clinical			KU Leuven				N/A	Sources	5/4/2020
86	Replicating viral vector	Replicating viral vector; measles vector	Pre-clinical			Zydus Cadila				N/A	Sources	Prior to 4/20/2020
87	Replicating viral vector	Replicating viral vector; measles vector	Pre-clinical	Start animal testing in April 2020		Institut Pasteur / Themis / University of Pittsburgh	Coalition for Epidemic Preparedness (CEPI)		Same platform as vaccine candidates for West nile, CHIKV, Ebola, Lassa, Zika, MERS	N/A	Sources	Prior to 4/20/2020
88	Replicating viral vector	Replicating viral vector; measles vector	Pre-clinical			FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo				N/A	Sources	4/28/2020
89	Replicating viral vector	Replicating viral vector; horsepox vector expressing S protein; TNX-1800	Pre-clinical			Tonix Pharma / Southern Research			Same platform as vaccine candidates for smallpox, monkeypox	N/A	Sources	5/19/2020
90	Replicating viral vector	Replicating viral vector, live viral vectored vaccine based on attenuated influenza virus backbone (intranasal)	Pre-clinical			BIOCAD / IEM				N/A	Sources	Prior to 4/20/2020
91	Replicating viral vector	Replicating viral vector, recombinant vaccine based on Influenza A virus, for the prevention of COVID-19 (intranasal)	Pre-clincial			FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo			Same platform as vaccine candidates for influenza	N/A	Sources	4/28/2020
92	Replicating viral vector	Replicating viral vector, replication-competent VSV chimeric virus technology (VSVdeltaG) delivering the SARS-CoV-2 Spike (S) glycoprotein	Pre-clinical			IAVI / Batavia			Same platform as vaccine candidates for Ebola, Marburg, Lassa	N/A	Sources	4/28/2020
93	Replicating viral vector	Replicating viral vector, influenza vector expressing RBD	Pre-clinical			The University of Hong Kong	Coalition for Epidemic Preparedness (CEPI)		Same platform as vaccine candidates for MERS	N/A	Sources	Prior to 4/20/2020
94	Replicating viral vector	Replicating viral vector; VSV-S	Pre-clinical			University of Western Ontario			Same platform as vaccine candidates for HIV, MERS	N/A	Sources	Prior to 4/20/2020
95	Replicating viral vector	Replicating viral vector; VSV vector	Pre-clinical			FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo				N/A	Sources	4/28/2020
96	Replicating viral vector	M2-deficient single replication (M2SR) influenza vector	Pre-clinical	Start Phase 1 trial in fall 2020		University of Wisconsin-Madison / FluGen/ Bharat Biotech			Same platform as vaccine candidates for influenza	N/A	Sources	5/4/2020
97	Replicating viral vector	Newcastle disease virus vector (NDV-SARS-CoV-2/Spike)	Pre-clinical			Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ.				N/A	Sources	5/19/2020
98	Replicating viral vector	Avian paramyxovirus vector (APMV)	Pre-clinical			The Lancaster University, UK				N/A	Sources	5/19/2020
99	RNA-based vaccine	RNA; LNP-encapsulated mRNA cocktail encoding VLP	Pre-clinical			Fudan University / Shanghai JiaoTong University / RNACure Biopharma				N/A	Sources	Prior to 4/20/2020
100	RNA-based vaccine	RNA; LNP-encapsulated mRNA cocktail encoding RBD	Pre-clinical			Fudan University / Shanghai JiaoTong University / RNACure Biopharma				N/A	Sources	Prior to 4/20/2020
101	RNA-based vaccine	RNA; Replicating defective SARS-CoV-2 derived RNAs	Pre-clinical			Centro Nacional Biotecnologia (CNB-CSIC), Spain				N/A	Sources	Prior to 4/20/2020
102	RNA-based vaccine	RNA; LNP-encapsulated mRNA	Pre-clinical			University of Tokyo / Daiichi-Sankyo			Same platform as vaccine candidates for MERS	N/A	Sources	Prior to 4/20/2020
103	RNA-based vaccine	RNA; several mRNA candidates	Pre-clinical			RNAimmune, Inc.				N/A	Sources	5/4/2020
104	RNA-based vaccine	RNA; mRNA	Pre-clincial			FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo				N/A	Sources	4/28/2020
105	RNA-based vaccine	RNA; mRNA	Pre-clinical			China CDC / Tongji University / Stermina				N/A	Sources	Prior to 4/20/2020
106	RNA-based vaccine	RNA; mRNA lipid nanoparticle (mRNA-LNP)	Pre-clinical			CanSino Biologics/Precision Nanosystems				N/A	Sources	5/21/2020
107	RNA-based vaccine	RNA; LNP-encapsulated mRNA (mRNA 1273)	Clinical	Phase 1 ongoing; Phase 2 to start May 2020; Phase 3 to start early summer 2020; FDA granted fast track designation May 2020; initial phase 1 data released May 18, 2020	NCT04283461	Moderna/NIAID/Lonza	Coalition for Epidemic Preparedness (CEPI)/ Biomedical Advanced Research and Development Authority (BARDA)	Moderna (https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-interim-phase-1-data-its-mrna-vaccine)	Same platform as vaccine candidates for multiple candidates	N/A	Sources	5/19/2020
108	RNA-based vaccine	LUNAR-COV19; RNA; mRNA	Pre-clinical	Start Phase 1 in summer 2020		Arcturus/Duke-NUS/ Catalent			Same platform as vaccine candidates for multiple candidates	N/A	Sources	5/5/2020
109	RNA-based vaccine	RNA; saRNA	Pre-clinical	Start Phase 1 in summer 2020		Imperial College London	UK Government		Same platform as vaccine candidates for EBOV, LASV, MARV, Inf (H7N9), RABV	N/A	Sources	4/23/2020
110	RNA-based vaccine	RNA; mRNA	Pre-clinical	Start Phase 1/2a trial June 2020		CureVac	Coalition for Epidemic Preparedness (CEPI); European Commission; Gates Foundation; Defense Advanced Research Projects Agency (DARPA)		Same platform as vaccine candidates for RABV, LASV, YFV, MERS, InfA, ZIKV, DengV, NIPV	N/A	Sources	5/19/2020
111	RNA-based vaccine	3 LNP-mRNAs; BNT162	Clinical	Phase 1/2 started April 2020; first data expected end of June or July 2020	EudraCT 2020-001038-36 NCT04368728	BioNTech / Fosun Pharma / Pfizer				N/A	Sources	5/19/2020
112	RNA-based vaccine	RNA; liposome-encapsulated mRNA	Pre-clinical	Animal studies begin in April 2020		BIOCAD			Same platform as vaccine candidates for cancer	N/A	Sources	Prior to 4/20/2020
113	RNA-based vaccine	LNP-mRNA	Pre-clinical			Sanofi Pasteur / Translate Bio				N/A	Sources	5/12/2020
114	RNA-based vaccine	RNA; mRNA in an intranasal delivery system (cross-strain protective COV-2 mRNA) vaccine for high-risk populations	Pre-clinical	Start Phase 1 early 2021		eTheRNA Immunotherapies / EpiVax/ Nexelis/ REPROCELL / Centre for the Evaluation of Vaccination of the University of Antwerp				N/A	Sources	5/4/2020
115	RNA-based vaccine	RNA	Pre-clinical			GeneOne Life Science / Houston Methodist				N/A	Sources	Prior to 4/20/2020
116	RNA-based vaccine	RNA; ZIP-1642, vaccine consists of a combination of mRNA molecules, encoding multiple SARS-CoV-2 antigens	Pre-clincial			Ziphius Therapeutics/ Ghent University				N/A	Sources	4/28/2020
117	RNA-based vaccine	mRNA	Pre-clinical			Greenlight Biosciences				N/A	Sources	5/12/2020
118	Virus-like particle	VLP; virus-like particle, based on RBD displayed on virus-like particle	Pre-clinical			Saiba GmbH				N/A	Sources	Prior to 4/20/2020
119	Virus-like particle	VLP; plant-derived VLP	Pre-clinical	Start Phase 1 in July/August 2020; Phase 2 by the end of 2020		Medicago Inc.			Same platform as vaccine candidates for flu, rotavirus, norovirus, West Nile virus, and cancer	N/A	Sources	5/21/2020
120	Virus-like particle	VLP; ADDomerTM multiepitope display	Pre-clinical			Imophoron Ltd / Bristol University's Max Planck Centre				N/A	Sources	Prior to 4/20/2020
121	Virus-like particle	VLP	Pre-clinical			Doherty Institute				N/A	Sources	Prior to 4/20/2020
122	Virus-like particle	VLP (COVID-19 and SARS1)	Pre-clincial			OSIVAX				N/A	Sources	5/4/2020
123	Virus-like particle	VLP; eVLP	Pre-clinical			ARTES Biotechnology			Same platform as vaccine candidates for malaria	N/A	Sources	5/4/2020
124	Virus-like particle	VLPs peptides/whole virus	Pre-clinical			University of Sao Paulo					Sources	5/19/2020
125	Virus-like particle	Enveloped virus-like particle (eVLP): Pan-coronavirus vaccine candidate, targeting COVID-19, SARS, and MERS, spike protein	Pre-clinical	Start Phase 1 testing by end of 2020		VBI Vaccines / National Research Council of Canada			Same platform as vaccine candidates for glioblastoma, cytomegalovirus, and Zika	N/A	Sources	4/28/2020
126	Unknown	Gene-encoded antibody vaccine, non-viral nanoparticle delivery	Pre-clinical			SmartPharm Therapeutics / Sorrento Therapeutics				N/A	Sources	Prior to 4/20/2020
127	Unknown	Self-assembling vaccine (fusion protein of a heat shock protein and Avidin, with biotinylated immunogenic peptides)	Pre-clinical	Animal study results by October 2020		HaloVax (Voltron Therapeutics) / The Vaccine & Immunotherapy Center at the Massachusetts General Hospital	Analog Devices Foundation			N/A	Sources	4/21/2020
128	Unknown	LV-SMENP-DC Dendritic cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins; administered with antigen-specific cytotoxic T lymphocytes	Pre-clinical		NCT04276896	Shenzhen Geno-Immune Medical Institute				N/A	Sources	5/12/2020
129	Unknown	Artificial antigen-presenting cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins	Pre-clinical		NCT04299724	Shenzhen Geno-Immune Medical Institute				N/A	Sources	5/12/2020
130	Unknown	ISR-50	Pre-clinical	Animal study results expected in Q2 2020, Phase 1 begins Q4 2020		ISR Immune System Regulation				N/A	Sources	Prior to 4/20/2020
131	Unknown	Unknown	Pre-clinical			ImmunoPrecise				N/A	Sources	Prior to 4/20/2020
132	Unknown	Unknown	Pre-clinical			Tulane University				N/A	Sources	Prior to 4/20/2020
133	Unknown	Unknown	Pre-clinical	Phase 1 begins as early as September 2020		SK Biosciences				N/A	Sources	Prior to 4/20/2020
134	Unknown	Unknown	Pre-clinical			Vir Biotechnology / GSK				N/A	Sources	Prior to 4/20/2020
135	Unknown	Unknown	Pre-clinical			Precision Vaccines Program at Boston Children's Hospital				N/A	Sources	Prior to 4/20/2020
136	Unknown	Unknown, tobacco plant technology	Pre-clinical			Kentucky BioProcessing (British American Tobacco)				N/A	Sources	Prior to 4/20/2020
137	Unknown	Unknown	Pre-clinical			Universite Laval				N/A	Sources	Prior to 4/20/2020
138	Unknown	Unknown	Pre-clinical	Phase 1 to start in summer 2020		Covaxx				N/A	Sources	4/21/2020
139	Unknown	Unknown	Pre-clinical			Catholic University/ Millennium Institute of Immunology and Immunotherapy/ Technological Consortium in Clinical Molecular Biomedicine, Chile				N/A	Sources	4/23/2020
140	Unknown	Unknown	Pre-clinical			Emergex Vaccines/ George Mason University's National Center for Biodefense and Infectious Diseases (NCBID)				N/A	Sources	4/24/2020
141	Unknown	TerraCoV2	Pre-clinical	Start Phase 1 in late 2020 or early 2021		Oragenics (Noachis Terra)/ Aragen Bioscience				N/A	Sources	5/21/2020
142	Unknown	AVI-205	Pre-clinical			AbVision				N/A	Sources	5/13/2020
143	Replicating bacterial vector	Recombinant LVS ΔcapB – vectored vaccine expressing multiple SARS-CoV-2 antigens	Pre-clinical			University of California, Los Angeles (Horwitz Lab)			Same platform as vaccines against select agents and emerging pathogens	N/A	Sources	5/10/2020
144
145
146
147
148
149
150
151
152
153
154
155
156
157

	A	B	D	O
1	Last Update: May 21, 2020 \| 12:37 pm ET00 © 2020 Milken Institute00 2020
2
3
4
5
6	Total Count: Vaccines and Treatments
7	Treatments	223		x
8	Vaccines	141
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24			\
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

	A	B	G
1		ABOUT THE TRACKER The Milken Institute is currently tracking the development of treatments and vaccines for COVID-19 (coronavirus). This document contains an aggregation of publicly available information from validated sources. It is not an endorsement of one approach or treatment over another but simply a list of all treatments and vaccines currently in development. Given the immediacy of the current public health emergency, we believe it is important to make the data accessible to the public in their current form. This overview will be updated as new findings come to light. We ask that you check this resource regularly.	ABOUT US The Milken Institute is a nonprofit, nonpartisan think tank that helps people build meaningful lives in which they can experience health and well-being, pursue effective education and gainful employment, and access the resources required to create ever-expanding opportunities for themselves and their broader communities. FasterCures, a center of the Milken Institute, is working to build a system that is effective, efficient, and driven by a clear vision: patient needs above all else. We believe that transformative and life-saving science should be fully realized and deliver better treatments to the people who need them.
2	MILKENINSTITUTE.ORG
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000